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Summary 
The malaria parasite P. falciparum invades human red blood cells (RBCs). During 
invasion a compartment surrounding the parasite, the so-called parasitophorous vacuole 
(PV), is formed. The parasite resides and develops within the PV, which protects the 
parasite from the host cell cytosol. During its intraerythrocytic growth the parasite 
exports a vast number of proteins to the host cell in order to maintain its survival within 
the RBC. Proteins, which are directed to the host cell cytosol and host cell membrane, 
respectively, therefore are challenged to cross the parasite plasma membrane, the PV 
and the parasitophorous vacuolar membrane (PVM). However, the secretion and export 
mechanisms of many parasite proteins are still not understood. 
 
The current study focuses on the discovery of an alternative secretory pathway to the 
ER/Golgi route in the malaria parasite P. falciparum in infected RBCs. Two proteins 
appeared to be promising candidates of an alternative secretory pathway: the PfADP-
ribosylation factor 1 (ARF1) and the Pfadenylate kinase 2 (AK2). Both proteins 
contained a N-myristoylation site at their N-terminus, which is indicative for N-
myristoylation. N-myristoylation is a co-translational modification of a protein, whereby 
a fatty acid (myristate) is irreversibly attached to the glycine residue at the N-terminus 
of a protein via the PfN-myristoyltransferase (NMT). A preceding proteomic analysis of 
the parasitophorous vacuole and a reporter construct study proposed for both PfARF1  
(determined by a proteomic study) and PfAK2 (determined by a reporter construct 
study) PV localization although both proteins lacked a signal peptide. That’s why it was 
hypothesized whether or not N-myristoylation would drive protein secretion across the 
parasite plasma membrane (PPM). The subcellular localization of the PfARF1/GFP 
parasites and the PfAK2/GFP parasites, respectively, were analyzed via epifluorescence 
microscopy and biochemical methods. In parallel, another batch of reporter constructs 
were generated and analyzed, where the N-myristoylation site of PfARF1 (this study) 
and PfAK2 (Ma et al., 2012), respectively, was removed (PfARF1G2A/GFP and 
PfAK2G2A/GFP). Live cell imaging showed that the fusion protein ARF1/GFP was 
localized as dot-like structures in the parasite. In contrast, the phenotype of the fusion 
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protein of the PfARF1G2A/GFP parasites showed an evenly distributed signal in the 
parasite cytosol. Further analysis of the subcellular localization of the PfARF1 strongly 
supports its localization to compartments of the early secretory pathway of the parasite, 
but no localization in the PV. In contrast, the fusion protein PfAK2/GFP localized to a 
ring-like structure around the parasite indicating PV localization. The PfAK2G2A/GFP 
parasites showed a cytosolic localization of the fusion protein (Ma et al., 2012). 
Biochemical analyses revaled that the fusion protein PfAK2/GFP was secreted into the 
PV when the N-myristoylation site was present. Furthermore, it could be shown that the 
N-terminus of the PfAK2 protein is sufficient for parasite plasma membrane targeting, 
stable membrane anchoring and subsequent protein translocation across the PPM. A 
possible role of the early secretory pathway in PfAK2 trafficking and the folding state 
of PfAK2 prior to translocation across the PPM was also examined. However, the exact 
mechanism how PfAK2 is translocated across the PPM still remains elusive. 
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Zusammenfassung 
Der Malariaerreger P. falciparum befällt rote Blutkörperchen im Menschen. Bei der 
Invasion der Erythrozyten formt der Parasit eine sogenannte parasitophore Vakuole 
(PV), die ihn dann umgibt. Der Parasit verbleibt und entwickelt sich in dieser PV, die 
ihn vom Zytosol der Wirtszelle schützt. Während des intraerythrozytären Wachstums 
exportiert der Parasit eine hohe Anzahl seiner eigenen Proteine in die Wirtszelle um 
sein Überleben in der Wirtszelle zu sichern. Proteine, die entweder in das Zytosol oder 
der Membran der Wirtszelle exportiert werden, müssen zunächst die Plasmamembran 
des Parasiten (PPM), die PV und die anliegende parasitophore Vakuolenmembran 
(PVM) passieren. Der Sekretions- und Exportmechanismus vieler Parasitenproteine ist 
jedoch noch immer unbekannt.  	  
Ziel dieser Arbeit ist es alternative Sekretionswege zum klassichen ER/Golgi 
Sekretionsweg im Malariaparasiten P. falciparum aufzudecken. Zwei Proteine schienen 
geeignete Kandidaten eines alternativen Sekretionsweges zu sein: der PfADP-
Ribosylierungsfaktor 1 (ARF1) und die PfAdenylat kinase 2 (AK2). Beide Proteine 
besitzen eine N-myristoylierungsstelle am N-terminus was auf eine N-myristoylierung 
des jeweiligen Proteins hindeutet. N-myristoylierung ist eine ko-translationale 
Modifizierung eines Proteins, wobei eine Fettsäure (Myristat) irreversibel am Glycinrest 
am N-terminus eines Proteins durch die PfN-myristoyltransferase (NMT) angehängt 
wird. Eine vorangegangene Proteomuntersuchung der parasitophoren Vakuole und eine 
Untersuchung mit Reporterkonstrukten ergab für PfARF1 (Proteomuntersuchung) und 
PfAK2 (Analyse der Reporterkonstrukte) eine PV Lokalisation, obwohl beiden ein 
Signalpeptid fehlt. Deshalb wurde die Hypothese aufgestellt, dass N-myristoylierung 
womöglich an der Proteinsekretion über die Plasmamembran des Parasiten beteiligt sein 
könnte. Demnach wurde die subzelluläre Lokalisation der PfARF1/GFP Parasiten  und 
der PfAK2/GFP Parasiten mithilfe von Epifluoreszenzmikroskopie und biochemischen 
Methoden untersucht. Parallel dazu wurden Reporterkonstrukte generiert und analyisert, 
bei denen die N-myristoylierungsstelle von PfARF1 (diese Arbeit) und  PfAK2 (Ma et 
al., 2012) entfernt wurden (PfARF1G2A/GFP und PfAK2G2A/GFP). Beim live cell 
imaging war das Fusionsprotein ARF1/GFP als punktförmige Struktur im Parasiten
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erkennbar. Der Phänotyp des Fusionsproteins der PfARF1G2A/GFP Parasiten dagegen 
zeigte ein zytosolisches Signal im Parasiten. Weitere Analysen im Hinblick auf die 
subzelluläre Lokalisation des PfARF1 deuten auf eine Lokalisation dieses Proteins mit 
Kompartimenten des frühen Sekretionsweges des Parasiten hin jedoch auf keine 
Lokalisation in der PV. Im Gegensatz dazu war das Fusionsprotein PfAK2/GFP als 
ringförmige Struktur sichtbar was auf eine PV Lokalisation hindeutet. Die 
PfAK2G2A/GFP Parasiten zeigten hingegen eine zytosolische Lokalisation des 
Fusionsproteins (Ma et al., 2012). Biochemische Untersuchungen konnten zeigen, dass 
das Fusionsprotein PfAK2/GFP in Anwesenheit der N-myristoylierungsstelle in die PV 
sekretiert wurde. Des Weiteren konnte gezeigt werden, dass der N-terminus von PfAK2 
das Protein zur Plasmamembran führt und eine stabile Membranverankerung hervorruft 
bevor die Translokation über die Plasmamembran des Parasiten erfolgt. Eine mögliche 
Rolle des frühen Sekretionsweges im Transport von PfAK2 und der Faltungszustand 
von PfAK2 vor der Translokation über die Parasitenplasmamembran wurden ebenfalls 
untersucht. Dennoch ist der genaue Mechanismus der Proteintranslokation über die 
Plasmamembran des Parasiten nicht bekannt. 
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1 Introduction 
1.1 Malaria  
Since ancient times a disease today referred to as malaria ('mal' 'aria' meaning 'bad air') 
has been noted to have a detrimental effect on people’s life quality, impeding 
population growth and affecting settling patterns throughout human history (Carter and 
Mendis, 2002; Sallares et al., 2004). Today malaria is recognized as one of the largest, 
life-threatening, infectious diseases in the world, caused by a eukaryotic parasite of the 
genus Plasmodium and transmitted by a bite of an infected female Anopheles mosquito. 
Although the causative agent of this disease was identified in the late 19th century 
malaria continues to be a major health problem in tropical and subtropical parts of the 
world, where billions of people are still exposed to this deadly disease (Fig. 1) (WHO 
2011; cdc). In 2010 approximately 216 million clinical cases were reported by the 
World Health Organisation with 80 % occurring in African regions alone. Also 90 % of 
the 655 000 cases of deaths by malaria were registered in Africa (WHO 2011). In 
malaria-endemic regions pregnant women and children under the age of five (86 % of 
malaria deaths) succumb to this lethal disease more frequently than other groups of 
people as stated by the WHO in 2011. Countries, in which malaria is prevalent are also 
the ones suffering from a high poverty rate and a low economic growth making malaria 
prevention control and treatment more difficult (Gallup and Sachs, 2001; Sachs and 
Malaney, 2002). 	  
 
 
 
 
 
 
 
 
Figure 1.1 Malaria distribution 
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To date five different species of the genus Plasmodium – P. vivax, P. ovale,  
P. malariae, P. falciparum and P. knowlesi - are known to cause malaria in humans. 
While P. vivax and P. ovale, the causative agents of tertian malaria, and P. malariae, the 
causative agent of quartian malaria, are less likely to lead to severe forms of malaria 
outbreaks in humans, P. falciparum infections are mostly responsible for the high 
morbidity and mortality rates in endemic regions of Africa (cdc). Only recently  
P. knowlesi, a Plasmodium species known to infect macaque monkeys with malaria, 
was discovered to cause malaria in humans as well. (Singh et al., 2004; Cox-Singh et 
al., 2008). 
 
Since the early 20th century many projects emerged to fight this deadly disease 
involving the use of the synthetic insecticide dichlorodiphenyl-trichloroethane (DDT) 
to prevent transmission by mosquitoes and the chemical compound chloroquine, known 
to inhibit the development of the blood-stage parasite. However, the increasing 
resistance in the mosquitoes and the Plasmodium-species, respectively, and the adverse 
effect of DDT on the environment made these attempts over the period of time 
unfruitful (cdc). Nevertheless, many malaria eradication programmes, especially in the 
early 21st century, are determined to reduce the high malaria casualties by the use of 
bed-nets treated with insecticide, artemisin-based combination therapies, etc. In fact the 
combination of these various methods has reduced the number of malaria cases of 
deaths by around 33 % since 2000 as registered in African regions, which are monitored 
by the WHO (WHO 2011). However, the number of malaria infections is still high and 
strains resistant to the available current anti-malarial drugs are already occurring. That 
is why continuous study on the biology of the parasite, to eventually develop an 
efficient vaccine and developments of new drugs against malaria, still needs to be 
continued. 
 
1.2 The complex life-cycle of Plasmodium falciparum 
Plasmodium falciparum has a very complex life-cycle involving mosquitoes as vectors 
and humans as hosts for its survival. The transmission of P. falciparum into a human 
occurs when an infected female Anopheles mosquito bites a human for a blood-meal 
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thereby injecting saliva into the human. The saliva of an infected mosquito contains 
asexual forms of the parasite, the so-called sporozoites, which after entering the 
circulatory blood system travel to and invade liver cells for invasion (exo-erythrocytic 
stage). After entering liver cells the sporozoites multiply asexually and re-differentiate 
into thousands of merozoites in a process referred to as schizogony (Shortt, 1951). 
These thousands of merozoites are initially released in so-called merosomes (detached 
membrane-bound structures from the host cell) into the blood stream to escape the 
immune system (Sturm et al., 2006). Once the merozoites are completely released into 
the blood stream they target and invade red blood cells (erythrocytic stage). Following 
invasion a single merozoite multiplies into 20-30 daughter cells in an asexual process 
which takes about 48 hours: Initially the merozoite (now called the ring-stage) increases 
in size (0-12 hours post invasion) resulting into the more mature trophozoite form (12-
30 hpi) before the nucleus of the trophozoite form divides into many nuclei forming the 
so-called multinucleated schizont (30-48 hpi). After division of the multinucleated 
schizont into many individual merozoite forms the red blood cell ruptures releasing the 
newly formed parasites into the circulatory system to invade new erythrocytes (Wenk 
and Renz, 2003; Cowman and Crabb, 2006). However, a late trophozoite-stage 
occasionally also differentiates into a sexual form of the parasite, the gametocytes, 
which remain in the erythrocyte. Only when the erythrocytes containing these 
gametocytes are taken up via a blood-meal by a mosquito do they transform into 
gametes - male and female - in the gut of the mosquito. Fusion of the male and female 
gametes leads to a diploid zygote, the motile ookinete, which forms eventually an 
oocyst in the midgut of the mosquito. There the haploid sporozoite-forms are produced 
after many rounds of mitotic division (Wenk and Renz, 2003; Beier et al., 1998; 
Matuschewski, 2006). Eventually, these asexual sporozoites travel through the mosquito 
body to the salivary glands of the mosquito, where they can enter the host, once the 
infested mosquito bites a human re-starting the cycle (Fig. 1.2) (Matuschewski, 2006). 
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The first symptoms caused by P. falciparum infection emerge after a week or even 
longer, when the infected individual suffers from headache, fever or chills. This is 
usually a result of the intraerythrocytic growth of the parasite, which is followed by 
rupture of the erythrocyte and the release of new merozoites. If the P. falciparum 
infection is not treated within the next 24 hours, it can lead to severe illness due to rapid 
spreading of infected red blood cells in the circulatory system. This affects several 
organs, for example the nervous system (cerebral malaria) and can lead to metabolic 
acidosis and anemia as a consequence of hemolysis, resulting in coma and death of the 
infected person (Miller et al., 2002; reviewed in WHO 2013).  
Figure 1.2 Life-cycle of P. falciparum 
A bite of a female Anopheles mosquito leads to the transmission of the malaria parasite into the 
human. Initial asexual multiplication takes place within the liver cells, before the infective 
merozoite form invades and multiplies within the red blood cells. The gametocytes, the sexual 
forms of the parasite, are produced in the human; however, the sexual development of  
P. falciparum occurs in the midgut of the mosquito (according to Ménard, 2005). 	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1.3 The intraerythrocytic stage 
1.3.1 P. falciparum-infection leads to extensive modification of the red blood cell  	  
Plasmodium belongs to the phylum Apicomplexa - a large and diverse group of obligate 
intracelluar parasitic protists – which has one feature in all of their invasive stages in 
common: the apical complex. The apical complex, containing three secretory organelles 
– the micronemes, the rhoptries and the dense granules – enables parasites like 
Plasmodium to actively invade their host cells distinguishing this group from other 
pathogens regarding their mode of invasion (Aikawa, 1971; Cowman and Crabb, 2006).  
Interestingly, the merozoites - the invasive forms of P. falciparum produced during 
infection in humans - choose to invade erythrocytes, terminally differentiated cells, 
which lack a nucleus, subcellular organelles and do not perform any lipid- and protein 
synthesis (Mohandas and Gallagher, 2008). To reside and asexually multiply within this 
kind of a host cell therefore demands extensive modifications of the erythrocyte by the 
parasite. Already the invasion process, which comprises 1) the initial binding of the 
parasite to the host cell, 2) its repositioning and 3) the formation of a tight junction with 
the host cell (Dvorak et al., 1975; Bannister and Dluzewski, 1990) accompanied by the 
discharge of various proteins from the secretory organelles (Kats et al., 2008; Dowse et 
al., 2008; Cowman and Crabb, 2006) leads to a disruption of the red blood cell 
membrane and also affecting its cytoskeletal protein composition (McPherson et al., 
1993; Roggwiller et al., 1996). However, the major alterations of the host cell takes 
place once the parasite has gained entry into the red blood cell and starts exporting a 
large number of its own proteins into the host cell cytosol and membrane (Maier et al., 
2009; Marti et al., 2005). One of the prominent protein, which is exported to the red 
blood cell membrane, is the so-called P. falciparum erythrocyte membrane protein 1 
(PfEMP1). PfEMP1 is a large protein of the size of 200-350 kDa and is responsible for 
antigenic variation. These proteins are the major cause of the pathogenicity of  
P. falciparum-infection due to their characteristics to adhere to receptors of the 
endothelium preventing destruction of infected red blood cells (RBCs) by the immune 
system (Su et al., 1995; Baruch et al., 1995). Their presentation on the surface of the 
RBC is supported by another kind of protein, the knob-associated histidine rich protein 
(KAHRP), which causes knob-like protrusions in the erythrocyte membrane (Culvenor 
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et al., 1987; Pologe et al., 1987; Trager et al., 1966; Crabb et al., 1997). The interaction 
between PfEMP1 proteins and KAHRP not only increases the chances of receptor 
binding and sequestration of infected cells under the flow conditions of the circulatory 
system (Crabb et al., 1997), but also leads to increased rigidity of the erythrocyte 
membrane (Glenister et al., 2002). Another key aspect in the survival of the parasite is 
the nutrient acquisition throughout its intraerythrocytic development. Therefore  
P. falciparum not only modifies host cell transporters for constitutive nutrient uptake, 
but was also found to create new permeability pathways (NPPs) in the membrane of the 
host cell (Kutner et al., 1985; Kirk, 2001).  
 
1.3.2 Novel structures and compartments in P. falciparum-infected red blood cell 
Apart from the already mentioned secretory organelles at the apical complex harbouring 
different lipids and proteins, which mainly play a role in the invasion process of the 
merozoite, other structures and compartments formed by P. falciparum during its 
intraerythrocytic development are also only found in the phylum Apicomplexa and in 
particular in Plasmodium (Fig. 1.3).  
An ultrastructural analysis of the infected RBC supported the long-standing notion of 
the existence of parasite produced membranous structures in the erythrocyte cytosol: the 
Maurer’s clefts. These thin structures are composed of an electron-dense coat with a 
translucent lumen most likely located in close proximity to the erythrocyte membrane, 
possibly supporting the trafficking of parasite proteins to the host cell membrane 
(Aikawa et al., 1986; Wickert and Krohne, 2007; Lanzer et al., 2006). Another set of 
membranous network also located in the red blood cytosol and found to play a role in 
nutrient acquisition is the so-called tubovesicular network (TVN) (Atkinson and 
Aikawa, 1990; Lauer et al., 1997). These tubular and vesicular membranous structures 
seem to be connected with the membrane of the parasitophorous vacuole (PV) (van Ooij 
et al., 2008), a compartment which is formed by the parasite during host cell invasion 
and which surrounds the parasite throughout its entire development inside the RBC 
(Lingelbach and Joiner, 1998). The PV is a compartment existing in some of the 
Apicomplexan parasites like Toxoplasma and Plasmodium and acts as a barrier between 
parasite and host cell cytosol. Although the PV itself is topologically different from the 
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parasite and the host cell, the parasitophorous vacuolar membrane (PVM) seems to 
consist of proteins and lipids of the host cell (Lauer et al., 2000; Murphy et al., 2004), 
but is also proposed to be of parasite origin (Bannister and Dluzewski, 1990), this still 
being a matter of debate. The cellular function of the PV is not fully understood, 
however, it is suggested to play a role in the protection of the parasite from detrimental 
substances of the host cell cytosol and enables nutrient uptake for parasite growth 
(Lingelbach and Joiner, 1998). According to two independent screening studies of 
parasite exported proteins to the host cell by Marti and colleagues and Hiller and 
colleagues more than 250 proteins were discovered to be secreted through the PVM 
(Marti et al., 2004; Hiller et al., 2004), many of them being responsible for the virulence 
of P. falciparum infection. However, a proteomic approach to study the PV content 
revealed not only a large number of proteases and chaperones possibly playing a role in 
the lysis process during parasite release, but also revealed many proteins of unknown 
function. In general, the role of the PV can be attributed to a sorting compartment for 
distinguishing between resident PV proteins and proteins en route to the host cell, 
leaving the latter ones to pass through the PVM (Nyalwidhe and Lingelbach, 2006).  
 
	  	  
Figure 1.3 Compartments of P. falciparum-infected red blood cell 
Left side: Trophozoite stage of P. falciparum-infected red blood cell displaying the nucleus, the ER, the 
Golgi-complex, the mitochondrion (M), the food (digestive) vacuole (DV) and the apicoplast (A) within 
the parasite cytosol. The parasite is surrounded by the PV, from which the TVN is formed and found 
located inside the erythrocyte cytosol similar to the Maurer’s clefts (MCs). At the erythrocyte membrane 
knob-like protrusions are shown (K). Right side: Schizont-infected RBC with the apical organelles: 
rhoptries (R), micronemes (MN) and dense granules (D) (modified according to Deponte et al., 2012).  	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Apart from the PV two other compartments are also present in the parasite: the food 
vacuole and the apicoplast (apicomplexan plastid). The food vacuole is formed by a 
cytosomal system, membrane-enclosed structures of parasite origin, which take up 
hemoglobin in portion – hemoglobin makes up 95 % of the red blood cell cytosol- 
during parasite growth. Inside the food-vacuole hemoglobin is degraded, and heme is 
crystallized to the dark-pigment hemozoin (Francis et al., 1997). The apicoplast is a 
non-photosynthetic four-membrane-bound plastid located in the cytosol of the parasite 
and found to be crucial for the parasite’s survival. Its function is not fully understood 
but it seems to play a role in fatty acid, isoprenoid and heme synthesis (Waller and 
McFadden, 2005). Although Plasmodium contains some compartments characteristic 
only of Apicomplexan parasites, the following common eukaryotic compartments are 
also found in the parasite: Plasmodium falciparum has a nucleus harbouring a haploid 
genome (Gardner et al., 2002), a single mitochondrion containing its own, but highly 
reduced genome (Bender et al., 2003) and the common compartments of the secretory 
system found in all eukaryotic cells. These are the endoplasmic reticulum (ER) and an 
unstacked Golgi-complex. Both compartments, however, show some differences in their 
morphology to their counterparts in higher eukaryotes (Couffin et al., 1998; Van Wye et 
al., 1996). 
 
1.3.3 Protein secretion mechanisms in the P. falciparum-infected red blood cell  
Being a eukaryotic organism, protein secretion in P. falciparum via the early secretory 
pathway is most likely to resemble that of other eukaryotes. However, there are many 
exceptions to the rule since Plasmodium harbours compartments, which are missing in 
other eukaryotic cells and to which proteins are directed to. Before focusing on the 
protein secretion mechanism during the intraerythrocytic stage of P. falciparum the 
general model for the early secretory pathway - keeping in mind that there are many 
variations to the rule across eukaryotes - in eukaryotes is described: 
The early secretory pathway in eukaryotes: Early studies on intracellular protein 
trafficking in eukaryotes included morphological, genetic and biochemical analyses 
mainly on yeast in order to identify the components of the secretory membrane system 
and to understand the underlying molecular mechanisms of its regulation (Palade, 1975; 
Rothman, 1994). In brief: secretory protein synthesis begins in the cytosol at ribosomes, 
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which are associated with the endoplasmic reticulum (rough ER) - a large intracellular 
compartment spread throughout the cytoplasm, consisting of many membranous layers 
interconnected with each other and mainly specialized in protein- and lipid biosynthesis. 
The pre-proteins contain a N-terminal signal peptide (SP) of mostly 15-30 hydrophobic 
amino acids, which is produced during translation and is recognized and bound to a so-
called signal recognition particle (SRP). The SRP stops protein translation, then binds 
to the SRP-receptor in the ER membrane that directs the entire SRP-ribosome complex 
to a translocator residing in the ER membrane – the Sec61 complex, which is known to 
be highly conserved in bacteria and eukaryotic cells – where protein translation 
proceeds once the SRP/SRP-receptor is released. The proteins are co-translationally 
transferred across the ER membrane, where soluble proteins are fully released into the 
lumen of the ER after translation, whereas integral membrane proteins become 
embedded in the ER membrane. The signal peptide is cleaved off by a signal peptidase. 
Many of the soluble and integral membrane proteins either become resident ER proteins 
or are further trafficked to the plasma membrane or other compartments. The forward 
trafficking of these proteins is dependent on another compartment, the Golgi-complex, 
which consists of tubular membranous structures, divided into functionally distinct cis-, 
medial and trans-Golgi stacks. The proteins leave the ER once they are packaged into 
vesicles termed COPII-coated-vesicles. These vesicles then fuse with the cis-Golgi and 
progressively move through the medial- and trans-Golgi (anterograde transport) in a 
budding and fusion process, before they are released from the Golgi-complex to the cell 
surface or to other compartments inside the cell. During the vesicular transport through 
the Golgi-complex proteins are post-translationally modified by resident Golgi-enzymes 
specialized in performing different kinds of glycosylation reactions. Retrograde 
transport from the cis-Golgi towards the ER via COPI-coated vesicles occurs when ER 
resident proteins accidentally enter the anterograde secretion pathway. They are 
recognized via their XDEL ER-retrieval sequence by specialized receptors located at the 
cis-Golgi and are trafficked back to the ER (Fig. 1.4) (Blobel and Dobberstein, 1975a; 
Blobel and Dobberstein, 1975b; Palade, 1975; Rothman, 1994; Alberts et al., 2008). 
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Early secretory pathway in P. falciparum: Many different in vitro and in silico 
studies on the intraerythrocytic stage of P. falciparum revealed the existence of some 
components playing a role in the early secretory pathway. These are for example the 
gene homologue of the mammalian α-subunit of the Sec61 translocon PfSec61 (Couffin 
et al., 1998) and the lumenal proteins of the ER PfERC2 and PfBIP (Kumar et al., 1991; 
La Greca et al., 1997) supporting the existence of an ER in the parasite cytosol. The 
existence of a Golgi apparatus was initially doubted since typical Golgi stacks could not 
Figure 1.4 Simplified model of the classical secretory pathway of the eukaryotic cell 
Protein translation begins in the cytosol at ribosomes associated with the ER. Proteins destined to be secreted 
to the extracellular space contain a signal peptide (SP) at their N-terminus, which is recognized and bound to a 
signal recognition particle (SRP). Translation stops until the SRP-ribosome complex is bound to a SRP-
receptor, which then trafficks the entire SRP-ribosome complex to a translocon in the ER-membrane (Sec 61 
complex), where the protein is co-translationally translocated across the ER membrane. This protein is then 
trafficked via vesicles generated from the ER to the Golgi-complex and is released from the Golgi-complex 
via vesicles into the extracellular space. The trafficking of proteins from the ER towards the plasma 
membrane is referred to as anterograde trafficking. However, ER-proteins, which accidentally escape the ER, 
are transferred back from the Golgi to the ER, in a process called retrograde transport.  
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be found by electron microscopy (Aikawa, 1988) and parasite proteins were not 
subjected to any kind of N-linked glycosylation (Dieckmann-Schuppert et al., 1992). 
However, other studies revealed the existence of typical Golgi proteins like the ERD2-
receptor, which binds to proteins with a KDEL-retrievel sequence (Elmendorf and 
Haldar, 1993), the GTPase Rab 6 (van Wye et al., 1996) and the Golgi re-assembly 
stacking proteins 1 and 2 (Struck et al., 2005; Struck et al., 2008a; Struck et al., 2008b) 
indicating the existence of a possible rudimentary Golgi-complex. Furthermore, the 
gene of the ADP-ribosylation factor 1, a small GTPase important for vesicular 
trafficking in the early secretory pathway, was isolated, expressed and characterized 
from P. falciparum and more recently its crystal structure was also determined (Stafford 
et al., 1996; Cook et al., 2010). These findings are in accordance with an in silico 
analysis by Gardner and colleagues in 2002. They identified potential homologue gene 
candidates of proteins involved in the early secretory pathway like for example the SRP, 
a signal peptidase and proteins involved in the budding and fusion of secretory vesicles 
(Gardner et al., 2002). Furthermore, studies with the fungal metabolite Brefeldin A 
(BFA), a known inhibitor of the secretory pathway, was shown to inhibit the secretion 
of a number of parasite proteins (Benting et al., 1994; Hinterberg et al., 1994; 
Baumgartner et al., 2001; Lippincott-Schwartz, 1989).  
Many of the proteins secreted from P. falciparum not only contain the 'classical' signal 
sequence found in other eukaryotic organisms, but also revealed a modified version of 
the SP: a prolonged stretch of hydrophobic amino acids of up to 80 amino acids and 
recessed from the N-terminus of the protein (Lingelbach, 1993; Cooke et al., 2004). In 
addition, it could be shown that proteins containing the classical signal sequence are 
directed towards the parasite plasma membrane (PPM), the PV and the PVM, 
respectively, while those containing the recessed signal are found transported beyond 
the PVM en route to the host cell (Albano et al., 1999; Lingelbach, 1993). Here, too, 
many exceptions to the rules exist, like in the case of STEVOR (Przyborski et al., 2005) 
and the histidine-rich protein 2 (HRP2) (Howard et al., 1986), both containing a 
classical signal sequence, but are found exported to the host cell. Further trafficking of 
exported proteins, after entering the classical secretory pathway, is postulated to occur 
in a vesicle-mediated process (two-step model): vesicles containing the exported 
proteins fuse with the PPM and release the content into the lumen of the PV, before the 
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protein is trafficked to the host cell across the PVM (Ansorge et  al., 1996; Charpian 
and Przyborski, 2008).  
Protein secretion beyond the PVM: Compared to protein secretion in higher 
eukaryotes, in which many secretory proteins are subsequently secreted to the 
extracellular milieu via exocytosis by just crossing one membrane - the plasma 
membrane of the respective cell - many malarial proteins are found and predicted to be 
exported beyond the PVM (Marti et al., 2004; Hiller et al., 2004). This calls for 
additional targeting signals in the amino acid sequence of these proteins. Indeed a 
conserved motif consisting of five amino acids (RxLxE/Q/D), referred to as 
Plasmodium export element (PEXEL) or host targeting signal (HT), was found in two 
independent in silico and reporter construct studies. They are present at the N-terminus 
of the exported proteins in close proximity to the recessed signal peptide (~ 20 amino 
acids downstream). These studies enabled the identification of a large number of 
proteins – soluble and transmembrane proteins -  coded in the parasite genome and 
containing the PEXEL motif (~ 8 % of proteins), which are ever since collectively 
called the 'exportome' of P. falciparum (Marti et al., 2004; Hiller et al., 2004). 
Furthermore, the predicted genes of the malarial 'exportome', containing the PEXEL 
motif are found to be localized at subtelomeric regions of the parasite genome, where 
proteins responsible for host cell modifications are normally found (Maier et al., 2008). 
Interestingly, more recent studies revealed that the first three residues of the PEXEL 
motif (RxL) are actually cleaved during the early secretory pathway in the ER by an 
aspartic protease, which has been identified as Plasmepsin V, followed by N-acetylation 
of the cleaved protein (Chang et al., 2008; Boddey et al., 2010; Russo et al., 2010). 
Although different models for further trafficking towards the PV involving the 
remaining PEXEL residues and Plasmepsin V dependent export, respectively, have 
been proposed, none of it has been verified (Boddey et al., 2010; Crabb et al., 2010). 
Another model, although heavily debated, suggests the role of 
Phosphatidylinositol(3,4,5)-triphosphate (PIP3) in PEXEL-protein delivery to the PV 
(Bhattacharjee et al., 2012). Whatever the mode of protein secretion in the late secretory 
pathway (Golgi è PPM è PVM) might be, it seems like that exported proteins are 
first secreted into the PV before being directly translocated across the PVM in an ATP-
dependent process as shown in two independent localization studies with exported 
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proteins (Ansorge et al., 1996; Wickham et al., 2001). This corresponds with the earlier 
mentioned two-step model in protein secretion (Charpian and Przyborski, 2008) 
assigning the PV as a transit compartment. This finding coincides with experiments 
using the dihydrofolate reductase system (DHFR) showing that exported proteins need 
to be unfolded before passing the PVM (Gehde et al., 2009). This observation strongly 
suggest the existence of a translocation system in the PVM. In fact, an ATP-driven 
translocon, composed of five different Plasmodium proteins, was found in the 
membrane of the PV and appears to be a possible candidate responsible for protein 
translocation of exported proteins across the PVM. Since PEXEL proteins seem to be 
unique to the Apicomplexan Plasmodium the translocon termed Plasmodium translocon 
of exported proteins (PTEX) also consists of parasite proteins restricted to the 
Plasmodium genome (de Koning-Ward et al., 2009; Bullen et al., 2012). However, this 
transport model system only seems to fit for the export of soluble parasite protein, since 
proteins containing a 'transmembrane domain' would rather end up in the parasite 
plasma membrane, when secreted via the secretory pathway. One solution to this 
dilemma would be the way these proteins are synthesized meaning that they are initially 
synthesized as 'soluble' proteins, which take up their membrane topology only after 
entering their destination in the host cell. This hypothetical model actually coincides 
with solubility studies of different transmembrane containing exported proteins 
(Papakrivos et al., 2005; Przyborski et al., 2005; Saridaki et al., 2009).  
However, some well-known exported proteins of P. falciparum lack the typical PEXEL 
motif and they are generally termed PEXEL-negative exported proteins (PNEPs). These 
are for example the skeletal-binding protein 1 (SBP1), the membrane-associated 
histidine-rich protein 1 (MAHRP1) and the ring exported proteins 1 and 2 (REX 1 and 
2). These proteins are resident proteins of the Maurer’s clefts, which not only lack a 
distinguishable PEXEL motif, but also a typical signal sequence for ER entry. However, 
localization and solubility studies revealed the existence of a single transmembrane 
region in each of these proteins - except for REX 1, which contains a recessed signal 
peptide – which appears to be responsible for entering the secretory pathway. This is 
furthermore supported by studies revealing their sensitivity to BFA (Saridaki et al., 
2009; Spycher et al., 2008; Dixon et al., 2008; Haase et al., 2009). However, the further 
transport of these proteins, which pass the PV and PVM until reaching their final 
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destination in the host cell cytosol, still remains enigmatic. The transport process 
possibly involves other, not yet identified atypical signals/regions in the amino acid 
sequence of these proteins and possibly also other kind of translocons in the PVM. 
Since the number of exported PNEPs in the malaria genome might be greater than 
known to date, the chance to discover alternative secretory pathways in  
P. falciparum is quite high.  
 
1.4 Unconventional protein secretion 
As described in the previous chapter, secretory proteins are released into the 
extracellular milieu via the conserved secretory pathway universal to almost all 
eukaryotic organisms: the 'classical secretory pathway' involving the ER/Golgi-
complex. In contrast, many studies in the past years have revealed the secretion of a 
small number of proteins, which lack a signal peptide to enter the classical secretory 
pathway and were not affected in their secretion to the cell surface in the presence of 
BFA (Rabouille et al., 2012). Thus, these proteins were found to be secreted in a mostly 
ER-to-Golgi independent manner into the extracellular space (Fig. 1.5). That is why this 
mode of secretion is referred to as 'unconventional protein secretion' and is used by a 
small number of proteins involved in cell survival, angiogenesis and in inflammatory 
responses (Nickel, 2005).  
In general, two mechanisms for unconventional protein secretion were discovered: 
vesicular pathways versus non-vesicular pathways. A well-studied candidate of the non-
vesicular pathway is the Fibroblast growth factor 2 (FGF2) – a protein involved in 
angiogenesis – which was found to be directly translocated across the plasma membrane 
(Schäfer et al., 2004). The translocation process requires the interaction with 
phosphoinositide phosphatidylinositol(4,5)-bisphosphate (PI(4,5)P2) - a component 
located at the inner leaflet of the plasma membrane - and heparan sulfates found at the 
outer leaflet of the plasma membrane (Temmerman et al., 2008; Zehe et al., 2006). 
Another candidate secreted in a non-vesicular mechanism is for example the yeast 
mating factor α, which is translocated via the membranous ABC transporter Step6 
(McGrath and Varshavsky, 1989). Other unconventional secretion pathways involve 
vesicle-mediated secretion, as in the case of interleukin 1β (IL1β) (Rubartelli et al., 
1	  	  Introduction	   15	  
1990). Although the mechanism of the processing pattern of IL1β and the components 
involved are mostly understood (Franchi et al., 2009), the nature of the vesicles 
responsible for trafficking IL1β to the plasma membrane is still not clear. One model 
proposes the secretion of IL1β via secretory lysosmes, a compartment assigned to have 
a dual function: degradation of proteins, but also storage of secretory proteins before 
regulated release to the extracellular space upon external stimuli (Andrei et al., 1999; 
Griffiths, 1996). However, two further mechanisms were also suggested to be involved 
in the secretion of IL1β: microvesicle shedding at the external side of the plasma 
membrane (MacKenzie et al., 2001) and the formation of multivesicular bodies (MVB), 
respectively, which are vesicles formed inside endosomes and are afterwards released as 
vesicles into the extracellular space, then referred to as 'exosomes' (Stoorvogel et al., 
2002). Just recently, other studies discovered an unusual vesicle-mediated secretion 
pattern of the acyl-CoA-binding protein A (AcbA) from Dictyostelium discoideum 
involving proteins responsible for the formation of autophagosomes. The 
autophagosomes then fuse with the plasma membrane to release AcbA (Cabral et al., 
2010; Duran et al., 2010; Manjithaya et al., 2010). In addition, some studies imply the 
role of endosomes, which form multivesicular bodies to fuse with the plasma 
membrane. This hypothesis is supported by the findings of proteins, which are 
characteristic of this pathway (Duran et al., 2010; Manjithaya et al., 2010). Furthermore, 
the yeast ortholog to the mammalian GRASP1 is proposed to play a role in secretion of 
AcbA as well (Kinseth et al., 2007). Last but not least, a pathway termed the 'Golgi 
bypass' is used by transmembrane proteins. These proteins initially enter the classical 
secretory pathway and are eventually released at the plasma membrane, but on their 
way avoid the Golgi-complex. This for instance is characterized by their insensitivity to 
BFA (Grieve and Rabouille, 2011).  
The appearance of the increasing number of unconventionally secreted proteins and the 
different mechanisms involved raises the question, why some proteins are differently 
secreted from the cell, compared to the huge majority of secretory proteins, which uses 
the classical ER-to-Golgi pathway. So far, two hypotheses to address this question exist: 
First, it is assumed that in the case of FGF2, this protein, while trafficked through the 
classical secretory pathway, would bind at a very early stage to glycoproteins, leading to 
aggregation of the protein and non-secretion of FGF2. The second model, however, 
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proposes the secretion of a non-functional protein due to posttranslational modification, 
caused while trafficking via the ER/Golgi pathway. Indeed, the latter model was 
supported by experiments with FGF2. A signal peptide was fused to FGF2 directing this 
protein into the classical secretory pathway, however, the protein was not secreted into 
the extracellular space in its functional form (Nickel, 2010; Wegehingel et al., 2008). 
Since many of the proteins involved in unconventional protein secretion seem to be 
biomedically relevant, they appear to be suitable drug targets, if their mode of secretion 
and the components involved would be totally independent of the ER-to-Golgi route.  
 
 
Interestingly, mechanisms of unconventional protein secretion also appear in protozoan 
parasites as described for the Leishmania hydrophilic acylated surface protein B 
(HASPB) (Denny et al., 2000) and the Calcium-dependent protein kinase 1 (CDPK1) 
of P. falciparum (Möskes et al., 2004). Both proteins show the same mode of 
unconventional protein secretion: dual acylation of the N-terminus of the respective 
Figure 1.5 Unconventional protein secretion mechanisms 
Four different types of unconventional protein secretion mechanisms are illustrated. Type1: Vesicular 
trafficking via lysosomal secretion. Type 2: Non-vesicular trafficking via plasma membrane resident 
transporters. Type 3: Vesicular trafficking via formation of multivesicular bodies. Type 4: Membrane 
blebbing is the microvesicle shedding at the external side of the plasma membrane. Missing in this 
illustration: Golgi-bypass pathway (according to Nickel, 2005). 
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proteins, which mediates export to the extracellular surface and the parasitophorous 
vacuole, respectively. The role of acylation-dependent export is discussed in the next 
chapter.   
 
1.5 Role of fatty acid acylation of proteins in plasma membrane 
binding 
1.5.1 Protein N-myristoylation 	  
N-myristoylation is a co- and post-translational modification of proteins found in all 
eukaryotic cells. Proteins are characterized as N-myristoylated, when a 14-carbon 
saturated fatty acid (myristate) is irreversibly attached to the N-terminal glycine residue 
of the target protein. The glycine residue at the N-terminus of a protein sequence is a 
prerequisite for N-Myristoylation to take place. At first, methionine - the initiating 
amino acid in the protein sequence 'Met-Gly-...' - is removed by a methionine 
aminopeptidase during translation, leaving the glycine residue at the 2nd position of the 
N-terminus exposed. The myristate from Myristoyl-CoA is then linked to the glycine 
residue via an amide bond by the N-myristoyltransferase (NMT) (Fig. 1.6). NMT is an 
enzyme present in all eukaryotic cells and was discovered to be essential for the 
viability of different eukaryotic organisms (Resh, 1999; Wright et al., 2010). 
Importantly, NMT protein substrates require in addition to the glycine residue at the N-
terminus specific amino acids downstream of the protein sequence – serine or threonine 
are usually found at position 6 and lysine and arginine, respectively, are found at 
position 7/8 - to be recognized by the NMT (Resh, 1999). However, more recent studies 
showed that N-myristoylation also posttranslationally takes place in cells undergoing 
apoptosis involving caspase cleavage (Zha et al., 2000).   
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N-myristoylation is commonly found in proteins involved in signal transduction (protein 
kinases and phosphatases), Gα proteins, calcium-binding proteins, ADP-ribosylation 
factors (ARF) and also MARCKS (membrane and cytoskeletal-bound proteins) as 
known for mostly animal and fungal cells. Most of these proteins play a role in 
signalling processes and in the case of the ARFs in vesicular shuttling revealing their 
functional importance in these organisms (Resh, 2006). Furthermore, bioinformatic 
studies, using prediction models, revealed that about 0.5 % of the proteome in 
eukaryotes appear to be substrates of the NMT (Maurer-Stroh et al., 2002). It appears 
that apart from viral proteins, bacterial proteins can also be subjected to  
N-myristoylation by the N-myristoyltransferase of their respective eukaryotic host cell 
(Maurer-Stroh and Eisenhaber, 2004). The myristoyl moiety enables a reversible 
binding of the protein to the plasma membrane and to other intracellular membranes in 
a eukaryotic cell, respectively. However, due to the low binding energy of myristate to 
the phospholipids of a membrane (approximately 10-4 M Kd) a myristoylated protein 
cannot efficiently anchor to the plasma membrane (Peitzsch and McLaughlin, 1993). In 
order to achieve a sufficient binding to the phospholipid bilayer, a second signal within 
the amino acid sequence of the myristoylated protein is required. This hypothesis is 
referrred to as the 'two-step model'. The second signal can either be another fatty acid 
group like palmitate (16-carbon saturated fatty acid) or a polybasic cluster of amino 
acids, located in proximity to the N-myristoylation site. The binding of the respective 
protein to the membrane occurs when ten of the fourteen carbon atoms of the myristate 
insert into the phospholipid bilayer and the polybasic cluster of amino acids interacts 
with the acidic phospholipids of the cellular membrane (electrostatic interaction). The 
dual binding property induced by the myristate and the polybasic domain synergize 
leading to a stable anchoring of the protein to the membrane (Murray et al., 1997; 
Murray et al., 1998; Sigal et al., 1994; Buser et al., 1994). A similar mechanism to 
establish a strong membrane attachment is achieved by dual acylation of a protein with 
a myristate and a palmitate moiety (Resh, 1999), which will be discussed in more detail 
Figure 1.6 Co-translational N-myristoylation 
During translation the initiating methionine is removed by a methionine aminopeptidase (MetAP). Then 
the 14-carbon saturated fatty acid (myristate) is irreversibly attached to the glycine residue at the second 
position of the protein sequence via the Myristoyl-CoA by the N-myristoyltransferase (NMT) (according 
to Wright et al., 2010).   
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in the next section. Interestingly, the attachment of a myristate to a respective protein 
also plays a role in membrane targeting to the right target membrane (Murray et al., 
1998), although the mechanisms involved here are not yet understood. Further, the 
membrane anchoring of N-myristoylated proteins can be characterized as a dynamic 
process, since the myristate moiety on the respective protein switches between two 
different conformations: it is either exposed on the outside of the protein enabling 
membrane attachment, or it is segregated into a hydrophobic groove of the protein 
leading to detachment from the membrane. This mechanism known as the 'myristoyl 
switch' can be induced by e.g. a ligand or electrostatic interaction (Fig. 1.7) 
(McLaughlin and Aderem, 1995). A ligand induced myristoyl switch has been 
characterized for the ADP-ribosylation factor (ARF) proteins, which are regulated by 
the binding of GTP, which induces the exposure of the myristoyl moiety - initially 
located in a hydrophobic pocket in its GDP-bound form - and subsequent binding to the 
membrane (Amor et al., 1994). MARCKS proteins, on the other hand, are regulated by 
protein kinase C (PKC), which phosphorylates the stretch of the N-terminal polybasic 
serine residues - the second motif required for membrane binding in the two-step model 
– leading to an increased negative charge at the polybasic domain. This diminishes the 
electrostatic interaction with acidic phospholipids leading to the dissociation of the 
respective protein from the plasma membrane (Thelen et al., 1991).  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure 1.7 Two-signal model of myristate-mediated protein binding to the membrane 
The low binding energy of the myristoyl-group on the protein promotes reversible binding to the 
membrane. A second signal is required for stable membrane anchoring: either a polybasic cluster of 
amino acids to interact with the negatively charged phospholipid groups of the membrane via 
electrostatic interaction or a second saturated fatty acid like palmitate. Blue circle (protein), red 
(myristate), pink (palmitate) (according to Wright et al., 2010).  	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1.5.2 Protein-Palmitoylation 
Similar to N-myristoylation protein palmitoylation is a lipid modification, whereby 
usually a 16-carbon saturated fatty acid is attached to a cysteine residue via a thioester 
bond. Compared to the irreversible attachment of myristate to a protein, palmitoylation 
was found to be a reversible modification (Linder and Deschenes, 2003). This is due to 
the labile thioester linkage between protein and palmitate. The dynamic feature of 
protein palmitoylation is regulated by palmitoylation and depalmitoylation in regard to 
the function and localization of the respective protein (Zacharias et al., 2002; 
Wedegaertner and Bourne, 1994). So far, two different classes of enzymes responsible 
for palmitoylation and de-palmitoylation have been discovered: Protein acyltransferases 
(PATs) catalyze palmitate transfer to the respective protein, while the protein 
acylthioesterases are in charge of removing palmitate from the protein (Resh et al., 
2006; Mitchell et al., 2006). Interestingly, no consensus sequence for palmitoylation 
exists except for the presence of the cysteine residue and in addition in vitro studies 
revealed a non-enzymatic addition of palmitate from palmitoyl-CoA to proteins (Bañó 
et al., 1998). However, proteins which are subjected to palmitoylation are usually 
peripherally attached membrane proteins or proteins containing a transmembrane 
domain. Proteins containing a transmembrane domain are usually palmitoylated at the 
junction between cytoplasm and membrane or at the C-terminus located in the 
cytoplasm. In contrast, the peripherally associated membrane proteins can be dually 
acylated or are just palmitoylated by adjacent cysteine residues. A cysteine residue at 
the N-terminus often exists in close proximity to a lipidation site like a preceding  
N-myristoylation site. Upon palmitoylation a protein becomes more hydrophobic, which 
leads to a strong protein-membrane anchoring (two-step model). Dually acylated 
proteins with palmitoylation and preceding N-myristoylation are found among Gα 
proteins and tyrosine kinases and frequently exhibit the motif 'Met-Gly-Cys' at their  
N-terminus (Smotrys and Linder, 2004; Nadolski and Linder, 2007). Mutational 
analyses revealed that substitution of either of the amino acids responsible for lipid 
modification leads to a decrease or even loss of the protein binding capacity to the 
plasma membrane (Resh, 1999). More intriguingly, some studies claim that these dually 
fatty acid acylated proteins are targeted to specific membrane regions of the plasma 
membrane, the so-called rafts. Rafts are microdomains in the plasma membrane, which 
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are enriched in cholesterol and sphingolipids. However, the mechanism responsible for 
this observation has not been verified to date (Smotrys and Linder, 2004). In summary, 
palmitoylation is an important feature of proteins in regard to protein-membrane 
attachment, trafficking of transmembrane proteins and regulation of intracellular 
signalling processes of many proteins (Linder and Deschenes, 2003). 
1.6 Acylated proteins as candidates of an alternative secretory 
pathway in P. falciparum? 
1.6.1 P. falciparum ADP-ribosylation factor 1 
Like other eukaroytic organisms, the malaria parasite Plasmodium falciparum also 
contains genes encoding the ADP-ribosylation factor (ARF), a small GTP binding 
protein, which plays a crucial role in vesicular trafficking (Stafford et al., 1996; Boman 
and Kahn, 1995). ARF proteins belong to the superfamily of Ras proteins – a small 
group of GTPases – and are involved in a number of cellular processes, like for example 
in vesicular biogenesis and trafficking processes of the secretory pathway (Boman and 
Kahn, 1995). To date six highly conserved members of the ARF protein family are 
known for mammalian cells (Kahn et al., 1991). However, so far, only one of the two 
genes encoding ARF proteins, the gene arf1, in P. falciparum, is isolated, expressed and 
characterized (Stafford et al., 1996) and structurally determined (Cook et al., 2010). One 
of the functions attributed to ARF proteins is their role in the COPI pathway (retrograde 
transport from cis-Golgi to the ER), where they recruit other coat proteins and initiate 
vesicle formation upon activation. Activation of the soluble GDP-bound ARF to the 
GTP-bound form, which is able to bind to the membrane is catalyzed by the guanine 
nucleotide exchange factors (GEFs). The attachment to the membrane occurs, when the 
N-myristoylation site at the N-terminus of the protein is exposed in the GTP bound 
conformation of ARF. However, once the GTP on the ARF protein is hydrolyzed to 
GDP by GTPase activating proteins (GAPs) ARF is released from the membrane and 
the myristoyl moiety is covered in a hydrophobic groove of the protein. The release of 
ARF from the vesicle also leads to the detachment of other coat proteins from the 
vesicle, whereby ARF functions as a trigger. The vesicle formation and cargo 
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trafficking in e.g. the anterograde pathway depends on the cycling of ARF between its 
soluble GDP-bound state and the membrane-associated GTP-bound state (Boman and 
Kahn, 1995; Kirchhausen, 2000).  
Although some components of the classical secretory pathway are gradually being 
identified within the parasite cytosol, some studies also report the export of these 
components and the presence of secretory vesicles in the host cell. These findings 
implicate the existence of a vesicle-mediated secretion pathway for some parasite 
proteins from the parasite cytosol to their host cell and host cell membrane, respectively 
(Trelka et al., 2000; Taraschi et al., 2001). Further studies, apart from 
electronmicroscopical evidence, supporting the model of a dual operating system in the 
parasite cytoplasm and the host cell cytosplasm, are missing. On the contrary, a new 
study with GFP reporter constructs proposed the localization of the components 
involved in the secretory pathway exclusively to the parasite cytosol (Adisa et al., 
2007). Another interesting aspect observed by Stafford and colleagues is that a high 
mRNA level of PfARF1 is reached during merozoite formation, shortly before a high 
level of msp1 mRNA – merozoite surface protein 1 (MSP1) is located on the merozoite 
surface - is expressed. They hypothesize a role of PfARF1 in MSP1 shuttling to the 
merozoite surface via the ER-to-Golgi pathway (Stafford et al., 1996). A different 
observation regarding the localization of ARF was made by a recent proteome analysis 
of the PV, where PfARF1 was found to be located in the PV of the parasite (Nyalwidhe 
et al., manuscript in preparation), this hypothesis, however, still needs to be reviewed. 
1.6.2 P. falciparum adenylate kinase (2) 
 
Adenylate kinases are ubiquitous enzymes, which play an important role in energy-
dependent and nucleotide signalling processes. This enzyme catalyzes the following 
magnesium dependent reversible reaction: ATP + AMP ⇔2 ADP maintaining the ratio 
between AMP and ATP in response to the cellular energy need. To date eight different 
isoforms of adenylate kinases have been discovered in mammalian cells showing 
distinct intracellular compartmentalization, a localization in different tissues and a 
developmentally regulated gene expression (Dzeja and Terzic, 2009). In contrast, two 
adenylate kinases (PfAK1 and PfAK2), a GTP:AMP phosphotransferase (PfGAK) and 
two adenylate kinase-like proteins (PfAKLP1 and PfAKLP2) have been characterized 
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in the malaria parasite P. falciparum to date (Ulschmid et al., 2004; Rahlfs et al., 2009; 
Ma et al., 2012). These findings reveal the need of the parasite for a high level of 
adenylate kinase activity to deal with the increased ATP-turnover rate due to the high 
energy consumption for example during invasion, but also for the biosynthesis of 
macromolecules. Indeed, infected erythrocytes compared to non-infected cells reveal an 
increased glucose uptake, a substrate of the glycolytic pathway, responsible for 
producing high amounts of ATP (Roth, 1990). Differences in the kinetic properties of 
adenylate kinases might be a result of the distinct subcellular localization and in case of 
the mammalian adenylate kinase isoenzymes also might be due to tissue-specificity. 
The mammalian AK1, for example, is mostly found in brain and muscle cells revealing 
its high activity in these cells and also in erythrocytes, whereas mammalian AK2 is 
predominantly found in the intramembrane space of the mitochondria in liver, kidney, 
heart and spleen. Mammalian AK3, however, is largely found in the mitochondrial 
matrix of the liver and the heart and is actually a GTP:AMP phosphotransferase 
showing a high substrate specificity to GTP rather than ATP (Khoo and Russell, 1972; 
Wilson et al., 1976; Tomasselli et al., 1979; Dzeja and Terzic, 2009). P. falciparum 
AK1 exhibits a higher substrate specificity (75 U/mg) compared to AK2 (10 U/mg), 
which might be a result of the distinct subcellular localization (Ulschmid et al., 2004). 
In fact, immunofluorescence analyses with reporter constructs revealed the localization 
of PfAK1, PfAKLP1 and PfAKLP2 in the parasite cytosol. The PfGAK, however, was 
assigned to the mitochondrion of the parasite being a possible homologue to the 
mammalian GAK. More intriguingly, the phenotype of PfAK2 was different, insofar, 
that the observed signal of the chimera was a ring-like structure around the parasite with 
a knob-like protrusion formed towards the PV and the host cell (Ma et al., 2012). The 
amino acid sequence of PfAK2 has a N-myristoylation site and studies on expressed 
recombinant PfAK2 and PfNMT revealed PfAK2 to be a substrate of  
PfNMT (Rahlfs et al., 2009). Further, the group of Becker could also show that 
substitution of the glycine residue by alanine at the N-terminus of PfAK2 changes the 
localization of adenylate kinase 2 to a rather cytosolic signal as observed for PfAK1 
(Ma et al., 2012). These results, taken together, identify PfAK2 as a N-myristoylated 
membrane-bound protein.  
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1.7 Objective 	  
Over the years many studies on the intraerythrocytic stage of the malaria parasite  
P. falciparum have already revealed a great amount of information on protein secretory 
pathways different from the ER/Golgi route as a result of the parasite’s development 
within the red blood cell. However, the secretory pathway of many parasite proteins, 
especially those involved in the pathogenesis, still remain obscure.  
 
This study focuses on the existence of alternative secretory pathways to the classical 
secretory pathway during the intraerythrocytic stage of P. falciparum. A preceding 
proteomic analysis of the parasitophorous vacuole revealed the secretion of parasite 
proteins into the PV, which lack any known signal sequence (Nyalwidhe et al, 
manuscript in preparation). A small percentage of the proteins identified in the PV 
contained a putative myristoylation site, including the P. falciparum ADP-ribosylation 
factor 1 (ARF1) – a protein known to be myristoylated in eukaryotic cells. Since it is 
known that the myristoylation site of ARF1 can anchor this protein to membranes, it 
was hypothesized that this protein might bind to the inner leaflet of the parasite plasma 
membrane and is subsequently flipped over into the PV. In order to validate these 
results on the subcellular localization of PfARF1 reporter construct studies, co-
localization studies, fluorescence analyses and biochemical analyses were performed. In 
parallel to PfARF1, a different study revealed the secretion of another protein into the 
PV, the so-called Pfadenylate kinase 2. Similar to PfARF1, this protein also lacks a 
signal sequence, but contains a N-myristoylation site and was found to be a substrate of 
PfNMT (Ma et al., 2012; Rahlfs et al., 2009). To further validate and investigate the 
subcellular localization of PfAK2 mutagenesis analyses, fluorescence analyses, 
biochemical analyses and a translocation study with the mDHFR fusion system were 
carried out. Finally, the sequences of the N-terminus of PfARF1 and PfAK2 were 
compared to each other to identify possible key differences in their amino acid 
sequences. Potential motifs in the sequence of PfAK2, which might play a role in the 
translocation process of this protein across the parasite plasma membrane, which were 
missing in the sequence of PfARF1, were sought. Subsequently, a chimeric reporter 
construct of the N-terminus of both proteins was designed and analyzed via 
fluorescence and biochemical methods.  
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2 Materials and Methods 
The appliances, materials and chemicals used are listed below, including the reference 
to the companies and the company headquarters they were purchased from.  
2.1 Materials and Chemicals 
2.1.1 Appliances 
 
Appliances Company Company headquarters 
Agarose gel chambers Gibco BRL Neu Isenburg 
Analytical balance 2412 Sartorius Göttingen 
Autoclave Thermo Scientific USA 
Blotting apparatus Phase Lübeck 
Centrifuge (5804R) Eppendorf Hamburg 
Flow Herasafe Thermo Scientific USA 
Gel documentation system INTAS Göttingen 
Electroporator (gene 
PulserII) Bio-Rad USA 
Incubator B5060-EC/CO2 Heraeus Hanau 
Incubator Shaker (G25) New Brunswick Scientific Co USA 
Magnetic columns Miltenyi Biotech Bergisch Gladbach 
Magnetic stirrer IKA Staufen 
Mikro 22 R Centrifuge Hettich Tuttlingen 
PCR cycler Biometra Göttingen 
pH meter  Bio-Rad München 
Powersupply Bio-Rad München 
Precision balance 1205 MP Sartorius Göttingen 
Thermoblock Heidolph Schwabach 
Thermomixer 5436 Eppendorf Hamburg 
VARIO Mac Separator Miltenyi Biotech Bergisch Gladbach 
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Vortexer (Reax 2000) Heidolph Schwabach 
Waterbath Köttermann Uetze/Hänigsen 
 
2.1.2 Materials 
 
Materials Company Company headquarters 
Centrifuge tubes  Eppendorf Hamburg 
Cryotubes Sarstedt Nümbrecht 
Culture flasks (25 cm2 and 
75 cm2) Greiner Frickenhausen 
Erlenmeyer flasks Kobe Marburg 
Electroporation cuvettes Bio-Rad USA 
Exposure cassettes Rego Augsburg 
Falcon tubes Greiner Frickenhausen 
Gel loader tips VWR Darmstadt 
Medical X-ray films RX 
NIF Fuji Japan 
Microscope slides VWR Darmstadt 
Nitrocellulose membrane Schleicher & Schuell Dassel 
Petri dishes VWR/Greiner Darmstadt 
Pipette tips Sarstedt/Greiner Nümbrecht/Frickenhausen 
Plastic material Sarstedt//Greiner Nümbrecht/Frickenhausen 
Whatman paper Schleicher & Schuell Dassel 
 
2.1.3 Chemicals 
 
Chemicals Company Company headquarters 
Agar Roth Karlsruhe 
Agarose Roth Karlsruhe 
Ammonium peroxodisulfate (APS) Roth Karlsruhe 
Ammonium sulfate ((NH4)2SO4) Roth Karlsruhe 
Ampicillin Roth Karlsruhe 
Bovine serum albumin PAA Cölbe 
Calcium chloride (CaCl2) Roth Karlsruhe 
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Chloroform Merck Darmstadt 
Cresol red Sigma Aldrich Taufkirchen 
Diethyl pyrocarbonate (DEPC) Roth Karlsruhe 
Dimethylsulfoxide (DMSO) Fluka Neu-Ulm 
1,4-dithio-DL-threitol (DTT) Fluka Neu-Ulm 
Dipotassium phosphate (K2HPO4) Roth Karlsruhe 
Disodium phosphate (Na2HPO4) Roth Karlsruhe 
Ethanol p.a. (EtOH) Roth Karlsruhe 
Ethidium bromide (EtBr) Sigma Taufkirchen 
Ethylendiamintetra-acetic acid 
(EDTA) Roth Karlsruhe 
EGTA Roth Karlsruhe 
Glutaraldehyde Roth Karlsruhe 
Glycine Roth Karlsruhe 
Glycerol anhydrous AppliChem Darmstadt 
Hoechst 33258 Molecular Probes USA 
Hydrochloric acid 37 % Roth Karlsruhe 
Hydrogen peroxide (H2O2) Merck Darmstadt 
Isopropanol Merck Darmstadt 
Luminol AppliChem Darmstadt 
LB-agar (Lennox) Roth Karlsruhe 
Magnesium chloride (MgCl2) Roth Karlsruhe 
Magnesium sulfate (MgSO4) Roth Karlsruhe 
Methanol Roth Karlsruhe 
Milk powder Roth Karlsruhe 
NNN’N-tetra methylene ethylene 
diamine (TEMED) Roth Karlsruhe 
o-Cresolsulfonephtalein (Cresol red) Sigma Aldrich Taufkirchen 
p-coumaric acid Roth Karlsruhe 
PageRuler Prestained Protein Ladder Fermentas USA 
Pepton Roth  Karlsruhe 
Phenylmethylsulfonyl fluoride 
(PMSF) Serva Heidelberg 
2	  	  Materials and Methods	   28	  
Potassium acetate (CH2CO2K) AppliChem Darmstadt 
Potassium chloride (KCl) Roth Karlsruhe 
Potassium dihydrogen phosphate 
(KH2PO4) 
Roth Karlsruhe 
Protease Inhibitor Cocktail Set III Calbiochem USA 
Proteinase K AppliChem Darmstadt 
RNaseOUT Invitrogen USA 
RostisolV®HPLC Gradient Grade 
Water Roth Karlsruhe 
Rotiphorese Gel 30 Roth Karlsruhe 
Saponin Roth  Karlsruhe 
SOB-Medium Roth Karlsruhe 
Sodium carbonate (Na2CO3) Roth Karlsruhe 
Sodium chloride (NaCl) Roth Karlsruhe 
Sodium sulfite (Na2SO3) Roth Karlsruhe 
Sodium dodecyl-phosphate (SDS) AppliChem Darmstadt 
Sodium hydroxide (NaOH) Merck Darmstadt 
Streptolysin O S.Bhakdi University Mainz 
Sucrose Roth Karlsruhe 
Trichloroacetic acid Roth Karlsruhe 
Tris AppliChem Darmstadt 
Triton X-100 Roth Karlsruhe 
TRIzol® Reagent Invitrogen Groningen 
Urea Roth Karlsruhe 
Yeast extract Roth Karlsruhe 
 
 
2.1.4 Cell Culture Materials 
 
Cell culture materials Company Company headquarters 
AlbuMaxII Invitrogen Groningen 
Blasticidin S InvivoGen USA 
D-Sorbitol Roth Karlsruhe 
Gelafundin B. Braun AG Melsungen 
Giemsa Merck Darmstadt 
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Human erythrocyte 
concentrate (A/rh+ and O/rh+) 
University medical centre 
Marburg, Bloodbank Marburg 
Human Plasma (A/rh+) 
University medical centre 
Marburg/Giessen, 
Bloodbank 
Marburg 
Hypoxanthine PAA Cölbe 
RPMI 1640 Gibco Karlsruhe 
RPMI 1640 PAA Cölbe 
WR99210 Jacobus Pharmaceuticals USA 
 
2.1.5 Molecular Biological Kits 	  
Molecular Kits Company Company headquarters 
Gel Extraction Kit Seqlab Göttingen 
PCR Purification Kit Seqlab Göttingen 
Minipreparation Kit Seqlab Göttingen 
Plasmid Maxi Kit  Qiagen Hilden 
 
2.2 Enzymes 
 
Enzymes Company Company Headquarter 
DNase AppliChem Darmstadt 
KOD DNA polymerase Novagen Darmstadt 
RNase AppliChem Darmstadt 
SuperScriptTM III one-step 
RT-PCR system Invitrogen Groningen 
T4 DNA Ligase Invitrogen Groningen 
Taq DNA polymerase New England Biolabs Schwalbach 
Restriction enzymes (AvrII, 
BsshII, KpnI, XhoI, XmaI,) New England Biolabs Schwalbach 
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2.3 Antibodies 
In the following table the primary and secondary antibodies used are listed, with a 
reference to the source of supply. 
 
Primary antibody 
Dilution 
factor  
(IFA) 
Dilution factor 
(Western 
blotting) 
 
Obtained from 
Chicken anti-GFP (polyclonal) 1:500 --- abcam 
Mouse anti-GFP (monoclonal) --- 1:1000 abcam 
Mouse anti-Band3 (monoclonal) --- 1:1000 Sigma aldrich 
Rabbit anti-aldolase (polyclonal) --- 1:5000 Group Lingelbach 
Rabbit anti-ARF (polyclonal) 1:2000 1:1000 Group Holder 
Rabbit anti-Exp1 (polyclonal) --- 1:500 Group Lingelbach 
Rabbit anti-SERP (polyclonal) --- 1:1000 Group Lingelbach 
 
 
Secondary antibody Company Company Headquarter 
Goat anti-chicken Cy2 JacksonImmunso Research Laboratories USA 
Goat anti-mouse HRP DAKO Glostrup 
Goat anti-rabbit HRP DAKO Glostrup 
Swine anti-rabbit HRP DAKO Glostrup 
 
2.4 Solutions and buffers 
In this section the solutions and buffers used for molecular biological and 
proteinbiochemical work are listed.  
Solutions and buffers Individual components 
Ammonium peroxodisulfate (APS) 10 % in ddH20 
Ampicillin stock: 50 mg/ml  working concentration: 50 µg/ml  
Blocking solution for IFA 3 % BSA in PBS (pH 7.4) 
Blocking solution for western blotting 5 % milk powder in PBS (pH 7.4) 
Colony mix 
1 ml Cresol red solution 
600 µl Taq buffer (10 x) 
120 µl dNTPs 10 mM 
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4.28 ml water, sterile 
Cresol red solution 
0.1 g o-Cresolsulfonephtalein 
60 % sucrose 
Developer (X-ray) 
 6.4 mM Metol 
80 mM Hydroquinone 
571 mM sodium sulfite (Na2SO4) 
452 mM sodium carbonate (Na2CO3) 
34 mM potassium bromide (KBr) 
DNA extraction buffer A 
100 mM sodium chloride (NaCl) 
50 mM sodium acetate (NaOAc), pH 5.2 
1 mM EDTA 
DNA loading dye (6x) 
1 % bromophenol blue 
30 % glycerol 
50 mM Tris/HCl, pH 8 
5 mM EDTA 
ECL solution 
5 mM Luminol 
0.8 mM p-coumaric acid 
200 mM Tris/HCl pH 8.5 
Electrophoresis running buffer 
124 mM Tris 
960 mM glycine 
0.05 % SDS 
Fixation buffer 
4 % paraformaldehyde 
0.00075 % glutaraldehyde 
in PBS (pH 7.4) 
Permeabilization buffer 0.1 % Triton X-100 in PBS (pH 7.4) 
Phosphate buffered saline (PBS) 
140 mM sodium chloride (NaCl) 
2.7 mM potassium chloride (KCl) 
1.4 mM monopotassium phosphate 
0.8 mM disodium phosphate 
Ponceau S staining solution 
0.2 % Ponceau S 
3 % trichloroacetic acid 
Quenching buffer 125 mM glycine in PBS (pH 7.4) 
Sample buffer (2x) for proteins 
100 mM Tris/HCl pH 6.8 
5 mM EDTA 
20 % glycerol 
4 % SDS 
0.2 % bromphenolblue 
100 mM dithiothreitol  
Separating buffer (4x) 1.5 M Tris/HCl pH 8.8 
Stacking buffer (4x)  
500 mM Tris/HCl pH 6.8 
0.4 % SDS 
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Taq buffer (10x) 
200 mM Tris/HCl pH 8.8 
100 mM potassium chloride (KCl) 
100 mM ammonium sulfate 
20 mM magnesium sulfate (MgSO4) 
1 % Trion X-100 
TE-buffer (10 x) 
890 mM Tris 
890 mM acetate 
20 mM EDTA 
Western blot transfer buffer 
48 mM Tris/HCl pH 9.5 
39 mM glycine 
0.04 % SDS 
20 % methanol 
 
The media used for culturing and growing bacteria are listed in the following: 
 
Media Individual components 
LB (Luria-Bertani)-agar 35 g/l LB agar 
SOC-medium 
SOB medium (autoclaved) 
20 mM glucose (sterile filtered) 
Super broth medium, pH 7.0 
35g/l tryptone 
20 g/l yeast extract 
5 g/l sodium chloride 
5 ml/l sodium hydroxide 
 
The solutions used for culturing P. falciparum are listed in the following:  
 
Solutions Individual components 
Blasticidin S hydrochloride 
Stock solution: 10 mg/ml 
working concentration: 4 µg/ml 
Cytomix  
120 mM KCl  
0.15 mM CaCl2 
2 mM EGTA 
10 mM K2HPO4/KH2PO4, pH 7.6 
25 mM HEPES, pH 7.6 
Freezing solution 
28 % glycerol 
3 % d-sorbitol 
0.65 % sodium chloride 
RPMI medium 
500 ml RPMI medium supplemented with 
- 50 ml of heat-activated human plasma 
- 20 µg/ml neomycin 
- 200 µM hypoxanthine 
Thawing solution I.   12 % sodium choride (NaCl) 
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II.  1.6 % sodium chloride (NaCl) 
III. 0.9 % sodium chloride, 0.2 % glucose 
WR99210 
20 mM stock (8.6 mg in 1ml DMSO) 
working concentration: 5 nM 
 
2.5 Vectors and oligonucleotides  
2.5.1 Vectors 	  
The following table displays the basic vectors used for this study. 
Basic vectors Selectable marker Resistance Tag Reference 
pARL2_GFP β-Lactamase, DHFR 
Ampicillin, 
WR99210 GFP 
J. Przyborski,  
N. Gehde 
pARL2_mCherry_BSD 
β-Lactamase, 
Blasticidin S 
deaminase 
Ampicillin, 
Blasticidin mCherry 
J. Przyborski, 
S. Külzer 
 
2.5.2 Oligonucleotides 	  
The following oligonucleotides were designed for this study and purchased from 
Eurofin MWG Operon. The restriction sites are underlined and the mutations introduced 
by site-directed mutagenesis in the following nucleotide sequences are highlighted. 
 
Denotation Primer sequence 5’à3’ 
Oligonucleotides used for the vectors 
pARL_F CGTTAATAATAAATACACGCAG 
pARL_R GGCGGATAACAATTTCACACAGG 
GFP+54_R GTGCCCATTAACATCACCATC 
Prefoldin subunit, putative (PF3D7_0904500) 
Pref_XhoI_F GGCTCGAGATGGGTGATATAAAACAAAACAAATATG 
Pref_XhoI_F_G2A GGCTCGAGATGGCTGATATAAAACAAAACAAATATG 
Pref_AvrII_R GGCCTAGGATTAAGATCTATCCTATTTCCAAACTTC 
Calcium dependent protein kinase 4 (PF3D7_0717500) 
CDPK4_XhoI_F GGCTCGAGATGGGACAAGAGGTATCGAG 
CDPK4_XhoI_F_G2A GGCTCGAGATGGCACAAGAGGTATCGAG 
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CDPK4_AvrII_R GGCCTAGGATAATTACAAAGTTTGACTAGCATATCC 
ADP-ribosylation factor 1 (PF3D7_1020900) 
ARF1_XhoI_F GGCTCGAGATGGGTTTATATGTAAGTAGGTTATTTAATCG 
ARF1G2A_XhoI_F GGCTCGAGATGGCTTTATATGTAAGTAGGTTATTTAATCG 
ARF1_AvrII_R GGCCTAGGTTTGGCATTATTTAAGTGTGTGGTTAGC 
ARF11-17/+ C4/-V5/AK2+18-
37 _XhoI (F) _ KpnI (R) 
(produced by GeneArt® 
Gene Synthesis) 
GGCTCGAGATGGGTTTATGCTATAGTAGGTTATTTAATC
GTTTATTTCAAAAGAAAGATGAAGAGGAAAAAAAGAA
GAGAAAAAAAAGAAAAAGAAAATATATATTTTAAATG
GAGCAGGTACCGC 
Adenylate kinase 2 (PF3D7_0816900) 
AK2_XhoI_F GGCTCGAGATGGGATCATGTTATAGTAGAAAAAATAAA 
AK2G2A_XhoI_F GGCTCGAGATGGCATCATGTTATAGTAGAAAAAATAAA 
AK2C4A_XhoI_F GGCTCGAGATGGGATCAGCTTATAGTAGAAAAAATAAA 
AK2G2AC4A_XhoI_F GGCTCGAGATGGCATCAGCTTATAGTAGAAAAAATAAA 
AK2_AvrII_R GGCCTAGGATTGGGGTTATCATCTATAATGGAG 
AK2(Δ21-30)_F_oe-PCR* CATTAGATGAAGAGGAAATATATATTTTAAATGGAGCATCTGGG 
AK2(Δ21-30)_R_oe-PCR* GATGCTCCATTTAAAATATATATTTCCTCTTCATCTAATGATATTGTTG 
AK21-37_KpnI_R GGGGTACCTGCTCCATTTAAAATATATATTTTTTTTTTCTTCTT 
Exported-protein1 (PF3D7_1121600) 
Exp1_XhoI_F CGCTCGAGATGAAAATCTTATCAGTATTTTTTC 
Exp1_AvrII_R GCCTAGGGTGTTCAGTGCCAGTTACGAGG 
* primers for overlapping-extension PCR (oe-PCR) 
 
 
2.5.3 Plasmids designed for this work 	  
The following table comprises the plasmids generated for this work. The basic vectors 
were used as backbone and the nucleotide sequences were introduced into these vectors. 
 
Vector 
Proteins 
selected/mutated/ 
detection system  
 
Origin 
pARL2_Pref_GFP Chaperone this work 
pARL2_mPref_GFP *G2A mutation this work 
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pARL2_CDPK4_GFP Kinase this work 
pARL2_mCDPK4_GFP *G2A mutation this work 
pARL2_ARF1_GFP GTPase, wildtype this work 
pARL2_ARF1G2A_GFP *G2A mutation this work 
pARL_AK2_GFP Kinase, wildtype Group Becker, Giessen 
pARL_AK2G2A_GFP *G2A mutation Group Becker, Giessen 
pARL2_AK2C4A_GFP ǂC4A mutation this work 
pARL2_AK2G2AC4A_GFP *G2AǂC4A mutation this work 
pARL2_AK2(Δ21-30)_GFP Deletion of polybasic amino acids (Δ 21-30) this work 
pARL2_AK21-37_GFP 1-37 amino acids of  N-terminus of AK2 this work 
pARL2_ARF11-17/+C4/-V5AK2+18-
37_GFP 
GTPase, ǂC4 addition, 
removal of V5, 
addition of polybasic 
cluster of AK2  
this work 
pARL2_AK2_mDHFR Kinase, wildtype this work 
pARL2_Exp1_mCherry_BSD PVM-marker this work 
pARL2_Grasp1_mCherry_BSD cis-Golgi-marker J. Riedel, bachelor thesis 
pARL2_Rab6_mCherry_BSD trans-Golgi-marker J. Riedel, bachelor thesis 
pARL2_Sec12_mCherry_BSD ER-marker J. Riedel, bachelor thesis 
*G2A = glycine replaced with alanine at 2nd position at the N-terminus 
ǂC4A = cysteine replaced with alanine at 4th position at the N-terminus 
 
 
2.6 Cells and Organisms 	  
Strain Genotpye Reference 
E. coli TOP 10 --- Invitrogen 
 
P. falciparum 3D7 
Clone derived from NF54 
(isolated in the 
Netherlands) 
The Walter and Eliza 
Insitute of Medical 
Research, Melbourne, 
Australia 
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2.7 Bioinformatics 
In silico analyses of the nucleotide sequences and the resulting proteins were performed 
using the following databases.  
Genetic databases websites 
BLAST http://blast.ncbi.nlm.nih.gov/Blast.cgi 
ClustalW http://www.ebi.ac.uk/Tools/msa/clustalw2 
ExPASy http://www.expasy.org/ 
GeneDB http://www.genedb.org/Homepage 
OrthoMCL DB http://orthomcl.org/orthomcl/ 
PlasmoDB http://plasmodb.org/plasmo/ 
SignalIP http://www.cbs.dtu.dk/services/SignalP/ 
 
2.8 Cell culture techniques 
2.8.1 In-vitro cultivation of Plasmodium falciparum  
All of the work was performed with the Plasmodium falciparum strain 3D7. The 
genome sequence of this clone, which was isolated from a patient in Amsterdam was 
analyzed by Gardner and his colleagues in 2002 (Gardner et al., 2002). 
 
Asexual stages of P. falciparum were cultivated in suspension culture flasks in A+ 
human erythrocytes at a hematocrit of 4 % and in RPMI medium, which was 
supplemented with 0.2 % hypoxanthine, 10 % human plasma and 0.1 mg/ml neomycin 
(stock 10 mg/ml) according to Trager and Jensen (Trager and Jensen, 1976). The culture 
was maintained at 37 °C and gassed with 90 % N2, 5 % O2 and 5 % CO2 in an incubator.  
The parasitemia was checked by Giemsa-stain every day. Therefore a blood-drop from 
the suspension culture was taken from the bottom of the flask and smeared onto the 
slide. The smear was air-dried, fixed in MetOH for 30 seconds and then stained with a 
diluted Giemsa-solution (1:10 in H2O) for at least 10 minutes. The Giemsa-stain was 
washed off the slide and the parasitemia was checked with a light microscope using 
immersion oil for a 100 x magnification of the specimen. The ratio of infected to non-
infected cells was calculated after looking at different optical sections of the slide and 
the parasitemia was determined. The culture was then further cultivated, accordingly. 
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Synchronized cultures at ring-stage were split only when they reached a parasitemia 
above 10 %, while cultures containing late-stage parasites, were split when reaching a 
parasitemia above 5 %. A high parasitemia was only maintained when the infected cells 
were harvested shortly after for experiments. 
2.8.2 Synchronization of Plasmodium falciparum with Sorbitol 
Sorbitol synchronization of parasites was performed on a mainly ring-infected culture to 
eliminate mature parasites based on the increased permeability of erythrocytes infected 
with late-stage parasites compared to ring-stage parasites. As a result, highly 
synchronized ring-stage parasites were obtained for further cultivation (Lambros and 
Vanderberg, 1979). The culture was centrifuged at 1,600 x g for 2 minutes before the 
cell pellet was resuspended in 5 % Sorbitol-solution and incubated for  
8 minutes at room temperature. Once the incubation was over, the entire mixture of 
Sorbitol and cells was spun at 1,600 x g for 2 minutes, and washed 2-3 times with RPMI 
before being further cultured.  
2.8.3 Enrichment of trophozoite-stage parasites via Gelafundin flotation  
Trophozoite-stage parasites were required and used for most of the experiments. That is 
why Gelafundin-based synchronization of trophozoite-infected cells was performed 
(Pasvol et al., 1978). Therefore a culture containing initially about 5 % late-stage 
parasites was sedimented in a centrifugation step, and the pellet was resuspended in  
8 ml of the Gelafundin-solution and incubated for 10 minutes at 37 °C in a water bath. 
During the incubation time knob-associated cells float into the upper phase of the 
Gelafundin cell mixture, while non-infected and ring-stage parasites are found at the 
bottom. The upper-phase, containing enriched trophozoite-infected cells, was 
transferred to a new tube and spun at 1,600 x g for 2 minutes. The pellet obtained was 
resuspended in RPMI and the parasitemia was determined. The volume of RPMI added 
to the pellet equalled 10 x the volume of the pellet. Usually a 50 – 60 % enrichment of 
trophozoites after Gelafundin treatment was achieved. 
2.8.4 High enrichment of late-stage parasites using a high gradient magnetic field 
A different method to obtain highly enriched parasites at late-stage was the application 
of a high gradient magnetic field. This method enables a high synchronization and 
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enrichment of late-stage parasites based on the property of the malaria parasite to digest 
hemoglobin (Fe(II) diamagnetic complex) to hemozoin (Fe(III) paramagnetic complex). 
The paramagnetic properties of hemozoin are used to isolate Plasmodium-infected red 
blood cells at late-stage in the presence of a high magnetic field (Paul et al., 1981). 
For the magnetic isolation of parasitized red blood cells a VarioMACS Separator 
(Miltenyi Biotec) and the appropriate magnetic columns (MACS; CS columns, Miltenyi 
Biotec), were used. Prior to magnetic isolation, the column was washed with 3 % BSA 
(dissolved in PBS, pH 7.4) and was fitted into the VarioMACS separator. The culture 
should contain initially a parasitemia of around 3-5 % infected cells at late stage. The 
culture was transferred from the flask into a 50 ml tube and then poured on the top of 
the CS column. The CS columns are composed of ferromagnetic fibers and when fitted 
to the VarioMACS Separator, the magnetic field is amplified, evoking a high gradient 
within the column. This allows an increased magnetic isolation of parasitized red blood 
cells. Once the entire culture was passed through the column, the column was washed 
with pre-warmed PBS (pH 7.4) until the eluent was free from red blood cells. The 
column was removed from the VarioMACS Separator and fitted into a bracket fixed to 
a stand and eluted with 2 x 15 ml PBS (7.4) in a 2 x 15 ml falcon tube. The eluent was 
centrifuged at 1,600 x g for 3 minutes, and the pellet from both tubes were pooled 
together, washed twice with pre-warmed RPMI medium before a blood-smear of 5 µl 
was prepared. The parasitemia, when using magnet-based isolation of infected cells, 
was always around 80 %.  
2.8.5 Transfection and Co-transfection of Plasmodium falciparum 
Transfection was performed with Plasmodium-infected erythrocytes at ring-stage with a 
parasitemia of 5 – 10 % (Wu et al., 1995). Plasmid-DNA (100 µg) was prepared by 
ethanol precipitation, air-dried and subsequently resuspended in 30 µl TE buffer. The 
DNA was properly mixed and dissolved at 50 °C before 370 µl of cytomix and 200 µl 
of ring-stage infected cells were added. The whole mixture was transferred to a 0.2 cm 
gap electroporation cuvette and pulsed at 0.310 kV at 950 µF (high capacitance). The 
time constant was always between 8 – 12 msec. Once electroporation was carried out, 
the cells were transferred to a 25 cm2 cell culture flask containing 12 ml of pre-warmed 
RPS (Gibco) media and 400 µl O+ erythrocytes. The media used for transfection was 
supplemented with 5 % human plasma, 0.25 % AlbuMax, hypoxanthine and neomycin. 
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The culture was maintained at 37 °C in an incubator. After 4-8 hours the appropriate 
drug, depending on the selection cassette integrated into the plasmid, was added to the 
culture. Either the parasites were selected with 5 nM WR99210, when the hDHFR was 
expressed or 4 µg/ml of BSD was added to the culture, when Blasticidin S deaminase 
was expressed from the selection cassette. In the first five days after transfection the 
medium was changed daily and the appropriate drug was added to the cells. Once no 
live parasites could be seen, the medium was only changed twice a week and the blood 
(O+ erythrocytes) was changed every two weeks after transfection. The parasites were 
held under drug pressure. Once parasites were seen, which usually took 2-3 weeks, 
three to five aliquots with a parasitemia of 5 -10 % were frozen as stocks. When the 
parasitemia was about 5 %, the parasites were transferred from a 25 cm2 to a 75 cm2 
culture flask and were cultured in RPMI medium and A+ erythrocytes.  
Co-transfection was performed as follows: P. falciparum ring-stage parasites were 
transfected successively with each of the constructs (construct 1 and construct 2, each 
containing a different selection cassette and a different gene of interest). Once one of 
the transfectants containing for example construct 1 started growing these parasites 
were synchronized with Sorbitol or Gelafundin. The synchronized ring-stage parasites 
can then be transfected with construct 2, containing a different gene of interest and 
another selection cassette. These newly co-transfected parasites were then kept under 
drug selection of WR99210 and BSD and after 2-3 weeks the co-transfected parasites 
started growing expressing both proteins from each constructs.  
2.8.6 Cryopreservation of Plasmodium falciparum-infected erythrocytes 
An in-vitro culture of P. falciparum-infected red blood cells was frozen at ring-stage 
when a parasitemia of 5 -10 % was reached. The whole culture was centrifuged at  
1,600 x g for 2 minutes and the cell sediment was mixed in a ratio of 1:1 with a freezing 
solution, transferred to a cryotube and instantly snap-frozen in liquid nitrogen. The 
cryotube containing the frozen cells was incubated for about 10 minutes in liquid 
nitrogen before being put into long-term storage in a liquid nitrogen tank. 
2.8.7 Thawing of cryopreserved Plasmodium falciparum-infected erythrocytes 
The snap-frozen parasites in a cryotube were thawed at room temperature and 
transferred to a 15 ml tube. 200 µl of solution I containing 12 % sodium chloride 
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dissolved in ddH2O (autoclaved) was added dropwise to the thawed parasites. After an 
incubation time of 3 minutes, 5 ml of solution II containing 1.6 % sodium chloride 
dissolved in ddH2O (autoclaved), was added dropwise to the cells. The cells were 
incubated again for 3 minutes at room temperature before solution III containing 0.9 % 
sodium chloride dissolved in ddH2O (autoclaved) mixed with 0.2 % glucose dissolved 
in ddH2O (sterile filtered), was added to the thawed cells drop by drop. Once the 
incubation time of 3 minutes was over, the cells were sedimented at 1,600 x g for  
2 minutes and washed twice with pre-warmed RPMI medium before being transferred 
to a new flask for culturing. Thawed transfectants were subjected to the appropriate 
drug 24 hours later after thawing. 
 
2.9 Molecularbiological methods 
2.9.1 Cultivation of Escherichia coli 
E.coli strain Top10 was grown in the common bacterial growth medium Super Broth 
liquid, supplemented with the antibiotic ampicillin to a final concentration of 50 µg/ml 
for selection. LB-agar (Luria-Bertani) was used as a growth substrate for culturing 
bacteria on a solid medium. 
Liquid cultures of E. coli were inoculated with the clone containing the desired plasmid 
and grown overnight at 37 °C with constant shaking. Plasmid DNA preparation was 
performed either in a small-scale (mini preparation) or large-scale (maxi preparation) 
isolation process. 
2.9.2 Preparation of electrocompetent bacterial cells (E. coli strain TOP10) 
A single colony of E. coli TOP10 was used to inoculate 10 ml of Super Broth at 37 °C 
to set up an overnight preculture. 600 ml of Super Broth were then inoculated with 6 ml 
of the preculture until the cells were grown to an OD of 0.6, which took about  
3.5 hours with constant shaking at 37 °C. The cells were then harvested at 6,000 x g for 
10 minutes at 4 °C. The supernatant was discarded and the pellet was resuspended in 
600 ml ddH2O and harvested again. This step was repeated three times before washing 
the pellet a final time with 600 ml of 10 % glycerol/ddH2O. The cells were kept on ice 
during the whole procedure. Finally, the pellet was resuspended in 1.2 ml of ice-cold  
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10 % glycerol. Aliquots of 100 µl were made using sterile 1.5 ml reaction tubes, snap 
frozen with liquid nitrogen and stored at – 80 °C.  
2.9.3 Mini- and Maxipreparation for isolation of plasmid DNA  
Plasmid DNA from E. coli was isolated using Plasmid-preparation kits from Qiagen 
according to the manufacturer’s protocols. The main steps in the isolation of plasmid 
DNA involve the disruption of the bacterial cells by alkaline lysis and neutralization of 
the lysate. A silica membrane column is used for the binding of the plasmid DNA from 
the cleared lysate, which is subsequently eluted in TE-buffer (Qiagen Protocol).  
To obtain plasmid DNA, using the Maxipreparation procedure, the bacterial pellet was 
resuspended in twice the volume recommended by the manufacturer’s protocol of the 
buffers P1, P2 and P3 (Przyborski et al., 2005).  
2.9.4 Transformation of E. coli cells 
E.coli TOP10 cells were transformed with plasmid DNA using electroporation. 50 µl of 
the electrocompetent cells were thawed on ice and then mixed with the ligation reaction. 
The ligation reaction contained the plasmid DNA, which was purified by precipitation 
with EtOH as described in section 2.9.13 and was then resuspended in 10 µl ddH2O. 
The mixture of electrocompetent cells and DNA-solution was then transferred to a pre-
cooled electroporation cuvette and pulsed by a voltage of 2 kV, with a capacitance of  
25 µF and a resistance of 200 Ω. Immediately after electroporation the cells were 
resuspended in pre-warmed SOC medium and incubated in a shaker at 37 °C for 1 hour. 
100 µl of the cell suspension was plated on a pre-warmed LB agar plate supplemented 
with ampicillin. The rest of the cell suspension was harvested by 1,000 x g for 2 
minutes to reduce the volume before plating. The plates were incubated at 37 °C 
overnight.  
2.9.5 Isolation of genomic DNA from Plasmodium falciparum 
Isolation of genomic DNA was performed with trophozoite stages of P. falciparum. The 
parasitemia was about 5–10 %, before the parasites were isolated from infected 
erythrocytes by saponin lysis at a final concentration of 0.1 %. The pellet was washed a 
couple of times before it was resuspended in 200 µl PBS (pH 7.4). In the next step, 2 x 
DNA extraction buffer A and 100 µl of 20 % SDS were added to the sample, mixed by 
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inversion before being extracted with an equal amount of phenol-chloroform followed 
by centrifugation at 28,600 x g for 30 minutes. The phenol-chloroform extraction leads 
to a separation between DNA and proteins, by which the DNA can be found in the 
upper phase. The DNA in the upper phase was transferred to a new 1.5 ml tube, 
precipitated with ethanol, and dissolved in 500 µl TE-buffer (pH 8.0). The DNA-
solution was then subjected two more times to phenol-chloroform extraction with a 
subsequent centrifugation step at 28,600 x g for 30 min to gain more purified DNA by 
removing all the other cell constituents. The top phase was collected and chloroform 
extraction was performed one more time to remove all the phenol left in the sample. In a 
final step the upper phase was collected once again and precipitated with ethanol before 
being dissolved in 50-100 µl TE-buffer (pH 8.0).  
2.9.6 Isolation of mRNA from Plasmodium falciparum 
Similar to the isolation of genomic DNA from P. falciparum RNA was obtained by 
saponin treatment of late-stage Plasmodium-infected cells. Therefore, a total of  
2 x 108 cells were subjected to 0.1 % saponin and incubated on ice for 5 min followed 
by a centrifugation step at 2,500 x g for 5 minutes. The supernatant was discarded and 
the pellet was washed twice with PBS (pH 7.4) before resuspending the pellet in 
preheated Trizol reagent. The pellet dissolved in Trizol was then incubated on a 
Thermomixer at 37 °C for 5 minutes. 200 µl of chloroform was added to the pellet, 
mixed and spun at 28,600 x g for 30 min. The supernatant was removed and the pellet 
was washed with 70 % ethanol several times, before the pellet was air-dried. Finally, the 
pellet was dissolved in an appropriate amount of DEPC-treated water and 1 µl of 
RNaseOUT was added. RNaseOUT is a non-competetive inhibitor, which inhibits 
RNase A, RNase B and RNase C.  
2.9.7 Quantification of nucleic acid  
DNA and RNA, respectively, absorb UV light. That is why the concentration of nucleic 
acids can be determined using a spectrophotometer. The optical density (OD) is 
measured at 260 nm using a quartz cuvette. An absorbance unit of 1 at 260 nm 
correlates to 50 µg/ml of double-stranded DNA and 40 µg/ml of RNA, respectively.  
If the DNA is not contaminated with proteins the OD at 260 nm/280 nm ratio will be 
1.8. A lower ratio, however, indicates a low contamination of the DNA.  
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2.9.8 Reverse transcriptase PCR  
Following isolation of total RNA from P. falciparum as described in 2.9.6 the mRNA 
was transcribed into cDNA by reverse transcriptase (RNA-dependent DNA 
polymerase). In vitro amplification of the coding sequences was performed in one-step 
using the SuperScript III one-step RT-PCR kit (Invitrogen), a system, which combines 
two enzymes, the SuperScript Reverse Transcriptase and the Taq High Fidelity enzyme. 
Initially the mRNA is converted into the single-stranded cDNA template at 45–60 °C 
degrees by the SuperScript Reverse Transcriptase, before the cDNA is used as a 
template for the Taq High Fidelity enzyme. The cycling conditions were set according 
to the primer annealing temperature and the size of the target sequences.  
Table 2.1 Standard reaction mix for cDNA synthesis 
Reagent Volume 
2 x reaction mix 25 µl 
sense primer (50 pmol/µl) 1 µl 
anti-sense primer (50 pmol/µl) 1 µl 
template (approximately 1 µg/µl) 1 µl 
SuperScript III RT / Platinum Taq 
Polymerase High fidelity enzyme mix 2 µl 
autoclaved distilled water to 50 µl 
 
 
Table 2.2 Standard program for cDNA synthesis followed by PCR amplification 
Reaction Temperature Time Cycles 
1. cDNA synthesis 50 °C 30 min 
1 
2. pre-denaturation 94 °C 2 min 
3. denaturation 94 °C 15 sec 
 
39 4. annealing 55 °C 30 sec 
5. extension 68 °C 1 min/kb 
6. final extension 68 °C 5 min 1 
7. end of program 4 °C --- --- 
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2.9.9 Polymerase chain reaction 
The polymerase chain reaction was performed according to Mullis and colleagues 
(Mullis et al., 1986). The oligonucleotides for in-vitro amplification of DNA- and RNA-
fragments were ordered from Eurofins MWG Operon and the list of primers can be 
found in section 2.5.2. The oligonucleotides were chosen according to a melting 
temperature between 50 °C – 65 °C, which was determined using the program 
Oligonucleotide Property Calculator. The stock-solution of the oligonucleotides was 
adjusted to 50 pmol/µl with DEPC-treated water and stored at -20 °C. 
 
DNA-fragments, which were required for further cloning, were amplified using the 
KOD Hot Start DNA Polymerase. For colony PCR, however, the Taq polymerase was 
used, since a proofreading activity of the polymerase was not required (colony PCR: 
section 2.9.16). The cycling conditions were set according to the primer annealing 
temperature and the size of the target sequences.  
Table 2.3 Standard reaction mix for PCR with KOD Hot Start DNA Polymerase 
Reagent Volumina 
10 x PCR buffer for KOD Hot Start DNA 
Polymerase 5 µl 
MgSO4 (25 mM) 3 µl 
dNTP (2 mM each) 5 µl 
sense primer (50 pmol/µl) 1 µl 
anti-sense primer (50 pmol/µl) 1 µl 
template (approx. 1 -200 ng/µl) 1 µl 
KOD Hot Start DNA Polymerase (1 U/ µl) 1 µl 
ddH2O (autoclaved) to 50 µl 
total amount 50 µl 
 
Table 2.4 Standard PCR program with KOD Hot Start DNA Polymerase 
Reaction Temperature Time Cycles 
1. activation 95 °C 2 min  
2. denaturation 95 °C 20 sec  
35 
 3. annealing 50 °C 30 sec 
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4. extension 72 °C 20 sec /1 kb 
5. final extension 68 °C 10 min  
6. end of program 4 °C ---  
 
Table 2.5 Colony PCR program with Taq polymerase 
Reaction Temperature Time Cycles 
1. denaturation 94 °C 2 min  
2. denaturation 94 °C 15 sec 
 
25 3. annealing 50 °C 30 sec 
4. extension 72 °C 60 sec /1 kb 
5. final extension 68 °C 10 min  
6. end of program 4 °C ---  
 
2.9.10 In-vitro site-directed mutagenesis 
In-vitro site directed mutagenesis is a technique used to introduce mutations like point-
mutations, deletions or insertions into the gene of interest. To obtain a deletion mutation 
via site-directed mutagenesis, two internal primers in addition to the flanked primers 
(forward and reverse primer), were required. As internal primers oligonucleotides were 
designed missing the bases to be deleted. These primers were designed to be 
complementary to the target sequence lacking the amino acids to be deleted and they 
were partially complementary to each other in order for them to hybridize in a final 
PCR reaction. In the first step, two PCR reactions were performed separately from each 
other according to the PCR standard program: the first PCR reaction mix contained the 
flanked forward primer and the internal reverse primer, while the second PCR reaction 
mix contained the internal forward primer and the flanked reverse primer. Initially, the 
5’à3’ part of the gene was amplified in each of the PCR reaction producing fragments 
with complementary overhangs, which then can hybridize in a final PCR reaction. 
Therefore the amplified products from each of the PCR reactions were mixed in a ratio 
of 1:1 being the template for the final PCR. The mutated DNA sequence was then 
amplified using both of the flanked primers (see Fig. 2.1) (Ho et al., 1989).  
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2.9.11 Agarose gel electrophoresis 
Agarose gel electrophoresis was used to separate DNA fragments based on their size. 
This method relies on the migration of negatively charged DNA in an electrical field 
towards a positive pole using agarose gel as medium (Sambrook and Russell, 2001). 
The DNA samples were mixed with 6 x times loading buffer and depending on the 
expected size of the DNA the DNA fragments were separated in an agarose gel at 
concentrations ranging from 0.8 – 1.0 %. Agarose was made by mixing agarose powder 
with 1 x TAE buffer, which was also used as electrophoresis buffer and heated in a 
microwave until complete melting. Ethidium bromide was added to a final 
concentration of 0.5 µg/ml. Ethidium bromide is a fluorescent dye, which intercalates 
with DNA molecules and enables the visualization of DNA fragments in a gel when 
exposed to UV-light. To determine the size of the DNA fragments ranging from 100 bp 
to 12 kb 5 µl of a DNA ladder was added to the gel as well and the gel was run at 90 V 
for 20 – 40 minutes, depending on size of the DNA fragments to be analyzed. The gel 
was visualized with an ultraviolet transilluminator and pictures were taken with the Gel 
IX Imager.  
2.9.12 Purification of DNA 
DNA purification, after amplification by PCR or restriction digests, was performed 
using a PCR purification kit (Seqlab) according to the manufacturer’s protocol; 
alternatively, the desired DNA fragment ('band') was excised from an agarose gel and 
then purified with a gel-extraction kit (Seqlab) following the manual of the supplier.  
2.9.13 Ethanol precipitation of DNA 
Precipitation of DNA with ethanol is required to concentrate DNA in aqueous solutions. 
Since ethanol is less polar than water nucleic acids are less soluble in ethanol. In the 
presence of ethanol and salt DNA tends to fall out of solution. Therefore 2 volumes of 
100 % ethanol and 1/10 volume of sodium acetate (pH 5.2) was added to the DNA, 
mixed well and spun at 33,000 x g for 20 min at 4°C. The supernatant was removed and 
the pellet was washed with 70 % ethanol at 28,600 x g for 20 minutes at 4 °C before 
being air-dried and dissolved in either ddH2O or TE-buffer.  
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2.9.14 Restriction of DNA 
Restriction of DNA was performed using specific restriction endonucleases, which are 
able to recognize, bind and cut to specific recognition sites in the DNA. Digestion of 
plasmids and PCR products was performed in a total volume of 10 – 30 µl, respectively, 
with the appropriate restriction enzymes, a suitable buffer and if required 1 mg/ml of 
BSA. Incubation times and temperature varied depending on the restriction enzymes 
used. Subsequently, the digested DNA was purified using a PCR purification kit 
(Seqlab) and analyzed by agarose gel electrophoresis. 
2.9.15 Ligation of DNA 
Insert and vector, which were digested with the same restriction enzymes creating 
matching sticky ends, were ligated in the general molar ratio of 3:1 (insert:vector). The 
ligation reaction was performed overnight at 16 °C in a total volume of 20 µl using 1 U 
of the T4 DNA ligase (Invitrogen) and a 5 x suitable ligase buffer (Invitrogen). Usually 
100 ng of the vector was used for the ligation reaction and the required amount of insert 
could be calculated according to the following formula:  
 
100 ng Vector * Insert (kb) * 3 = Insert (ng) 
Vector (kb) 
 
 
Subsequently, the DNA was ethanol-precipitated (section 2.9.13) and dissolved in 10 µl 
ddH2O before transformation of electrocompetent E. coli cells was performed (section 
2.9.4). 
2.9.16 Screening for positive clones with colony PCR  
Colony PCR enables the screening of E. coli colonies after transformation for 
identification of those clones containing the desired plasmid insert. Therefore a single 
bacterial clone on an agar plate was first transferred to a replica plate, before being 
added to the PCR reaction mix as the template. Cresol red was used as loading dye. The 
oligonucleotides selected were both the forward or reverse primer of the insert and the 
forward or reverse primer starting from a region inside the vector, respectively. The 
colony PCR was performed in a total volume of 25 µl containing the concentration of 
the dNTPs, the Taq polymerase, the Taq buffer and the primers in proportion to a 
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standard PCR (Table 2.4). The PCR program was similar to the standard PCR program, 
except for the reduction in the number of cycles to 25 (Table 2.5).  
2.9.17 Sequencing of DNA 
Plasmids sent for sequencing were isolated and purified with a purification kit from 
Seqlab according to the manufacturer’s protocol. Samples were sequenced either at 
Seqlab Sequence Laboratories (Göttingen GmbH) or at GATC Biotech (Konstanz).  
2.9.18 Generation of plasmid constructs for transfection 
2.9.18.1 Overview of the vector used 
The following vectors were designed by J. Przyborski, N. Gehde and Simone Külzer. 
The pARL2_GFP vector contains the coding region for the human dihydrofolate 
reductase, which confers resistance to WR99210. The pARL_mCherry vector contains 
the coding region for Blasticidin S deaminase, which confers resistance to Blasticidin. 
The genes of interest were not integrated into the genome. The CRT (chloroquine 
resistance transporter) promoter is a low-expression promoter and was used for 
episomal gene expression.  
 
 
 
2.9.18.2 Constructs designed using the pARL2_GFP vector  
In-vitro amplification of the cDNA from RNA from P. falciparum (strain 3D7) was 
performed for the following genes of P. falciparum using the one-step RT-PCR Kit 
(Invitrogen). The stop codon was omitted.  
 
• PF3D7_0904500 (Prefoldin subunit, putative) 
• PF3D7_0717500 (Calcium-dependent protein kinase 4) 
• PF3D7_1020900 (ADP-ribosylation factor 1) 
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The primers used contained a XhoI (forward primer) and AvrII (reverse primer) 
restriction site for integration of the PCR product into the pARL2_GFP vector. Both the 
PCR product and the vector were digested with the same restriction enzymes XhoI and 
AvrII. The resulting construct was denoted with the Plasmodb ID, the restriction site 
and the orientation of the primer as exemplified for the coding sequence of ARF: 
PF3D7_1020900_XhoI_F. Another set of constructs was made with the above-
mentioned coding sequences by in-vitro site directed mutagenesis. The genes selected 
(PF3D7_0904500, PF3D7_0717500, PF3D7_1020900 and PF3D7_0816900) for 
analysis contained a supposed myristoylation site, glycine, at the 2nd position of the N-
terminus, which was changed to alanine (G2A) using a forward primer containing the 
respective mutated codon. The PCR products contained the respective point mutation 
and were integrated into the pARL2_GFP vector (e.g. PF3D7_1020900G2A_XhoI_F). 
Genomic DNA of P. falciparum was extracted to obtain the coding sequence of 
PF3D7_0816900 (adenylate kinase 2). Five further constructs using PF3D7_0816900 as 
the gene of interest were generated via site-directed mutagenesis. When making the first 
construct a putative palmitoylation site with cysteine at the 4th position of the N-
terminus was changed to alanine by designing a forward primer with the respective 
mutated codon. A second construct was generated by mutating both the myristoylation 
and the putative palmitoylation site of PF3D7_0816900 by using a forward primer with 
both of the mutations. The forward and reverse primer contained a XhoI and AvrII 
restriction site, respectively, to be integrated into the pARL2_GFP vector. Each of the 
PCR products comprising the respective mutated codon was amplified with the standard 
PCR program and was subsequently integrated into the pARL2_GFP vector following 
digestion of the PCR product and vector with the same restriction enzymes prior to 
ligation. Another construct with the coding sequence of PF3D7_0816900 was generated 
via site-directed mutagenesis by overlap extension PCR (Ho et al., 1989) deleting a 
stretch of polybasic amino acids at the N-terminus (Δ 21-30) of the gene. As internal 
primers oligonucleotides were designed missing the bases to be deleted 
[AAGAAAAAAAAAATATATATTTTAAATGGA corresponding to amino acids 21-
30 of the N-terminus of PF3D7_0816900]. The PCR was performed in a two-step 
reaction as described in section 2.9.10. The final PCR product lacking the amino acids 
21-30 at the N-terminus was integrated into pARL2_GFP after digestion with XhoI and 
2	  	  Materials and Methods	   50	  
AvrII restriction enzymes. The following figure exemplifies the steps required in a site-
directed mutagenesis PCR for the following gene: PF3D7_0816900 (Fig. 2.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Another construct was designed by amplifying the N-terminus of PF3D7_0816900 up to 
37 amino acids with a forward primer containing a XhoI restriction site and a reverse 
primer containing KpnI as restriction site. The N-terminus of PF3D7_0816900 was 
fused upstream to GFP into the pARL2_GFP vector. The amplified PCR product and 
the vector were digested with the restriction enzymes XhoI and KpnI. Additionally, a 
chimeric construct of PF3D7_1020900 (ADP-ribosylation factor1) and 
PF3D7_0816900 (adenylate kinase 2) was created. Therefore, the N-terminus of 
PF3D7_1020900 with up to 17 amino acids was synthesized, introducing a putative 
palmitoylation site at position 4 and removing the valine residue at position 5. The 
Figure 2.1 In-vitro site directed mutagenesis by overlap extension PCR (modified according 
to Ho et al., 1989) 
2	  	  Materials and Methods	   51	  
sequence was further extended with part of the N-terminus of PF3D7_0816900 ranging 
from the amino acid at position 18 to 37, which contains the polybasic stretch of amino 
acids of PF3D7_0816900. The synthesized sequence contained the restriction sites XhoI 
and KpnI and was cloned into the pARL2_GFP vector by fusing the insert upstream to 
GFP.  
The list of the constructs made with the corresponding primer sequences can be found 
in section 2.5.  
 
2.9.18.3 Constructs designed for co-localization studies inserted into the pARL_BSD 
vector  
The sequences of the following genes from P. falciparum (3D7 strain) were amplified 
using cDNA, which was transcribed from the RNA and integrated into the pARL_BSD 
vector. The following three constructs were generated by Jan Riedel (BSc candidate / 
Group Lingelbach).  
 
• PF3D7_1116400 (Sec 12) 
• PF3D7_1017300.1 (Grasp 1) 
• PF3D7_1144900 (Rab 6) 
 
The sequence of PF3D7_1121600 was amplified from the genomic DNA of  
P. falciparum (3D7 strain) designed with the restriction sites XhoI (forward primer) and 
AvrII (reverse primer). The PCR product was cloned into pARL_BSD vector after 
digestion with the respective restriction enzymes.  
 
2.10 Biochemical methods 
2.10.1 Cell fractionation of Plasmodium falciparum-infected red blood cells 
Trophozoite-infected cells were enriched using Gelafundin flotation or magnet based 
separation and subjected to hypotonic lysis. A total amount of 2 x 108 cells was 
resuspended in 1 mM Tris (stock: 10 mM) and lysed by repeated cycles of freezing and 
thawing in liquid nitrogen. Following centrifugation at 36,000 x g for 20 minutes at  
4 °C, the lysate was separated into soluble and pellet fraction. The soluble fraction was 
spun again at the same speed to remove any remaining membrane contaminants before 
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being boiled in sample buffer at 100 °C for 10 minutes. The pellet fraction was washed 
4-6 times in PBS (pH 7.4) containing 1 mM PMSF and PIC (1:200 dilution), boiled in 
sample buffer at 100 °C for 10 minutes and used for analysis by SDS-PAGE and 
immunoblotting.  
2.10.2 Streptolysin O permeabilization of Plasmodium falciparum-infected 
erythrocytes 
Streptolysin O (SLO) is known to be an important toxin produced by gram-positive 
bacteria of the genus Streptococcus. This toxin is able to bind to surface-exposed 
membrane cholesterol permeabilizing the membrane by causing holes up to 30 nm to 
the membrane (Bhakdi et al., 1985). SLO treatment of Plasmodium-infected cells leads 
to permeabilization of the erythrocyte membrane leaving the PVM and the parasite 
intact.  
To identify and further analyze the subcellular localization of P. falciparum proteins in 
infected erythrocytes SLO treatment was performed. Immediately after enrichment of 
the trophozoite-stage infected erythrocytes with Gelafundin or magnet based separation 
a total of 2 x 108 cells were treated with 3 hemolytic units (HU) of SLO in 188 µl of 
PBS (pH 7.4). The cells were incubated at room temperature for 6 minutes and gently 
mixed every 2 minutes. Following incubation the cells were spun at 1,000 x g for  
3 minutes. The supernatant was transferred to a new 1.5 ml eppendorf tube, washed two 
more times to remove any remaining contamination with the membrane fraction. The 
pellet was washed 4-6 times with PBS (pH 7.4) containing 1 mM PMSF and PIC (1:200 
dilution). Subsequently, the pellet containing the intact parasite and intact PV was 
resuspended in an appropriate volume of PBS (pH 7.4) and was either directly used for 
experiments or was further separated into soluble and pellet fraction. Therefore the 
pellet fraction containing the intact parasite with the surrounding PV was dissolved in  
1 mM Tris buffer (stock: 10 mM Tris in ddH2O) and subjected to three repeated cycles 
of freeze and thaw. The lysed cells were spun at 28,600 x g for 20 minutes and the 
supernatant containing the soluble fraction was transferred to a new tube and washed 
two more times. The pellet fraction was washed 4 to 6 times with PBS (pH 7.4) 
containing protease inhibitors and was finally dissolved in an appropriate amount of 
PBS. All the samples obtained so far 1) supernatant fraction and 2) pellet fraction were 
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diluted in sample buffer and immediately boiled at 100 °C for 10 minutes in heating 
block before being stored at – 80 °C.   
2.10.3 Saponin lysis of Plasmodium falciparum-infected erythrocytes 
Saponin is a glycoside, which is commonly found in plants and is able to lyse 
erythrocytes by forming complexes with cell membrane cholesterol leading to the 
permeabilization of the membrane. Saponin is known to disintegrate the erythrocyte 
membrane and the parasitophorous vacuolar membrane of P. falciparum but leaves the 
parasite intact (Beaumelle et al., 1987).  
Following Gelafundin or magnet based enrichment of trophozoite-stage infected 
erythrocytes a total of 2 x 108 cells were treated with 0.02 % saponin (stock 1mg/ml) 
dissolved in PBS (pH 7.4) containing 1 mM PMSF. The cells were incubated at room 
temperature for 3 minutes with only gently mixing. Once the incubation time was over, 
the cells were immediately centrifuged at 2,800 x g for 5 minutes at 4 °C. The 
supernatant was transferred to a new 1.5 ml eppendorf tube, while the pellet was 
washed 4-6 times with PBS (pH 7.4) containing 1 mM PMSF and PIC (1:200 dilution). 
To remove all the residual membrane in the supernatant fraction another centrifugation 
step was performed at 36,000 x g for 20 minutes at 4 °C. Sample buffer was added to 
the supernatant and the pellet, which was dissolved in PBS (pH 7.4) containing 1 mM 
PMSF and PIC (1:200 dilution). Both samples were boiled at 100 °C for 10 minutes in a 
heat block before further usage.   
2.10.4 Protease protection assay 
The protease protection assay was performed with trophozoite-stage parasites. 
Therefore the parasites were enriched using Gelafundin flotation or magnet based 
separation and treated with 0.02 % saponin (stock: 1 mg/ml) and SLO (3 HU), 
respectively. The supernatant was separated from the pellet fraction by centrifugation at 
2,500 x g for 5 minutes followed by further centrifugation steps of the supernatant at 
28,600 x g for 20 minutes at 4 °C removing all remaining cell debris. Subsequently, 
sample buffer was added to the supernatant fraction and the whole sample was boiled at 
100 °C for 10 minutes. The saponin and SLO pellet, respectively, was washed 4-6 times 
with PBS (pH 7.4) and divided for the majority of the experiments into two samples 
each containing 1 x 108 cells. Sample 1) was just dissolved in PBS (pH 7.4) being the 
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negative control, while sample 2) was treated with 1 mg/ml Proteinase K being the test 
sample. The samples were then incubated on ice for 30 minutes. Once the incubation 
time was over, 1 mM PMSF and PIC were added to the samples to prevent further 
protease activity and incubated for 3 minutes at room temperature. Subsequently, 
sample buffer was added to the samples and they were boiled at 100 °C for 10 minutes 
in a heat block before storage at – 80 °C.  
2.10.5 SDS-PAGE 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) is a widely 
used method to separate proteins on the basis of their molecular weight. SDS is a 
detergent known to disturb the 3-dimensional structure of the protein and applies an 
overall negative charge to the proteins forming SDS-polypeptide complexes. This 
enables the separation of proteins in a polyacrylamide gel, based only on their 
molecular weight, eliminating the differences in mass:charge ratio of the proteins. 
Protein samples were mixed and heated in 2 x loading buffer containing the reducing 
agent dithiothreitol (DTT), which reduces the disulfide bonds within the proteins. The 
samples obtained after 1) saponin lysis, 2) SLO-lysis, 3) cell fractionation or after  
4) treatment with Proteinase K were dissolved in an appropriate buffer before being 
mixed 1:1 with 2 x sample buffer and heated at 100 °C for 10 minutes in a heat block.  
Electrophoresis was performed using a discontinuous buffer system and a 12 % 
polyacrylamide gel. The protein samples were run initially at 90 V leaving the proteins 
to migrate in the stacking gel, before the voltage was increased to 120 V once the 
proteins entered the separation gel. The protein ladder used to determine the molecular 
weight of the proteins was a Prestained Protein Ladder (Fermentas).  
Table 2.6 Pipetting scheme for a 12 % gel 
Reagent Stacking gel Separation gel (12 %) 
Gel buffer (4x) 2.5 ml 7.5 ml 
30 % acrylamide 1.3 ml 12 ml 
ddH2O 6.2 ml 10.25 ml 
APS 250 µl 200 µl 
TEMED* 15µl 25 µl 
*N,N,N’,N’-Tetramethylethylenediamine 
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2.10.6 Semi-Dry-Immunoblotting 
After separation of the proteins by gel electrophoresis they were electrophoretically 
transferred from the gel onto a nitrocellulose membrane for detection of the proteins by 
antibodies. The membrane was placed on the polyacrylamide gel and 'sandwiched' 
between 3 Whatman papers on each side, which were prior submerged in a western blot 
transfer buffer. Then the entire 'sandwich' was transferred to a blotting chamber. The 
transfer was carried out at 1 mA/cm2 for approximately 1 hour. The electric field 
enables the proteins to move from the gel onto the membrane, displaying a copy of the 
protein pattern, which was originally in the polyacrylamide gel. After the 
electrophoretic transfer the membrane was stained with Ponceau red solution for five 
minutes and then rinsed in distilled water until protein bands were visible. The Ponceau 
staining was washed off with PBS (pH 7.4) for about 10 minutes before the membrane 
was blocked with 5 % milk powder (dissolved in PBS) for 1 hour at room temperature 
with constant shaking. This blocking step of the membrane is important to avoid 
unspecific binding of antibodies. The primary antibody was diluted in a 5 % milk 
solution to the desired working concentration (section 2.3) and incubated with the blot 
for 2 -3 hours at room temperature or overnight at 4 °C, depending on the antibody 
used. The membrane was then washed 3 times for 10 minutes with PBS (pH 7.4) to 
remove all unbound primary antibodies. The secondary antibody conjugated to 
Horseradish Peroxidase (HRP) was diluted 1:2000 in 5 % milk solution and added to 
the membrane for 1-2 hours at room temperature with constant shaking. Once the 
incubation time was over, the membrane was washed 3 x times with PBS (pH 7.4) to 
remove unbound antibodies. Antibody reactive-proteins were detected using the 
Enhanced Chemiluminescence (ECL) detection system. Therefore the membrane was 
incubated with a substrate (luminol) that reacts with the conjugated secondary antibody 
in an enzyme-substrate reaction producing a fluorescent signal. The chemiluminescence 
was detected using a medical X-ray film.  
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2.11 Fluorescence microscopy 
2.11.1 Live cell imaging  
Plasmodium-infected cells were visualized using the Zeiss Axio Observer inverse 
epifluorescence microscope system. The cells were sedimented via a centrifugation step 
to obtain a cell pellet containing Plasmodium-infected and non-infected cells. The pellet 
was then washed 3 times with RPMI medium. For staining of nuclear DNA Hoechst dye 
was added (10 µg/ml) to the cells, which were resuspended in 1 ml RPMI, and 
incubated for 5 - 10 min at room temperature on a shaker. The cells were then ready to 
be visualized at room temperature using the inverse epifluorescence microscope with 
the appropriate filter sets and the Axiovision 4 software. Appropriate exposure times 
were chosen to prevent bleach out of the samples. All the data shown, represents at least 
6-12 images taken for each sample.   
2.11.2 Immunofluorescence assay  
The immunofluorescence assay was performed according to Tonkin (Tonkin et al., 
2004). Plasmodium-infected cells were fixed with 4 % paraformaldehyde/0.0075 % 
glutaraldehyde dissolved in PBS (pH 7.4) for 30 minutes at 37 °C. In a next step, 
glycine at a final concentration of 125 mM in 0.1 % TritonX-100/PBS 
(solubilization/permeabilization buffer) was added to the cells and incubated for  
15 minutes on a roller at room temperature before the cells were sedimented at  
1,000 x g for 2 minutes. The cells were then blocked in 3 % BSA/PBS for 1 hour. The 
primary antibody used was prepared in 3 % BSA/PBS and the cells were incubated with 
the primary antibody overnight at 4 °C. Once the primary antibody was removed, the 
cells were washed 3 times for 10 minutes with PBS (pH 7.4) before they were incubated 
with the appropriate secondary antibody for 2 hours at room temperature. The cells 
were washed again 3 times for 10 minutes with PBS (pH 7.4) before they were 
visualized by epifluorescence microscopy. The nuclear DNA of the fixed parasites was 
stained with Hoechst (50 ng/ml). Depending on the primary antibodies used (section 
2.3) the appropriate Cy2- or Cy3-conjugated secondary antibody was employed in a 
1:2000 dilution range.  
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2.11.3 Image processing with Image J 
ImageJ is an open source Java-written program (http://rsbweb.nih.gov/ij/) used to 
process images. Images taken with the aforementioned epifluorescence microscope 
were imported into ImageJ64, converted to 8-bit grayscale and each image was 
subjected to background subtraction. Using the ImageJ plugin RGBmerge the RGB 
channels were split into red, green and blue before the individual images were overlaid. 
Before the images were saved as TIF files they were adjusted with the 
brightness/contrast tool. In order to make the figures, the figures were imported from 
ImageJ to PowerPoint (Microsoft). The figures were then compiled and saved as TIF 
files.  
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2.12 Experimental design 
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3 Results 
 
A previous study of the parasitophorous vacuolar proteome of the intraerythrocytic 
stage of P. falciparum revealed the secretion of a number of proteins without a signal 
sequence. Approximately 50 % of the proteins lacked a signal sequence or any other 
known motifs responsible for the secretion of P. falciparum proteins into the PV. 
However, ~ 5 % of these proteins contained a glycine residue at the N-terminus, which 
is indicative for potential N-myristoylation (Nyalwidhe et al., manuscript in 
preparation). Proteins which lack a signal peptide but are N-myristoylated like the 
Leishmania HASPB and the Plasmodium CDPK1 have already been shown to be 
secreted into the extracellular space and the PV, respectively, suggesting that  
N-myristoylation can be seen as a mode of protein secretion among protists (Denny et 
al., 2000; Möskes et al., 2004). This hypothesis was further supported by a recent study 
of the P. falciparum adenylate kinase 2 (PfAK2). This protein was proposed to be 
secreted into the PV, potentially involving N-myristoylation in the secretion process 
(Ma et al., 2012).  
 
3.1 Selected candidate proteins 
The selected candidate proteins for this study - Prefoldin (PF3D7_0904500), Calcium-
dependent protein kinase 4 (CDPK4) (PF3D7_0717500) and the ADP-ribosylation 
factor 1 (ARF1) (PF3D7_1020900) - were first analyzed with the Myristoylator 
prediction program (www.expasy.com), from which the PfCDPK4 (PF3D7_0717500) 
and the PfARF1 (PF3D7_1020900) were highly predicted to be myristoylated, 
compared with PfPrefoldin (PF3D7_0904500). Another selected candidate protein of 
this study was the PfAK2 (PF3D7_0816900), which has already been shown to be 
myristoylated by the PfNMT (Rahlfs et al., 2009). In addition, all of these proteins were 
checked for the presence of a signal peptide using the prediction program SignalP 4.1. 
Server and none of them were predicted to contain a signal peptide.  
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Table 3.1 Prediction of N-myristoylation according to the Myristoylator prediction tool 
 PF3D7__0904500 
Prefoldin 
PF3D7__0717500 
CDPK4 
PF3D7__1020900 
ARF1 
Myristoylator: 
Predicted as ... 
non-myristoylated 
myristoylated 
(High confidence) 
myristoylated 
(High confidence) 
 
In the following each of the proteins is described briefly: 
Prefoldin is a molecular chaperone – a chaperone promotes correct protein folding – 
which interacts with other chaperones and was found in both eukaryotes and archaea 
(Vainberg et al., 1998). The function of Prefoldin fits with the identification of a great 
number of chaperones in the PV proteome analysis (Nyalwidhe and Lingelbach, 2006).  
CDPK4 contains a putative myristoylation site similar to CDPK1, a parasite protein, 
which was found to be myristoylated and secreted beyond the parasite plasma 
membrane due to N-myristoylation (Möskes et al., 2004). Therefore it is reasonable to 
hypothesize that CDPK4 might also be targeted to the PV in an acylation-dependent 
manner.  
ADP-ribosylation factor 1 is a highly conserved eukaryotic protein, which was found 
to be myristoylated at the N-terminus in various organisms including other protists.  
PfARF1 shows an overall structural and sequence similarity to the human ARF1 (Cook 
et al., 2010). Although ARFs are known to be mainly involved in vesicular trafficking 
of the secretory pathway (Boman and Kahn, 1995), the PV proteome approach assigned 
the localization  of PfARF1 to the PV.  
Pfadenylate kinase 2 was suggested to be located in the PV according to localization 
studies with GFP reporter constructs and fluorescence analyses of the respective protein 
(Ma et al., 2012). However, biochemical evidence and the mechanisms involved in the 
secretion of PfAK2 into the PV are still missing.  
 
To further analyze and investigate the localization of these candidate proteins and the 
potential secretion mechanism mutagenesis, fluorescence and thorough biochemical 
analyses were performed.  
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3.1.1 PfARF1 shows a different subcellular localization upon removal of the  
N-myristoylation site in P. falciparum-infected red blood cells 
To figure out whether or not PfPrefoldin, PfCDPK4 and PfARF1 were indeed secreted 
into the PV and whether this is dependent on myristoylation, plasmids were constructed 
to express each of these proteins fused to GFP, creating chimeric fusion proteins. In 
parallel, a similar batch of these constructs was generated, where the glycine residue at 
the N-terminus of each of the proteins was changed to alanine (G2A) removing the 
putative N-myristoylation site. All of these constructs driven by the low-expression 
CRT promoter in the pARL2 plasmid were then transfected individually into the  
P. falciparum 3D7 strain for episomal expression. The resulting transgenic parasites 
were then analyzed via epifluorescence microscopy regarding the subcellular 
localization of the protein (wildtype versus G2A mutant). Both the PfPrefoldin/GFP 
fusion protein and the variant PfPrefoldinG2A/GFP showed a strong cytosolic signal in 
the parasite indicating no difference in the subcellular localization between these two 
transgenic parasite lines (Fig. 3.1 A). The subcelluar localization of both 
PfCDPK4/GFP and PfCDPK4G2A/GFP also showed a strong cytosolic signal in the 
parasite and no differences in their subcellular localization pattern (Fig. 3.1 B). These 
findings with PfPrefoldin and PfCDPK4 contradict the outcome of the PV proteome 
analysis, since a ring-like structure around the parasite would be expected for PV 
localization as was found with the PfAK2/GFP (Fig. 3.4 A and Ma et al., 2012). 
Furthermore, the removal of the putative N-myristoylation site did not have any effect 
on the subcellular localization of the respective proteins. 
The wildtype PfARF1/GFP also did not show the expected ring-like structure around 
the parasite indicative of PV localization. However, PfARF1/GFP was found to be 
localized to 1 to 2 dot-like structures in the parasite cytosol, while the variant of it, the 
PfARF1G2A/GFP, showed a cytosolic localization (Fig. 3.1 C). This difference was 
further analyzed by subjecting the wildtype and variant parasite lines to hypotonic lysis 
and analyzing the samples via SDS-PAGE, western blotting and immunodetection. 
Hypotonic lysis was performed to distinguish between soluble and membrane-bound 
proteins. The full-length PfARF1 has a molecular weight of 21 kDa, while GFP has a 
molecular weight of 27 kDa. In the western blot analysis a band of approximately  
48 kDa was detected in the supernatant fraction of the PfARF1/GFP and the 
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PfARF1G2A/GFP parasite samples corresponding to the size of the fusion protein. As 
expected, a band of similar size could also be detected in the membrane-bound protein 
fraction of the PfARF1/GFP sample, but was missing in the PfARF1G2A/GFP sample. 
These results indicate that the removal of the N-myristoylation site indeed affects the 
subcellular localization of the PfARF1 protein in the parasite. Band 3 was used as a 
marker protein for the membrane fraction, while the plasmodial aldolase was used as a 
marker protein for the soluble fraction and both proteins were detected in the expected 
fractions with the respective antibodies. 	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Figure 3.1 Live cell imaging of selected candidate proteins and biochemical analysis of  
PfARF1/GFP and PfARF1G2A/GFP 
(A, B) The fluorescence images of the PfPrefoldin/GFP compared to the corresponding mutant transgenic 
parasite line and PfCDPK4/GFP compared to PfCDPK4G2A/GFP parasites, respectively, show no 
differences between their phenotypes. The subcellular localization of the wildtype and the respective 
modified form of the protein appears to be similar. (C) The PfARF1/GFP fusion protein appears like  dot-
like structures in the parasite cytosol, while the phenotype of the ARF1G2A/GFP variant shows an evenly 
distributed cytosolic signal. This indicates that the N-myristoylation site affects the subcellular 
localization of the protein. (D) Hypotonic lysis performed on the wildtype and the variant  
PfARF1/GFP parasite line, respectively, revealed a soluble protein pool in both samples. However, a 
membrane-bound protein pool could only be detected with an α-GFP antibody in the PfARF1/GFP 
parasite sample. As a control for proper hypotonic lysis Band 3 was used as a marker protein for the 
membrane fraction and aldolase was used as a marker protein for the soluble fraction and detected with 
the respective antibodies. DIC channel for high-contrast; in merge: green (GFP),  blue (Hoechst = nucleus 
dye). Scale bar – 3 µm. 
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3.1.2 PfARF1 shows co-localization with marker proteins of the compartments of 
the secretory pathway  
To further analyze the subcellular localization of PfARF1 a co-localization study with 
already verified marker proteins of the secretory pathway of P. falciparum was 
performed. Since ARF proteins are involved in the vesicle biogenesis of the secretory 
pathway PfARF1/GFP transgenic parasites were co-transfected with each of the 
following constructs individually: PfSec12 fused to mCherry in pARL2; PfGrasp1 fused 
to mCherry in pARL2; PfRab6 fused to mCherry in pARL2. PfSec12 was identified as 
localized to the ER (Lee et al., 2008) and is a protein known to be involved in the 
vesicle formation of the anterograde transport (Barlowe and Schekman, 1993).  
PfGrasp1 – Grasp proteins were found to play a role in the stacking of the Golgi- 
complex (Barr et al., 1997) – and was found to localize to the less elaborate Golgi-
complex of P. falciparum (Struck et al., 2005). PfRab6 - the Rab6 protein of the Rab 
GTPase family was found to play a role in the intra-Golgi transport in eukaryotic cells 
(Martinez and Goud, 1998) – was found at the P. falciparum Golgi-complex (de Castro 
et al., 1996). Furthermore, a co-localization study with PfExp1 - an integral membrane 
protein localized to the PVM of the parasite during the blood-stage (Günther et al., 
1991) - was performed as another attempt to investigate further the findings of the PV 
proteome analysis. Therefore PfARF1/GFP transgenic parasites were co-transfected 
with PfExp1 fused to mCherry in the pARL2 vector. As a control PfARF1G2A/GFP 
transgenic parasites were transfected with each of the marker constructs individually.  
During live cell imaging the signal of PfSec12/mCherry was observed in close 
proximity to the nucleus as a discrete structure that to a certain extent overlapped with 
the dot-like cytosolic signal of PfARF1/GFP indicating partial co-localization, which 
can be seen in the merge channel. PfGrasp1/mCherry showed similar to PfARF1/GFP 
dot-like structures in the parasite cytosol near the parasite nucleus, which also resembles 
the fluorescence analyses of PfGrasp/GFP transgenic parasites performed by Struck and 
colleagues (Struck et al., 2005). Merged images of PfARF1/GFP and 
PfGrasp1/mCherry showed a strong co-localization of both proteins. PfRab6/mCherry 
also showed dot-like structures in the parasite. This observation coincides with the 
findings of de Castro and colleagues, where they claim that the maximal expression of 
this protein occurs at the trophozoite stage of P. falciparum during intraerythrocytic 
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development (de Castro et al., 1996). PfRab6/mCherry partially co-localizes with 
PfARF1/GFP, however, a complete co-localization like that seen for  
PfGrasp1/mCherry and PfARF1/GFP could not be observed between the dot-like 
cytosolic signal of PfARF1/GFP and PfRab6/mCherry in the merged images. These 
findings, taken together, clearly reveal the localization of PfARF1 to compartments 
involved in the secretory pathway inside the parasite cytosol. In the co-localization 
study with the PfARF1/GFP protein co-expressed with PfExp1/mCherry a prominent 
ring-like structure around the parasite could be visualized during live cell imaging for 
PfExp1/mCherry. However, some signal could also be seen within the cytoplasm of the 
parasite. This finding corresponds to the results of a previous study where the fusion 
protein PfExp1/GFP was analyzed with respect to its localization during the blood-stage 
and was found to be partially localized to the food-vacuole of the parasite in addition to 
a PVM localization (Adisa et al., 2003). Merged images of PfARF1/GFP and 
PfExp1/mCherry showed no overlapping of the signals. This indicates that no co-
localization between PfARF1 and the PVM marker of PfExp1 was detected, which is 
contradictory to the hypothesis of PV localization of PfARF1.  	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Figure 3.2 Co-localization of PfARF1/GFP with proteins localized to compartments of the secretory 
pathway  
(A) PfARF1/GFP shows partial co-localizaton with the plasmodial ER marker protein PfSec12. (B)  
PfGrasp1, a marker protein of the cis-Golgi-complex, shows dot-like structures within the parasite, which 
strongly overlap with the dot-like structures of PfARF1/GFP. (C) PfRab6, a marker protein of the trans-
Golgi-complex, also show dot-like structures within the parasite, which partially overlap with the dot-like 
signals of the wildtype PfARF1. (D) PfExp1 is an integral PVM protein as can be seen from the 
prominent ring-like structure; however no overlap of the signal with PfARF1/GFP was visible. (A,B,C,D) 
The marker proteins of each compartment were also co-expressed with the PfARF1G2A/GFP. DIC channel 
for high-contrast; in merge: green (GFP), red (mCherry), blue (Hoechst = nucleus dye). Scale bar – 3 µm. 
 
3.1.3 PfARF1 is not secreted into the PV in the blood-stage according to 
biochemical analyses 
Since the data from the PV proteome analysis and the fluorescence microscopy study 
are contradictory, a biochemical approach was performed. Therefore the PfARF1/GFP 
and PfARF1G2A/GFP transgenic parasite lines were subjected to Streptolysin O and 
saponin treatment, respectively, and were then further analyzed by SDS-PAGE, western 
blot analysis and immunodetection. Streptolysin O is a bacterial-pore forming protein, 
which induces pores in the red blood cell membrane (RBCM) resulting in the release of 
the erythrocyte cytosol but leaving the PV and the parasite intact (Bhakdi et al., 1985). 
Saponin, however, is a detergent, which disintegrates the red blood cell membrane and 
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the parasitophorous vacuolar membrane resulting in the release of the erythrocyte 
cytosol and the vacuolar content and only leaving the PPM and the parasite intact 
(Beaumelle et al., 1987). The supernatant fraction after SLO lysis contains the red blood 
cell cytosol, while after saponin treatment the erythrocyte cytosol and the content of the 
PV is found in the supernatant fraction. The pellet fraction after SLO lysis contains the 
permeabilized RBCM, the intact PV and the intact parasite, while the pellet fraction 
after saponin lysis contains the parasite with an intact parasite plasma membrane and 
the permeabilized PVM and RBCM.  
SLO Lysis Saponin Lysis 
and 
 
An analysis in which the respective transgenic parasite line is subjected to each of these 
methods and then the results are compared with each other enables the identification of 
the subcellular localization of the examined protein. In addition to the SLO and saponin 
treatment, a protease protection assay was performed. Therefore the pellet fraction after 
each of the two treatments was divided into two aliquots containing equal cell numbers, 
then one of the aliquots was treated with Proteinase K and leaving the other untreated 
(control). After SLO lysis and Proteinase K treatment those proteins which are located 
outside of the PV will be degraded by the presence of Proteinase K, while proteins 
protected by the PVM and the PPM remain unaffected. After saponin lysis followed by 
Proteinase K treatment those proteins which would be located beyond the parasite 
plasma membrane will be degraded, while the proteins protected by the PPM meaning 
inside the parasite, remain unaffected. The plasmodial soluble serine rich protein 
(SERP) located in the PV was used as a control to demonstrate that the PV remained 
intact after SLO lysis. Pfaldolase - a protein found in the cytosol of the parasite - was 
used as a control protein to show that the parasite remained intact after SLO and 
saponin treatment, respectively. A positive control for an efficient protease digestion in 
each of the experiment itself was not performed; however, the efficiency of protease 
digestion was shown for one of the variants of PfAK2 (detailed in Fig. 3.7 C): the 
fusion protein analyzed (PfAK2G2AC4A) was protected by the PPM after saponin 
treatment. Proteinase K was given access to the fusion protein by permeabilizing the 
PPM of the saponin treated cells with a detergent (Triton X 100) and it was shown that 
Proteinase K was able to digest the fusion protein. This example indicates the efficiency 
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of Proteinase K for digestion of the fusion protein of one of the PfAK2 variants. The 
protease protection assay was performed for each of the different variants with the same 
concentration and incubation time as performed for this particular variant (see Fig 3.7 C 
for further detail).  
In the following experiment the GFP antibody detected PfARF1/GFP in the western 
blot analysis, while an antibody directed against PfARF1 detected both the endogenous  
PfARF1 and the fusion protein PfARF1/GFP. Fig 3.3 displays the results of the SLO 
and saponin lysis performed on the PfARF1/GFP and the PfARF1G2A/GFP transgenic 
parasite lines, respectively. The PV marker protein PfSERP and the parasite marker 
protein Pfaldolase are both found after SLO lysis and Proteinase K treatment 
predominantly in the pellet fraction. This indicates that the PV and the parasite almost 
remained intact and that both proteins were not accessible to Proteinase K. However, a 
faint band of approximately 40 kDa could also be detected with an α-aldolase antibody 
in the SLO supernatant fraction of the PfARF1/GFP transgenic parasite sample. The 
band size, however, is much weaker compared to the band size in the SLO pellet 
fractions. Although the majority of the control proteins were found in the SLO pellet 
fraction indicating an almost proper lysis, some lysis of parasites during the SLO and 
saponin treatment and during the incubation time did occur. This, however, is difficult 
to be avoided completely, which is a general issue of this treatment procedures as was 
also found in other studies using these lysis methods for investigation of protein 
localization in P. falciparum infected cells (Ansorge et al., 1997; Spielmann et al., 
2006; Heiber et al., 2013). A band of approximately 50 kDa was detected with the α-
GFP antibody which corresponds to the size of the fusion protein in both the SLO pellet 
fraction treated with Proteinase K and the untreated one of the ARF1/GFP and 
ARF1G2A/GFP transgenic parasite samples, respectively. This indicates that the fusion 
proteins ARF1/GFP and ARF1G2A/GFP, respectively, are not located beyond the PVM 
since the band in the SLO pellet fraction treated with Proteinase K was not digested. 
This indicates that both of the fusion proteins do not cross the PVM to be secreted into 
the host cell (Fig. 3.3 A). A positive control of efficient Proteinase K digestion for this 
particular experiment is missing, however, the efficiency of Proteinase K digestion of a 
fusion protein in general is shown for one of the variants (PfAK2G2AC4A/GFP in Fig. 3.7 
C). After saponin treatment and Proteinase K treatment of the samples of both 
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transgenic parasite lines PfSERP was detected in the supernatant fraction meaning that 
the PV was lysed as expected. Pfaldolase was detected in both the saponin pellet 
fraction treated with Proteinase K and the untreated saponin pellet fraction indicating an 
almost retention of an intact parasite. Similar to the result of the SLO treatment aldolase 
was also detected in the supernatant fraction of the PfARF1/GFP sample as a very faint 
band. Thus, a small amount of aldolase was released during the lysis procedure 
indicating some lysis of parasites during the saponin treatment. However, the majority 
of the protein was detected in the pellet fraction.	  PfSERP could also be detected in the 
saponin pellet fraction, but the band of approximately 130 kDa disappeared upon 
Proteinase K treatment. This probably means that SERP sticks to membranes and was 
difficult to wash off the membrane despite many washing steps of the pellet fraction 
during sample preparation. Upon proteinase treatment it could be removed from 
sticking to the membrane. However, a band of ~ 50 kDa corresponding to the 
PfARF1/GFP and the PfARF1G2A/GFP fusion protein, respectively, was found in the 
saponin pellet fraction when detected with an α-GFP antibody and in the saponin pellet 
treated with Proteinase K (Fig. 3.3 A). This indicates that the fusion protein was not 
accessible to Proteinase K digestion and therefore is not secreted beyond the parasite 
plasma membrane. This result corresponds to the fluorescence and co-localization 
studies showing that PfARF1 is solely found in the parasite cytosol and is not secreted 
beyond the parasite plasma membrane. To further support this observation the 
PfARF1/GFP transgenic parasite line was subjected to a co-localization study with an 
antibody against plasmodial ARF1, which was also used to detect the endogenous 
PfARF1 after SLO and saponin treatment, respectively. Indeed the antibody co-
localized partially with the fusion protein PfARF1/GFP as can be seen in the 
overlapping dot-like structures, but also endogenous plasmodial ARF1 could be 
detected as punctuate structures in the parasite cytosol. Furthermore, a band 
corresponding to the endogenous PfARF1 of about 21 kDa and to the fusion protein of 
50 kDa could be detected with the plasmodial α-ARF1 antibody in both the SLO and 
saponin pellet fractions (Fig. 3.3 C). Furthermore, the bands were also detected in each 
of the fractions, which were treated with Proteinase K. The endogenous ARF1 and the 
PfARF1/GFP fusion protein were not affected by Proteinase K treatment indicating that 
they were protected within the parasite cytosol. A small amount of the endogenous ARF 
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protein could also be detected in the supernatant fraction after SLO and saponin 
treatment, respectively. This indicates that some of the parasites were lysed during each 
of the treatment why some of the endogenous ARF protein could be detected in the 
supernatant fraction similar to the amount of the marker protein aldolase found in the 
supernatant fraction. A possible reason why the GFP-tagged ARF protein was not found 
in the supernatant might be that the amount of protein episomally expressed might be 
far less than the amount of the expression of the endogenous aldolase and ARF protein 
in the parasite, why despite some lysis of the parasites during the procedures the amount 
of GFP-tagged ARF was too less to be detected. This explanation is furthermore 
supported by the intensity of the bands of the endogenous ARF compared to the GFP-
tagged version. However, a band of around 35 kDa appears strongly in the supernatant 
fraction after SLO and saponin treatment, but also to a less extent in the SLO pellet 
fractions (+/- Proteinase K). This could be the result of cross-reactivity of the antibody 
to exported parasite proteins in the host cell or host cell proteins and also within the 
parasite (Fig. 3.3 C). Images of the immunofluorescence study also occasionally, but 
not always revealed a weak detection of structures in the host cell cytosol by the 
plasmodial α-ARF1 antibody. Taken together, although PfARF1 was hypothesized to be 
localized to the PV according to the PV proteome approach, fluorescence and 
biochemical analyses revealed its localization solely within the parasite cytosol to 
compartments of the classical secretory pathway.  
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Figure 3.3 PfARF1/GFP is not secreted beyond the parasite plasma membrane according to a 
biochemical approach 
(A) The PfARF1/GFP transgenic parasites and the respective variant were both subjected to SLO and 
saponin lysis, followed by a protease protection assay. PfSERP and Pfaldolase were used as controls as a 
PV marker protein and parasite marker protein, respectively. All of the marker proteins could be detected 
with their respective antibodies after SLO and saponin lysis of the two transgenic parasite lines 
predominantly in the expected compartments. However, lysis of some parasites did occur during the SLO 
and saponin treatment, respectively, why a small amount of aldolase was also detected in the supernatant 
fraction. The fusion proteins PfARF1/GFP and PfARF1G2A/GFP were detected with an α-GFP antibody 
after SLO and saponin lysis, respectively, in the pellet fractions and also the pellet fractions treated with 
Proteinase K. (B) Co-localization between the PfARF1/GFP and an α-ARF1 antibody directed against the 
plasmodial endogenous ARF1 (which will also detect the fusion protein tagged with GFP) can be seen in 
the fluorescence images. According to the biochemical approach the plasmodial α-ARF1 antibody 
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detected a strong band at 21 kDa and a weaker band of approximately 50 kDa in the SLO and saponin 
pellet fractions (-/+ Proteinase K addition). A small amount of the endogenous ARF protein was also 
detected in the supernatant fraction, which might be due to lysis of some parasites during the procedure. 
A strong protein band of ~ 35 kDa was also detected in the supernatant fraction and in both pellet 
fractions (-/+ Proteinase K) of saponin treated PfARF1/GFP parasites which might result from cross-
reactivity of the antibody with other parasite proteins. DIC channel for high-contrast; in merge: green 
(GFP), red (α-ARF1), blue (Hoechst = nucleus dye). Scale bar – 3 µm.  	  	  
3.2 Is PfAK2 secreted beyond the parasite plasma membrane? 	  
Similar to the reporter construct studies designed for PfPrefoldin, PfCDPK4 and  
PfARF1 Ma and colleagues generated fusion proteins with the full-length PfAK2 fused 
to GFP and created a variant of it, the PfAK2G2A/GFP. In the variant the  
N-myristoylation site was removed by changing the glycine residue at the N-terminus of 
the protein to alanine. Both of these constructs were transfected individually into the  
P. falciparum 3D7 strain and were episomally expressed with the low-expression 
promoter CRT by Ma and colleagues. A repetition of the fluorescence analysis of the  
PfAK2/GFP transgenic parasite line and the PfAK2G2A/GFP - first shown by Ma and 
colleagues (Ma et al., 2012) - was performed in this study to visualize the difference 
between the wildtype phenotype of the PfAK2/GFP fusion protein and the  
PfAK2G2A/GFP fusion protein and for subsequent comparison with the following 
variants made and analyzed in this study. Interestingly, the phenotypes of the  
PfAK2/GFP fusion protein and PfAK2G2A/GFP fusion protein differed in their protein 
localization pattern when visualized by fluorescence microscopy. While the 
PfAK2/GFP showed a ring-like structure around the parasite with a knob-like 
protrusion, which are referred to as 'loops' the signal from the PfAK2G2A/GFP was 
rather found to be evenly distributed in the cytosol of the parasite (Fig. 3.4 A and Ma et 
al., 2012). This indicates that the N-myristoylation site has an effect on the localization 
of PfAK2. These findings were further analyzed via hypotonic lysis by Ma and 
colleagues with samples of both transgenic parasite lines (PfAK2/GFP and 
PfAK2G2A/GFP, respectively). While the AK2/GFP fusion protein was found in the 
membrane fraction consistent with the role of membrane-anchoring due to myristate, 
the variant form, where the N-myristoylation site was removed, was found entirely in 
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the soluble fraction (Ma et al., 2012). Further, Ma and colleagues proposed that the full-
length AK2 localizes to the PVM. This was shown by a co-localization study of 
PfSERP and PfExp1 with the PfAK2/GFP parasite line by the overlap of the signals of 
PfExp1 and PfAK2/GFP in the merged image (Ma et al., 2012). However, biochemical 
evidence on the subcellular localization of PfAK2 and further explanation on the 
secretion process of PfAK2 are still missing.  
 
To verify the findings of Ma and colleagues the transgenic parasite lines of  
PfAK2/GFP and PfAK2G2A/GFP were subjected to Streptolysin O and saponin lysis 
before being analyzed by SDS-PAGE, western blotting and immunodetection. SLO 
treatment was performed on the sample of the PfAK2/GFP transgenic parasite line (Fig. 
3.4 B). The pellet fraction after SLO lysis contains the intact PV and parasite and the 
permeabilised RBCM, while the SLO supernatant fraction only contains the erythrocyte 
cytosol. The band of approximately 60 kDa detected in the SLO pellet fraction by an α-
GFP antibody corresponds to the size of the fusion protein consisting of the full-length 
PfAK2 (32.5 kDa) and GFP (27 kDa). Proteinase K treatment of the SLO pellet fraction 
did not lead to the disappearance of the band indicating that the fusion protein 
PfAK2/GFP was not digested by Proteinase K, hence it is not located at the outer face 
of the PVM. Bands corresponding to the size of the marker proteins PfSERP and 
Pfaldolase were each found in the pellet fractions meaning that the PV was not lysed 
after SLO treatment of the parasitized cells but remained intact. In a next step the 
saponin lysis in combination with Proteinase K treatment was performed to figure out 
whether or not the AK2 protein was secreted beyond the PPM. Saponin treatment of 
parasitized cells leads to the retention of an intact parasite and to disintegration of the 
RBCM and PVM resulting in the release of the erythrocyte cytosol and the vacuolar 
content (supernatant fraction). Hence the pellet fraction after saponin treatment contains 
the intact parasite, the permeabilized PVM and RBCM, while the supernatant fraction 
after saponin treatment contains the erythrocyte cytosol and the vacuolar content. After 
saponin treatment bands corresponding to the size of the the marker proteins of both 
compartments - PV (marker protein: SERP) and parasite (marker protein: aldolase) - 
were found predominantly in the expected fractions. A positive control of efficient 
Proteinase K digestion for this particular experiment is missing, however, the efficiency 
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of Proteinase K digestion of a fusion protein is shown for one of the variants 
(PfAK2G2AC4A/GFP in Fig. 3.7 C).  
Although a band of 130 kDa corresponding to PfSERP could also be detected in the 
saponin pellet fraction of the PfAK2/GFP parasitized cells the band disappeared after 
Proteinase K treatment indicating that SERP sticks to membranes and was not properly 
removed during the washing steps after saponin treatment. Also a small amount of 
aldolase was detected in the supernatant fraction after saponin treatment, the majority of 
aldolase was found in the pellet fraction. This is a general issue of this procedure which 
could also be seen in different P. falciparum studies (Ansorge et al., 1997; Spielmann et 
al., 2006; Heiber et al., 2013). However, the band of ~ 60 kDa in the saponin pellet 
fraction of the sample from the PfAK2/GFP transgenic parasite line when treated with 
Proteinase K disappeared. This indicates that Proteinase K had access to the fusion 
protein (Fig 3.4 B) what indicates that AK2 fused to GFP was not protected by the 
parasite plasma membrane. This finding corresponds to the findings of Ma and 
colleagues in which they claim PfAK2 to be located beyond the PPM. To further 
support the role of N-myristoylation in the secretion process beyond the PPM the 
PfAK2G2A/GFP variant was analyzed in the same manner. Since the marker proteins of 
the PV (SERP) and parasite (aldolase), respectively, were almost found in the expected 
fractions after SLO and saponin treatment, respectively, an almost proper lysis did take 
place. However, similar as observed for the saponin treated PfAK2/GFP parasites, the 
PV marker protein SERP also was detected in the pellet fraction, but almost disappeared 
in the saponin pellet fraction treated with Proteinase K. This suggets that SERP sticks to 
membranes and is difficult to remove despite many washing steps during sample 
preparation. However, the band in the saponin pellet fraction of the variant 
PfAK2G2A/GFP still could be detected by an α-GFP antibody after Proteinase K 
treatment. This indicates that the fusion protein was not digested by proteinase and that 
Proteinase K had no access to the fusion protein. From this observation it can be 
concluded that the N-myristoylation site indeed plays a role in the localization of the  
P. falciparum AK2 protein. Two different phenotypes could be observed in the 
fluorescence analyses comparing the wildtype protein and one where the  
N-myristoylation site was removed (Ma et al., 2012). This is consistent with the 
findings of the biochemical approach in which the wildtype fusion protein was found 
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digested upon Proteinase K treatment after saponin lysis. This indicates that the 
wildtype protein is secreted into the PV, while the variant of this protein, which lacks 
the N-myristoylation site, remained protected within the parasite cytosol (Fig. 3.4).  
 
DIC GFP Overlay 
DIC GFP Overlay 
CRT 
GFP AK2 
MGSCYS... 
CRT 
GFP AK2G2A 
MASCYS... 
A 
 
 
 70 
 55 
130 
100 
 55 
 40 
1   2 3 1   2 3 
1: Supernatant  2: Pellet 3: Pellet treated with Proteinase K 
kDa 
AK2WT 
SLO Saponin 
α-GFP 
α-SERP 
α-Aldolase 
1 
  
2 3 1 
  
2 3 
AK2G2A 
SLO Saponin 
B 
 
3	  	  Results	   78	  
Figure 3.4 Live cell imaging and a biochemical approach of the PfAK2/GFP transgenic parasite line 
and the variant PfAK2G2A/GFP  
(A) Live cell imaging of the PfAK2/GFP expressing parasites reveals a ring-like structure of the fusion 
protein, while the signal of the fusion protein of the PfAK2G2A/GFP parasites appears to be cytosolic. DIC 
channel for high-contrast; overlay (green =GFP; Hoechst = nucleus dye). Scale bar – 3 µm. (B) The 
PfAK2/GFP transgenic parasites and the respective variant were both subjected to SLO and saponin lysis, 
followed by a protease protection assay. PfSERP and Pfaldolase were used as PV marker protein and 
parasite marker protein, respectively. All of the marker proteins could be detected with their respective 
antibodies predominantly in the expected compartments after SLO and saponin lysis. However, aldolase 
was also sometimes detected in the supernatant fraction, which indicates that a small amount of parasites 
did lyse during the whole procedure. The fusion proteins PfAK2/GFP and PfAK2G2A/GFP were detected 
with an α-GFP antibody after SLO and saponin lysis in the SLO pellet fraction and also the pellet fraction 
treated with Proteinase K. However, while the variant of the fusion protein PfAK2G2A/GFP was detected 
in both saponin pellet fractions (-/+ Proteinase K addition), the wildtype fusion protein could not be 
detected in the saponin pellet fraction treated with Proteinase K. This indicates that the protein was 
accessible to Proteinase K. The size-marker is presented in kDa.  
 	  
3.2.1 A multiple sequence alignment  
Ma and colleagues already performed a multiple sequence alignment with PfAK2,  
PfAK1, the two PfAKLPs, PfGAK and the human AK6, in which they showed that the 
N-terminus of PfAK2 differed from the N-termini of the other aligned proteins (Ma et 
al., 2012). In this study, a further multiple sequence alignment (MSA) of PfAK2 with 
putative adenylate kinase 2 proteins of other Plasmodium species and other 
Apicomplexa was performed. Except for Plasmodium cynomolgi (B strain) – a 
Plasmodium species known to infect monkeys – which harbours the adenylate kinase 2 
protein, only putative adenylate kinase 2 proteins were identified for the other 
Plasmodium species. Interestingly, other parasitic protozoa such as Babesia bovis and 
some Leishmania species also contain an adenylate kinase 2 protein. That is why 
Babesia bovis and Leishmania infantum were also included in the MSA.  
Only the N-terminus (1-50 positions) is presented in the following graphic (Fig. 3.5). 
The entire sequence alignment can be found in the appendix. The N-terminus of PfAK2 
clearly revealed motifs, which are missing in the N-terminus of PfAK1, but also in the 
N-termini of the other adenylate kinase 2 proteins of the other Plasmodium species and 
the other parasitic protozoa. Apart from the glycine residue at the N-terminus, which 
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has already been shown to be myristoylated by plasmodial NMT (Rahlfs et al., 2009), a 
cysteine residue at the 4th position was found at the N-terminus of plasmodial AK2 
indicative for a putative palmitoylation site. According to the 'two-step model' a stable 
membrane anchoring of a myristoylated protein requires either a palmitoylation site or a 
polybasic cluster of amino acids close by. The N-terminus of PfAK2 harbours in 
addition to a putative palmitoylation site a polybasic cluster of lysine residues at the N-
terminus. These motifs might play a role in stable protein anchoring and secretion 
beyond the parasite plasma membrane as was already shown for the Leishmania 
HASPB and the Plasmodium CDPK1: both proteins contained in addition to a N-
myristoylation site a palmitoylation site at their N-terminus (Denny et al., 2000; Möskes 
et al., 2004). However, these  motifs were not found in the other verified and putative 
adenylate kinase 2 proteins aligned. 
 
	  
Figure 3.5 A multiple sequence alignment of the N-terminus of PfAK2 and other verified and 
putative adenylate kinase 2, respectively, in other Plasmodium species and other parasitic protozoa 
PfAK2 (PF3D7_0816900) was aligned to PfAK1 (Pf3D7_1008900), PbAK2, putative 
(PBANKA_071390), PcAK2, putative (PCHAS_072300), PkAK2, putative (PKH_051560),  
PvAK2, putative (PVX_094660), PyAK2, putative (PYYM_071400), PcAK2 (PCYB_081850),   
BbAK2 (bbov|XP_001609458.1) and LiAK2 (linf|LinJ.34.0130). The N-terminus of PfAK2 clearly 
differs from the N-termini of the other aligned proteins, insofar as it contains a verified N-myristoylation 
site (Rahlfs et al., 2009), a putative palmitoylation site at the 4th position and a polybasic cluster of lysine 
residues (each motif marked in grey). None of the other AK2 proteins contain either of these motifs. The 
alignment was created using ClustalW and only the first 50 positions are shown. The entire sequence 
alignment can be found in the appendix.  	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3.2.2 A putative palmitoylation site at the N-terminus of PfAK2   
In order to figure out whether or not PfAK2 has a putative palmitoylation site at the N-
terminus the cysteine residue at position 4 was changed to alanine. The resultant  
PfAK2C4A/GFP transgenic parasite line was first visualized by fluorescence microscopy 
before being subjected to hypotonic, SLO and saponin lysis followed by SDS-PAGE, 
western blotting and immunodetection. Fluorescence analysis of the PfAK2C4A/GFP 
transgenic parasites reveals a different phenotype to the wildtype PfAK2/GFP (Fig. 3.4 
A). Instead a ring-like structure as visualized for the wildtype PfAK2/GFP expressing 
parasites the GFP signal of this variant lacking the putative palmitoylation site appears 
cytosolic. Interestingly, patch-like accumulation at some regions within the parasite 
cytosol can be seen especially in the early trophozoite stage of the parasite (marked with 
a white arrow in Fig. 3.6 A), but also in late-stage parasites. This observation coincides 
with the findings of the hypotonic lysis, which was used to distinguish between soluble 
and membrane fraction of the parasitized cells. For the soluble fraction the plasmodial 
aldolase was used as a marker protein, while for the membrane fraction the PfExported 
protein 1 (Exp1) - an integral membrane protein of the PVM (Günther et al., 1991)- was 
used as a marker protein. A band of about 60 kDa could be detected with an α-GFP 
antibody in both fractions corresponding to the size of the fusion protein  
PfAK2C4A/GFP. A soluble and membrane-bound pool of this protein could be detected. 
Antibodies against PfExp1 and Pfaldolase were used to detect these proteins in the 
soluble and membrane fraction, respectively, as a control for proper separation (Fig. 3.6 
B). SLO treatment of the transgenic parasites of the PfAK2C4A/GFP line revealed that 
the GFP chimera was found in both SLO pellet fractions (+/- Proteinase K). This 
indicates that no digestion of the fusion protein took place. A positive control of 
efficient Proteinase K digestion for this particular experiment is missing, however, the 
efficiency of Proteinase K digestion of a fusion protein in general is shown for one of 
the variants (PfAK2G2AC4A/GFP in Fig. 3.7 D). The detection of the marker proteins 
PfSERP and Pfaldolase by their respective antibodies in the SLO pellet fraction 
indicates that proper lysis by SLO had occured since their correct localization indicates 
an intact PV. A strong GFP signal was obtained in the pellet fraction of saponin treated 
PfAK2C4A/GFP transgenic parasites, which was detected by the α-GFP antibody. The 
band in the saponin pellet fraction treated with Proteinase K was of similar size and 
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intensity indicating that the fusion protein lacking the putative palmitoylation site was 
protected by the parasite plasma membrane, hence not secreted beyond the PPM. Also 
the compartments seem to be almost intact after saponin treatment of the parasitized 
cells since the bands corresponding to the size of PfSERP and Pfaldolase were 
predominantly detected in the expected fractions. Again SERP sticks to the membrane 
in the saponin pellet fraction but almost disappeared after Proteinase K treatment. Here 
also a small amount of aldolase is detected in the supernatant fraction indicating some 
lysis of the parasites during the treatment. From these observations it can be concluded 
that the PfAK2C4A variant exists in a soluble and membrane-bound form possibly 
resulting from the unstable binding of the myristoyl moiety to a membrane. This can be 
seen by the fluorescence images due to some patch-like accumulation of the GFP signal 
in the overall cytosolic signal inside the parasite. Further, a partial soluble and 
membrane-bound pool of the protein was found after hypotonic lysis. The lack of the 
cysteine residue at the N-terminus prevented secretion of the protein beyond the parasite 
plasma membrane as indicated by saponin lysis and the protease protection assay.   
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Figure 3.6 The PfAK2C4A/GFP transgenic parasite line shows a cytosolic localization and is not 
secreted beyond the parasite plasma membrane 
(A) Live cell imaging of the PfAK2C4A/GFP parasite line in early and late trophozoite stages show patch-
like structures within the parasite, which is different to the wildtype phenotype. DIC channel for high-
contrast; in merge: green (GFP),  blue (Hoechst = nucleus dye). Scale bar – 3 µm. (B) After hypotonic 
lysis a band corresponding to the size of the fusion protein could be detected in the soluble and membrane 
fraction. Pfaldolase was used as a control for the soluble fraction and PfExp1 was used as a control for the 
membrane fraction. (C) PfAK2C4A/GFP parasites were subjected to SLO and saponin lysis. The marker 
proteins PfSERP of the PV and Pfaldolase of the parasite were both found predominantly in the expected 
fractions indicating an almost proper SLO lysis and saponin lysis, respectively. However, minimal 
amounts of aldolase could also be detected in the supernatant fraction and a small amount of SERP was 
also found in the saponin pellet fraction even after Proteinase K treatment. This indicates that some 
parasites did indeed lyse during the whole procedure. The size markers are presented in kDa.   	  
3.2.3 The PfAK2G2AC4A expressing parasites localize to the parasite cytosol 
To further examine the role of the N-myristoylation site and the putative palmitoylation 
site a further transfectant line was generated. Therefore the N-myristoylation and the 
putative palmitoylation site were removed from PfAK2 by changing the respective sites 
to alanine. The resultant PfAK2G2AC4A/GFP transgenic parasite line was visualized by 
fluorescence microscopy and then subjected to biochemical analyses. The  
PfAK2G2AC4A/GFP parasites showed a strong cytosolic signal of the fusion protein when 
observed by fluorescence microscopy (Fig. 3.7 A), which differs in location from the 
GFP signal seen with the wildtype transgenic parasite strain. The cytosolic localization 
of the GFP chimera is further supported by the hypotonic lysis study where a band 
corresponding to the PfAK2G2AC4A/GFP of 60 kDa could be detected in the soluble 
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fraction by an α-GFP antibody. PfExp1 was detected in the membrane fraction, while 
Pfaldolase was detected in the soluble fraction showing that a clear separation took 
place during the lysis procedure (Fig 3.7 B). The parasites were subjected to SLO and 
saponin lysis. This time the pellet fraction of the SLO and saponin lysis, respectively, 
were equally divided into for samples and were treated as followed: 1) untreated 
(control), 2) addition of Proteinase K, 3) addition of Proteinase K and Triton X-100 and 
4) addition of Triton X-100 and PIC/PMSF. Triton X-100 was used to permeabilize the 
PPM giving Proteinase K access to degrade the GFP chimera, once it is released upon 
Triton X-100 treatment of the cells. This positive control shows the efficacy of 
Proteinase K digestion of the fusion protein (disappearance of the protein band in this 
fraction). Treatment of the parasizited cells with only Triton X-100 showed that the 
protein band of the GFP chimera is still present meaning that Triton X-100 is not 
causing the disappearance of the protein band (negative control). PIC and PMSF were 
added to prevent degradation of the fusion protein by endogenous proteases. The fusion 
protein was affected by Triton X-100 permeabilization and Proteinase K treatment, but 
not by Triton X-100 permeabilization alone. In the SLO and saponin treated samples of 
the PfAK2G2AC4A/GFP transgenic parasite line, respectively, the GFP chimera was 
detected in the pellet fraction treated with Proteinase K and in the untreated one. This 
indicates that the fusion protein is not secreted beyond the PVM and the PPM, 
respectively. The marker proteins ensuring correct lysis and correct performance of the 
protease protection assay were detected predominantly in the expected fractions. 
However, in the SLO treated samples a small amount of SERP could also be detected in 
the supernatant fraction indicating that some lysis during the SLO treatment of the 
parasitized cells did occur (Fig. 3.7 C). In saponin treated samples a minimal amount of 
Pfaldolase and the GFP chimera could also be detected in the supernatant fraction, 
however the protein signal detected was much weaker compared to the signal found in 
the pellet fraction (Fig. 3.7 C). This indicates that some parasites were lysed during this 
sensitive procedure. This extended biochemical analysis of PfAK2G2AC4A/GFP was 
performed with a positive control for verification of Proteinase K efficacy towards the 
fusion protein. In conclusion, it can be stated that these findings are similar to the 
findings of the PfAK2G2A/GFP variant, which lacks the N-myristoylation site and was 
also localized to the cytosol of the parasite. The N-myristoylation motif seems crucial 
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for membrane binding and probably membrane targeting. This conclusion can be made 
since no membrane bound pool of proteins could be detected following hypotonic lysis. 
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Figure 3.7 Removal of acylation sites at the N-terminus of PfAK2 localizes the fusion protein to the 
cytosol of the parasite(A) Fluorescence analyses of the PfAK2G2AC4A/GFP parasites clearly showed a 
cyotosolic localization of the fusion protein PfAK2G2AC4A/GFP. DIC channel for high-contrast; in merge: 
green (GFP), blue (Hoechst = nucleus dye). Scale bar – 3 µm. (B) After hypotonic lysis performed on this 
transgenic parasite line a band of approximately 60 kDa corresponding to the GFP chimera was detected 
solely in the soluble fraction with an α-GFP antibody. Pfaldolase was used as a marker protein for the 
soluble fraction and PfExp1 was used as a marker protein for the membrane fraction. (C) The parasites 
were subjected to SLO and saponin lysis. The pellet fraction of the SLO and saponin lysis, respectively, 
were equally divided into for samples and were treated as followed: 1) untreated (control), 2) addition of 
Proteinase K, 3) addition of Proteinase K and Triton X-100 and 4) addition of Triton X-100 and 
PIC/PMSF. Triton X-100 was used to permeabilize the PPM so that Proteinase K is able to degrade the 
GFP chimera, once it is released upon Triton X-100 treatment of the cells. This positive control shows the 
efficacy of Proteinase K degradation of the fusion protein (disappearance of the protein band in this 
fraction). Treatment of the parasizited cells with only Triton X-100 showed that the protein band of the 
GFP chimera is still present meaning that Triton X-100 is not causing the disappearance of the protein 
band (negative control). PIC and PMSF were added to prevent degradation of the fusion protein by 
endogenous proteases. PfSERP of the PV and Pfaldolase of the parasite were both found predominantly 
in the expected fractions indicating an almost proper SLO lysis and saponin lysis, respectively. However, 
aldolase was also found in the supernatant fraction of saponin treated parasitized cells and a small amount 
of SERP was detected in the supernatant fraction of SLO treated samples. This indicates that some of the 
parasites did lyse during the procedures. Both proteins were affected by Triton X-100 permeabilization 
and Proteinase K treatment, but not by Triton X-100 permeabilization alone. The size markers are 
presented in kDa.   
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3.2.4 Is a third motif involved in the secretion process of Pf AK2? 
The MSA revealed a stretch of lysine residues (ten lysines with one interspersed 
glutatmate residue) at the N-terminus of PfAK2 at close proximity to the  
N-myristoylation site. According to the 'two-step model' of membrane binding by 
myristoylated proteins a polybasic stretch of amino acids in addition to the myristoyl 
moiety leads to a stable membrane anchoring of myristoylated proteins to a membrane 
(Murray et al., 1997). To investigate the role of the lysine residues at the N-terminus of 
PfAK2 these amino acids were deleted via overlapping extension PCR and the resultant 
construct PfAK2Δ21-30/GFP was transfected into the 3D7 P. falciparum line. Live cell 
imaging showed a ring-like structure with a protrusion similar to the wildtype GFP 
chimera, although the protrusion is less prominent compared to the wildtype 
PfAK2/GFP (Fig. 3.8 A). Subsequent analyses on the subcellular localization of this 
protein were performed via hypotonic lysis, SLO and saponin lysis followed by SDS-
PAGE, western blotting and immunodetection. The hypotonic lysis clearly separated the 
soluble from the membrane fraction of proteins, since Pfaldolase was detected in the 
soluble fraction and PfExp1 was found in the membrane fraction. The GFP signal from 
the PfAK2Δ21-30/GFP fusion protein could be detected with an α-GFP antibody in the 
membrane fraction showing that this variant protein is membrane-bound, which is in 
accordance with the findings of the fluorescence analyses (Fig. 3.8 B). In the SLO 
treated samples a band corresponding to the size of the GFP chimera could be detected 
in both the untreated SLO pellet fraction and the SLO pellet fraction treated with 
Proteinase K. This indicates that PfAK2Δ21-30/GFP is not secreted beyond the PVM. 
Faint bands observed with a slightly lower molecular weight than the  
PfAK2/GFP fusion protein possibly are degradation products. A positive control of 
efficient Proteinase K digestion for this particular experiment is missing, however, the 
efficiency of Proteinase K digestion of a fusion protein was shown for one of the 
variants (PfAK2G2AC4A/GFP in Fig. 3.7 C). 
Surprisingly, a band of ~ 60 kDa was detected with an α-GFP antibody in the saponin 
pellet fraction treated with Proteinase K and in the untreated saponin pellet fraction. 
This indicates that the fusion protein was protected by the PPM. The marker proteins for 
each compartment – PV (marker protein: SERP) and parasite (marker protein: aldolase) 
– were found predominantly in the expected fractions, although a faint band of  
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Pfaldolase could also be detected in the supernatant fraction after SLO and saponin 
treatment, respectively. However, the signal detected in the pellet fraction was much 
stronger indicating that the parasites almost remained intact after SLO and saponin 
treatment, respectively. A faint band of PfSERP could also be detected in the pellet 
fraction but almost disappeared after Proteinase K treatment. This indicates that SERP 
stuck to the membrane and was not fully removed during the washing steps after 
saponin treatment (Fig. 3.8 C).  
Although a stable membrane anchoring was achieved with the PfAK2Δ21-30/GFP fusion 
protein in the parasitized cells as evidenced by fluorescence and hypotonic lysis, no 
secretion of the GFP chimera was found based on the results of the saponin treatment. 
From this, it can be concluded that the variant chimeric protein is stably bound to the 
parasite plasma membrane by the myristoyl moiety and by potential palmitoylation. 
However, the lack of the lysine residues seem to prevent the secretion of this protein 
beyond the PPM.   
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Figure 3.8 Deletion of a polybasic-cluster at the N-terminus of PfAK2 prevents secretion beyond the 
parasite plasma membrane 
(A) Live cell imaging of PfAK2Δ21-30/GFP parasites showed a ring-like structure of the fusion protein with 
a knob-like protrusion similar to the wildtype PfAK2/GFP. DIC channel for high-contrast; in merge: 
green (GFP),  blue (Hoechst = nucleus dye). Scale bar – 3 µm. (B) After hypotonic lysis of the PfAK2Δ21-
30/GFP parasites a band of ~ 60 kDa could be detected with an α-GFP antibody in the membrane fraction. 
Pfaldolase was used as a marker protein for the soluble fraction and PfExp1 was used as a marker protein 
for the membrane fraction. (C) The parasites were also subjected to SLO and saponin lysis.  
PfSERP of the PV and Pfaldolase of the parasite were both found predominantly in the expected fractions 
indicating proper SLO and saponin lysis, respectively. The band corresponding to the size of the fusion 
protein PfAK2Δ21-30/GFP was detected with an α-GFP antibody in the SLO and saponin pellet fraction 
(+/- Proteinase K addition). The size markers are presented in kDa.   	  
   
3.2.5 Is the N-terminus of PfAK2  - containing a N-myristoylation site, a putative 
palmitoylation site and a polybasic cluster of amino acids - sufficient for protein 
secretion? 
The preceding mutagenesis analyses of PfAK2 revealed that a N-myristoylation site is 
required for membrane binding and that a putative palmitoylation site likely plays a role 
in stabilizing the membrane anchoring of this protein. However, secretion of PfAK2 
beyond the PPM was not achieved when a polybasic cluster of amino acids was 
removed indicating its potential role in the secretion mechanism. To figure out whether 
or not these three motifs found at the N-terminus of PfAK2 are sufficient for an atypical 
secretion pathway the following chimeric construct was designed: the 1-37 amino acids 
of the PfAK2 protein sequence containing all three above mentioned motifs was fused 
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to GFP in the pARL2 vector and then transfected into the 3D7 P. falciparum parasite 
line. Fluorescence analyses of the respective transgenic parasite line revealed a similar 
phenotype to the wildtype AK2 that is a ring-like structure with a clear knob-like 
protrusion (Fig. 3.9 A). Furthermore, live cell imaging of the schizont-stage of the 
parasite showed a ring-like structure around each individual parasite (Fig. 3.9 A). 
Hypotonic lysis performed on this parasite line revealed that the GFP chimera was in 
the membrane-bound fraction. Faint bands of low molecular weight in the supernatant 
fraction could be degradation products of the fusion protein. Pfaldolase was used as a 
marker protein for the soluble fraction and PfExp1 was used as a marker protein for the 
membrane fraction. Both proteins were found in the expected fractions (Fig. 3.9 B). The 
SLO treated sample of the PfAK21-37/GFP transgenic parasite line revealed a band of 
approximately 25 kDa detected with an α-GFP antibody corresponding to the size of the 
fusion protein in the untreated SLO pellet fraction and the SLO pellet fraction treated 
with Proteinase K. Low molecular weight bands which appear in both pellet fractions 
possibly are degradation products. The detection of the marker proteins with the 
respective antibodies revealed their localization predominantly to the respective 
compartments displaying an almost proper SLO lysis, thus an intact PV and parasite. 
However, a a small amount of SERP was also detected in the supernatant fraction after 
SLO treatment indicating that some parasites did lyse during the SLO procedure.  
Interestingly, a GFP signal was found in the saponin pellet fraction, but not in the 
saponin pellet fraction treated with Proteinase K. This indicates that the protein was not 
protected by the PPM and was accessible to Proteinase K digestion. The marker 
proteins assuring proper saponin lysis were detected with an α-SERP antibody and an α-
aldolase antibody in the expected fractions: SERP in the supernatant fraction, whereby 
the signal detected in the pellet fraction was almost removed after Proteinase K 
treatment. This means that SERP sticks to membranes and was not sufficiently washed 
off despite many washing steps. Aldolase, however, was predominantly found in the 
pellet fractions (sample treated with Proteinase K and untreated sample), and only a 
faint band was also detected by an α-aldolase antibody in the supernatant fraction (Fig. 
3.9 B) indicating that some of the parasites did lyse during the procedure. These results 
indicates that the N-terminus of PfAK2 is sufficient for secreting the GFP chimera 
across and to the outer face of the PPM.  
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Figure 3.9 Live cell imaging and biochemical analyses of the PfAK21-37/GFP transgenic parasite line 
(A) The fluorescence analyses of the PfAK21-37/GFP parasites showed a ring-like structure with a clear 
knob-like protrusion of the fusion protein very similar to the phenotype of the wildtype PfAK2/GFP 
parasites. The schizont-stage of these parasites showed a clear signal of the fusion protein around each of 
the individual daughter cells. DIC channel for high-contrast; in merge: green (GFP),  blue (Hoechst = 
nucleus dye). Scale bar – 3 µm. (B) Biochemial analyses showed the fusion protein to be membrane-
bound, since the GFP chimera could be detected in the membrane fraction after hypotonic lysis.  
Pfaldolase was used as a marker protein for the soluble fraction and PfExp1 was used as a marker protein 
for the membrane fraction and were found in the expected fractions. Faint bands in the supernantant 
fractions might be degradation products of the fusion protein (C) The parasites were also subjected to 
SLO and saponin lysis. The marker protein of the PV PfSERP and the marker protein of the parasite 
Pfaldolase were both found predominantly in the expected fractions after SLO lysis and saponin lysis, 
respectively. The band corresponding to the size of the fusion protein PfAK21-37/GFP was detected by an 
α-GFP antibody in the SLO pellet fractions (+/- Proteinase K addition) and in the saponin pellet fraction. 
However, no band could be detected in the saponin pellet fraction treated with Proteinase K. The size 
markers are presented in kDa.    	  
3.2.6 The ARF1-AK2/GFP chimera is targeted to the parasite plasma membrane  
Plasmodial ARF1 contains a N-myristoylation site and it has been shown that it 
localizes to compartments of the early secretory pathway (by fluorescence analyses) and 
is partially membrane-bound (by hypotonic analyses). In contrast to PfAK2 plasmodial 
ARF1 lacks a putative palmitoylation site and a polybasic cluster of amino acids at the 
N-terminus. To figure out whether these two motifs are sufficient for secretion of 
N-myristoylated proteins to the plasma membrane and subsequent secretion beyond the 
parasite plasma membrane a chimeric construct consisting partially of the N-terminus of 
ARF1 and partially of the N-terminus of AK2 was generated and fused to GFP in the 
pARL2 vector prior to transfection in the P. falciparum 3D7 strain. Fluorescence 
analyses showed a phenotype similar to the wildtype AK2 with a ring-like structure 
containing a 'loop' like protrusion. However, occasionally also a ring-like structure with 
a dot-like protrusion was also observed (Fig. 3.10 A). Live cell imaging of the schizont-
stage of the PfARF11-17/+4C/-V5AK2+18-37/GFP parasites showed a ring-like structure 
around the individual parasites (Fig. 3.10 B). According to the results of the hypotonic 
lysis a strong GFP signal corresponding to the size of the GFP chimera could be 
detected in the membrane fraction and a faint band could also be seen in the soluble 
fraction. The soluble amount of the protein indicate some degradation products or it 
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could result from the pool of protein which at the time-point of harvest was not 
anchored to the membrane. However, the majority of this protein was found membrane-
bound. The marker proteins Pfaldolase and PfExp1 were detected in the respective 
fractions ensuring that proper separation of soluble and membrane fraction by hypotonic 
lysis had occured (Fig. 3.10 C). A proper SLO lysis on the PfARF11-17/+C4/-V5AK2+18-
37/GFP line was performed since the marker proteins PfSERP and Pfaldolase were both 
predominantly found in the pellet fractions. However, a small amount of SERP was also 
found in the supernatant fraction, which indicates that some of the parasites did lyse 
during the procedure, however the majority of the SERP protein was detected in the 
pellet fractions. The protease protection assay was almost efficient since a strong  
PfExp1 signal could be detected in the pellet fraction and only a faint band was found in 
the pellet fraction treated with Proteinase K. A saponin treatment was also performed on 
the respective transgenic parasite strain where aldolase could be detected solely in both 
pellet fractions (-/+Proteinase K treatment), while PfSERP was found in the supernatant 
and the pellet fraction. A strong GFP signal in the saponin pellet fraction without 
Proteinase K addition could be detected by an α-GFP antibody, but was also found 
present in the Proteinase K treated pellet fraction. This indicates that the  
PfARF11-17/+C4/-V5AK2+18-37/GFP fusion protein was protected by the parasite plasma 
membrane and that the protein is not secreted into the PV (Fig. 3.10 D). These results 
initially seem contradictory, since the phenotype of PfARF11-17/+C4/-V5AK2+18-37/GFP 
resembles that of the wildtype PfAK2/GFP but the protease protection assay showed no 
secretion of the GFP chimera of this transgenic parasite line compared to the wildtype 
fusion protein. One possible explanation might be that although the additional cysteine 
residue and the polybasic cluster of lysine residues added to the N-terminus of 
plasmodial ARF1 seem to traffic the chimeric protein to the parasite plasma membrane 
(determined by fluorescence analyses) and leads to a stable membrane anchoring 
(determined by hypotonic lysis), further amino acids in the N-terminal region of PfAK2 
also seem to play a role in the secretion process. The N-terminal part of PfARF1 
modified by the addition of the two AK2 motifs (cysteine residue at position 4 and a 
stretch of lysine residues with one interspersed glutamate residue) still differs by 11 
amino acids from the N-terminus of PfAK2.  
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Figure 3.10 Fluorescence and biochemcial analyses of the PfARF11-17/+C4/-V5AK2+18-37/GFP 
transgenic parasite line 
(A) Live cell imaging of the PfARF11-17/+C4/-V5AK2+18-37/GFP parasite line showed two slightly different 
phenotypes: some of the parasites show a ring-like structure with a knob-like protrusion, while others 
rather revealed just a ring-like structure with a prominent dot at one edge of the parasite. (B) Live cell 
imaging on the schizont stage of this parasite line showed a ring-like structure around each of the 
individual parasites separately. DIC channel for high-contrast; in merge: green (GFP),  blue (Hoechst = 
nucleus dye). Scale bar – 3 µm. (C) Biochemial analyses showed the fusion protein to be predominantly 
membrane-bound, since the GFP chimera could be detected in the membrane fraction after hypotonic 
lysis. However, a small amount of the fusion protein was also detected in the soluble fraction and a low 
molecular weight band might be degradation products. Pfaldolase was used as a marker protein for the 
soluble fraction and PfExp1 was used as a marker protein for the membrane fraction. (D) The parasites 
were also subjected to SLO and saponin lysis. PfSERP of the PV and Pfaldolase of the parasite were both 
found predominantly in the expected fractions after SLO lysis and saponin lysis, respectively. However, 
SERP was also detected in the SLO supernatant fraction meaning that some lysis of the parasite did take 
place during the SLO treatment. A small amount of aldolase was also found in the SLO and saponin 
supernatant fractions, respectively, which also indicates that some lysis of the parasites did occur. 
However, the majority of SERP and aldolase still could be detected in the expected fractions. The band 
corresponding to the size of the fusion protein PfARF11-17/+C4/-V5AK2+18-37/GFP was detected with an α-
GFP antibody in the SLO and saponin pellet fractions (+/- Proteinase K addition), respectively. The size 
markers are presented in kDa.   	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3.3 The mDHFR fusion system 
Dihydrofolate reductase is a ubiquitous eukaryotic enzyme responsible for the catalysis 
of dihydrofolate to tetrahydrofolate in a NADP-dependent manner. It is also known to 
be involved in the de novo synthesis of certain amino acids (Schnell et al., 2004). 
Interestingly, Eilers and Schatz used the murine DHFR as an experimental system to 
analyze the folding state of a protein regarding import into mitochondria. They found 
that mDHFR could be stabilized in its tertiary structure in the presence of a folate 
analogue and was not unfolded even in the presence of chaperones (Eilers and Schatz, 
1986; Salvador et al., 2000). This characteristic feature of mDHFR was used to study 
the translocation of mitochondrial proteins into mitochondria by fusing the pre-
sequence of a mitochondrial protein to mDHFR and detecting its localization in the 
absence and presence of a folat analogue, respectively (Eilers and Schatz, 1986). Since 
then the mDHFR system has been used to study the folding state of proteins and to 
understand translocation mechanisms in various compartments, such as mitochondria 
and glycosomes (Eilers and Schatz, 1986; Häusler et al., 1996).  
To analyze the folding state and the possible involvement of a translocon in the 
secretion process of PfAK2 beyond the PPM the protein was fused to mDHFR in 
addition to GFP, cloned into the pARL2 vector and the plasmid was then transfected 
into the P. falciparum 3D7 line. These parasites were not negatively affected by WR 
treatment, since they expressed a hDHFR. Fluorescence and biochemical analyses were 
performed. The following fluorescence images show PfAK2/mDHFR/GFP expressing 
parasites in the presence of WR after incubation at 37 °C for 12 hours and in the 
absence of WR (control). According to the microscopical pictures no differences 
between the WR treated and untreated parasites could be seen (Fig. 3.11 A). Both 
parasite cultures show a similar phenotype corresponding to the wildtype PfAK2/GFP 
parasite strain indicating that the addition of WR does not seem to have an effect on 
protein localization. This observation was supported with further analyses by hypotonic 
and saponin lysis, SDS-PAGE, western blotting and immunodetection. Hypotonic lysis 
performed on the PfAK2/mDHFR/GFP parasites (+/-WR) revealed a band 
corresponding to the size of the GFP chimera in both samples, which was detected with 
an α-GFP antibody solely in the membrane fraction in the WR treated and untreated 
parasites. The marker proteins, Pfaldolase and PfExp1 were detected in the respective 
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fractions ensuring that proper separation of soluble and membrane fraction by hypotonic 
lysis had occured. To analyze the subcelluar localization of the fusion protein in the WR 
treated and untreated parasites saponin lysis was performed. Pfaldolase was detected in 
both pellet fractions (-/+Proteinase K treatment), while PfSERP was found in the 
supernatant and the pellet fraction indicating that proper lysis was achieved. A strong 
GFP signal in the saponin pellet fraction without proteinase K addition could be 
detected with an α-GFP antibody, but was not found in the Proteinase K treated pellet 
fraction of both parasite cultures: + WR and – WR. This indicates that the  
PfAK2/mDHFR/GFP fusion protein was not protected by the parasite plasma 
membrane in the absence and presence, respectively, of WR.    
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Figure 3.11 The mDHFR system was used to analyze the folding state of the PfAK2 protein in the 
blood-stage parasite 
The PfAK2/mDHFR/GFP parasites were split into two cultures: one was treated with the folate analogue 
WR for 6 hours, while the other parasite culture was left untreated (control). After 6 hours the cells were 
visualized via fluorescence microscopy (A) and harvested for biochemical analyses (B).   
(A) Live cell imaging on the PfAK2/mDHFR/GFP parasites in the absence and presence of WR, 
respectively, was performed showing a ring-like structure with a loop distribution of the fusion-protein. 
The phenotypes did not differ from each other regardless of WR addition. DIC channel for high-contrast; 
in merge: green (GFP),  blue (Hoechst = nucleus dye). Scale bar – 3 µm. (B) After hypotonic lysis a band 
corresponding to the size of the fusion protein was detected in the membrane fraction with an α-GFP 
antibody in the WR treated and untreated sample, respectively. Pfaldolase was used as a marker protein 
for the soluble fraction and PfExp1 was used as a marker protein for the membrane fraction and both 
proteins were detected in the expected fractions. (C) After saponin treatment of each of the  
PfAK2/mDHFR/GFP parasites (-/+WR) a band corresponding to AK2/mDHFR/GFP was only detected in 
the saponin pellet fraction, but not in the saponin pellet fraction treated with Proteinase K indicating that 
the fusion protein was not protected by the PPM. PfSERP of the PV and Pfaldolase of the parasite were 
both found predominantly in the respective fractions after saponin lysis. The size markers are presented in 
kDa.    
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4 Discussion 
Over the years more and more light has been shed on the secretion and export 
mechanisms for secretory proteins expressed by P. falciparum in infected RBCs. In 
particular, the existence of the PV, which separates the parasite from the host cell, calls 
for further secretory signals apart from the classical signal peptide. The identification of 
recessed hydrophobic domains instead of the classical signal peptide in many exported 
parasite proteins was an early hallmark of the parasite’s atypical protein secretory 
mechanisms (Lingelbach, 1993). The discovery of the PEXEL/HT motif in exported 
proteins led to the in silico identification of approximately 250 proteins, which were 
predicted to be exported to the host cell (malarial 'exportome') (Marti et al., 2004; Hiller 
et al., 2004). The PEXEL/HT motif resembles a motif (RxLR) found in some proteins 
of fungal plant pathogens, which are exported to the host plant cells (Dou et al., 2008).  
 
Some parasite proteins exported to the host cell such as for example the SBP1, REX1 
and REX2 lack a classical N-terminal signal sequence and the PEXEL motif and are 
generally termed PEXEL negative exported proteins (PNEPs) (Saridaki et al., 2009; 
Haase et al., 2009). The number of PNEPs are steadily growing indicating the possible 
existence of pathways different from the classical secretory pathway in the malaria 
parasite (Heiber et al., 2013). The importance of understanding the secretory 
mechanisms in parasite protein trafficking is based on the fact that many of these 
exported proteins are key players in the pathogenesis and the adherence properties of 
the infected RBC.  
 
Therefore the identification of unconventional secretory mechanisms - like found for a 
small number of proteins in other eukaryotic systems (see introductory section 1.4) - of 
the parasite and the components involved increases the chances of finding a suitable 
potential drug-target for the development of antimalarial drugs against the 
intraerythrocytic stage.  
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This study deals with the analysis of P. falciparum parasite proteins, which lack a signal 
peptide or a hydrophobic stretch of amino acids at the N-terminus but were found 
secreted beyond the parasite plasma membrane, with a focus on the P. falciparum 
adenylate kinase 2 (Ma et al., 2012). This protein was proposed to contain a N-
myristoylation site at its N-terminus, which was hypothesized to play a role in the 
secretion mechanism. This hypothesis was followed up in this work by further reporter 
construct studies, co-localization studies and biochemical analyses and the results are 
discussed here.  
 
4.1 The secretion hypothesis is based on the result of a preceding PV 
proteome analysis 
The parasitophorous vacuole is a compartment with a very small lumen surrounding the 
parasite and separating it from the host cell cytosol (Lingelbach and Joiner, 1998). An 
experimental approach to identify proteins of the PV already revealed 27 vacuolar 
proteins assigning many of them via in silico analysis as chaperones and proteases 
(Nyalwidhe and Lingelbach, 2006). Since it has already been shown that many exported 
proteins, which contain the PEXEL motif, cross the PVM before entering the host cell it 
can be hypothesized that chaperones might play a role in the unfolding of these proteins 
(Ansorge et al., 1996; Wickham et al., 2001; Gehde et al., 2009; Nyalwidhe and 
Lingelbach, 2006). A second vacuolar proteome analysis of the parasite from a similar 
proteomic study of the PV enabled the identification of ~ 200 vacuolar proteins, from 
which 96 proteins were analyzed for topogenic signals. Approximately 50 % of these 
proteins lacked any distinguishable signal peptide. To further validate these findings 
two proteins from the latter group were randomly selected, fused to GFP and their 
subcellular localization was analyzed. Indeed both of the proteins were found secreted 
confirming the proteomic results, although the mode of secretion was not understood. 
More interestingly, 5 % of the proteins of the PV proteome analysis which lacked any 
known signal peptide contained instead a putative N-myristoylation site indicating the 
role of N-myristoylation in protein secretion. The role of N-myristoylation in protein 
secretion has already been shown for P. falciparum CDPK1 (Möskes et al., 2004) and 
the Leishmania HASPB (Denny et al., 2000). Both studies showed by mutational 
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analyses that the N-myristoylation site at the N-terminus of CDPK1 and HASPB, 
respectively, is a prerequisite for membrane attachment.  
 
4.1.1 Does the 'Met-Gly...' motif at the N-terminus of PfPrefoldin 
(PF3D7_0904500), PfCDPK4 (PF3D7__0717500) and PfARF1 (PF3D7_1020900) 
affect their subcellular localization? 
One of the selected proteins from the proteome analysis is the chaperone Prefoldin 
(PF3D7_0904500), which contains a 'Met-Gly...' motif at the N-terminus. Although the 
secretion of a chaperone into the PV would fit a role of being a resident PV protein due 
to its function in promoting protein folding, the Myristoylator prediction tool did not 
predict Prefoldin to be myristoylated. This prediction was confirmed experimentally: a 
reporter construct study showed no difference in the subcellular localization of the 
fusion protein between the wildtype phenotype and the variant. In the variant the 
putative myristoylation site was removed by exchange of the glycine residue to alanine 
at the N-terminus of the protein. According to the GFP fluorescence analysis it seems 
like Prefoldin is located in the parasite cytosol. Due to the limited resolution of 
epifluorescence microscopy it cannot be completely ruled out that a small portion of 
Prefoldin is also located beyond the parasite plasma membrane indicating a dual 
localization of the protein. However, according to the fluorescence analysis the majority 
of the protein was localized to the parasite cytosol. Hypotonic lysis and cell 
fractionation should be performed to examine the solubility of this protein in order to 
find out whether or not this protein is completely soluble or a small amount of it is also 
membrane-bound, which however cannot be distinguished via live-cell imaging. If a 
membrane-bound population would be identified this could mean that the protein is able 
to bind to a membrane due to a myristate moiety and further experiments could involve 
metabolic labelling or recombinant expression of PfPrefoldin and PfNMT together in 
bacterial cells with subsequent analysis of myristoylation. This would help to find out 
whether or not PfPrefoldin is capable of being N-myristoylated. After these experiments 
are performed a biochemical analysis involving SLO and saponin lysis could be carried 
out to identify the accurate localization of PfPrefoldin. Although these experiments 
seem to be reasonable to perform recombinant expression of P. falciparum proteins in 
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bacterial cells is often tricky and difficult to conduct due to the high AT-content of the 
parasite genes (Gardner et al., 2002).  
 
PfCDPK4 (PF3D7__0717500) was also hypothesized to be N-myristoylated based on 
the 'Met-Gly...' motif at the N-terminus and predicted to be myristoylated according to 
the myristoylator prediction tool. In addition, a second P. falciparum CDPK, CDPK1, 
was shown to be secreted across the PPM and the process involved N-myristoylation 
(Möskes et al., 2004). CDPKs are found only in plants and Alveolates (including 
ciliates and Apicomplexa) and protein kinases of protists generally are evolutionarily 
remote to human kinases, which is why they are considered to be suitable drug targets 
(Tsekoa et al., 2009). Although CDPK4 is predicted to be N-myristoylated the 
fluorescence analysis showed no difference in the location of the fusion protein between 
the wildtype phenotype and the G2A variant. This result differs from the findings for 
CDPK1. The CDPK1 fusion protein showed a ring-like structure around the parasite 
compared to the parasites expressing the PfCDPK1G2A  protein where the signal was 
found to be cytosolic (Möskes et al., 2004). As found for Prefoldin, CDPK4 seem to be 
predominantly located in the parasite cytosol, however, the protein was only recently 
verified to be N-myristoylated (Wright et al., 2013). Therefore further analysis of the 
accurate subcellular localization of PfCDPK4 are required.  
 
ARF1 is another protein, which was identified in the proteome analysis of the PV and 
was proposed to be secreted into the PV. In contrast to PfPrefoldin and PfCDPK4 the 
fluorescence images of the PfARF1 (PF3D7_1020900) transgenic parasites clearly 
showed 1 to 2 dot-like structures of the fusion protein in the parasite cytosol. However, 
the exchange of the glycine residue to alanine at the N-terminus altered the localization 
of PfARF1G2A/GFP in the parasite to completely soluble. Since ARF1 is ubiquitous in 
eukaryotic cells and highly conserved among eukaryotes (Boman and Kahn, 1995) it 
can be hypothesized that PfARF1 is myristoylated as well, since N-myristoylation is 
crucial for its biological role. Cook and colleagues have already shown that similar to 
human ARF1, PfARF1 also contains a helix at the N-terminus, which is important for 
the biological function of ARFs (Cook et al., 2010). Hence, it is not surprising to see an 
effect on the subcellular localization of the G2A variant upon removal of the  
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N-myristoylation site. Furthermore, the results of the hypotonic lysis revealed a 
membrane-bound PfARF1/GFP in the PfARF1/GFP transgenic parasites in contrast to 
the PfARF1G2A/GFP form, where a membrane-bound pool of the fusion protein was 
absent. This indicates that upon myristoylation the protein is able to associate with a 
membrane once it is activated by GTP. GTP is hydrolyzed by ARFGAPs and in the 
GDP-bound form the protein is predominantly cytosolic (Stafford et al., 1996; Memon, 
2004). Although the fluorescence images (dot-like structures of PfARF1/GFP within the 
parasite) suggest a greater membrane-bound pool of the GFP chimera in the 
PfARF1/GFP parasites, the cell fractionation study shows a more prominent band in the 
soluble fraction. This discrepancy possibly results from the low resolution of the 
epifluorescence microscopy in which the membrane-associated pool of the ARF1/GFP 
chimera compared to the soluble pool cannot be distinguished. This observation can be 
supported by further studies on human ARF1 where it is postulated that the Golgi 
membrane actually presents a platform for the exchange of GTP and GDP to take place 
(Franco et al., 1996; Weiss et al., 1989). This indicates that the GDP-bound form of 
PfARF1 is in close proximity to the GTP-bound form, but is still cytosolic. Application 
of for example super resolution microscopy would help to provide a better visualization 
of the ratio of membrane-bound to cytosolic PfARF1 in the parasite.  
 
In summary it can be concluded that the findings of the proteome analysis contradicts to 
the results of the fluorescence analysis of the reporter constructs. Analyzing the PV 
proteome with the given methods (high-throughput-analysis) is not only a very difficult 
challenge but also has a high probability of identifying false-positives during the entire 
procedure. This is mainly because the PV has a very small lumen and contamination is 
likely to occur with proteins of the parasite cytosol or host cell cytosol, respectively, 
during the experimental procedure. However, with the given methods it cannot be 
completely ruled out that Prefoldin or CDPK4 do not have a dual localization. It could 
be that a very small amount of this protein is also present in the PV, and this is why it 
was detected in the proteome analysis. However, as mentioned before further analysis 
of the localization of these proteins are required.  
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Since ARF proteins are structurally and functionally well conserved in eukaryotes 
(Boman and Kahn, 1995) their physiological role is probably the same across all 
eukaryotic organisms including P. falciparum. That is why it is quite surprising that this 
protein was detected in the PV, since its function is to mediate vesicular formation and 
trafficking in the early secretory pathway (Boman and Kahn, 1995). Although 
recombinant PfARF1 was expressed in E. coli and characterized (Stafford et al., 1996) 
and its structure even determined (Cook et al., 2010) a localization study of this protein 
is still missing.   
  
4.1.2 Analysis of the subcellular localization of PfARF1 in P. falciparum-infected 
RBC 
According to the co-localization studies with marker proteins of the early secretory 
pathway PfARF1 shows partial co-localization with the ER-marker PfSec12 and the 
trans-Golgi-marker PfRab6. A strong co-localization could be observed with PfGrasp1, 
the cis-Golgi marker. These results are in accordance with what is known about the role 
of ARF1 in vesicular trafficking in eukaryotes. The human ARF1 for instance has been 
shown to be mostly present at the cis-Golgi complex according to immunofluorescence 
and electronmicroscopy studies (Stearns et al., 1990). Furthermore, the protein is 
involved in vesicle formation and trafficking mainly from the Golgi to the ER and also 
between the Golgi cisternae (D'Souza-Schorey and Chavrier, 2006). Since ARF1 
proteins are structurally and functionally highly conserved across eukaryotes the 
localization and function of this protein will possibly be similar in P. falciparum. This is 
probably the reason why the signal of the PfARF1/GFP chimera shows a strong overlap 
with the signal of the PfGRASP1/mCherry chimera. PfARF1 also shows partial co-
localization with PfRab6, a protein found to be ubiquitous across eukaryotes and 
involved in trans-Golgi trafficking (Martinez and Goud, 1998). Although the Golgi-
complex in P. falciparum is less elaborate compared to its counterpart in higher 
eukaryotes a trafficking pathway via the Golgi exists within the parasite. That is why 
the dot-like signals of PfARF1 overlapped predominantly with PfGrasp1, but also with 
PfRab6. In accordance with its function in retrograde trafficking a partial co-
localization of PfARF1 with the ER-marker PfSec12 – a protein, which has already 
been shown to localize to the ER of Plasmodium (Lee et al., 2008) – was also detected. 
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As found in the study of Lee and colleagues the distribution of PfSec12/mCherry was 
perinuclear (Lee et al., 2008). All of these results strongly support the localization of 
PfARF1 to the early secretory system of the parasite rather than a PV localization. In 
addition, a co-localization study with the PVM marker Exp1 clearly showed no overlap 
of the GFP signal of PfARF1/GFP with the signal of the PVM marker PfExp1/mCherry. 
The biochemical analysis of the fusion protein PfARF1/GFP supports the findings of 
the fluorescence analysis. The results obtained from the SLO and saponin lysis analyses 
in combination with the protease protection assay revealed that PfARF1/GFP is not 
secreted beyond the parasite plasma membrane. Using a plasmodial α-ARF1 antibody 
against the endogenous protein also showed the presence of PfARF1 in the parasite 
cytosol according to the biochemical analysis. This indicates that the endogenous 
protein is protected by the parasite plasma membrane. Taken together, the localization 
of PfARF1 can be assigned exclusively to the parasite cytosol according to the 
fluorescence study, the co-localization study and the biochemical analysis. This finding 
very much fits with the general physiological role of ARF1, which is the vesicular 
shuttling between compartments of the secretory pathway (Boman and Kahn, 1995). 
The finding of PfARF1 in the PV according to the preceding proteomic approach falls 
into the category of a false-positive candidate. 
 
 
4.2 Is PfAK2 a candidate protein of an alternative secretory 
pathway? 
Ma and colleagues created a reporter construct consisting of the adenylate kinase 2 
(PF3D7_0816900) fused to GFP in a pARL vector and transfected the plasmid into 3D7 
parasites. The fluorescence image clearly showed a ring-like structure with 'loops' of the 
fusion protein. They proposed that this protein is localized to the PV (Ma et al., 2012). 
However, the AK2 protein lacks a signal peptide or any other known signal motif 
typical for the parasite which would drive secretion into the PV. Interestingly, earlier 
studies had already revealed AK2 to be a substrate of the PfNMT indicating that this 
protein is myristoylated (Rahlfs et al., 2009). To find out whether N-myristolyation 
plays a role in secretion they generated another reporter construct, where the  
N-myristoylation site was removed (PfAK2G2A/GFP). The plasmid was transfected into 
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3D7 parasites and in these transgenic parasites the subcellular localization of the GFP 
chimera was clearly altered to being cytosolic and different from the ring-like structure 
seen for the fusion protein PfAK2/GFP. Further analysis of the PfAK2/GFP parasites 
revealed co-localization with Exp1, the integral membrane protein of the PVM, but not 
with the soluble serine rich protein (SERP) located in the PV. From this Ma and 
colleagues concluded that PfAK2 is localized to the PVM and with the membrane stain 
Bodipy-TR-ceramide the 'loops' were identified as membranous structures (Ma et al., 
2012). Their hypothesis was that this protein is secreted into the PV driven by  
N-myristoylation similar to the findings of PfCDPK1 (Möskes et al., 2004). Möskes and 
colleagues showed that PfCDPK1 was myristoylated in vivo and proposed its 
localization to the PV according to reporter construct and immunoelectron microscopy 
studies. In a further mutational analysis the N-terminal glycine residue was replaced 
with valin and the fusion protein CDPK1VG2/GFP relocated entirely to the parasite 
cytosol indicating the role of N-myristoylation in targeting and localization of this 
protein to the parasite plasma membrane (Möskes et al., 2004). Apart from  
P. falciparum CDPK1 the Leishmania HASPB is another candidate protein where it was 
shown via reporter construct studies that a myristate moiety at the N-terminus of this 
protein is a prerequisite for membrane anchoring (Denny et al., 2000).  
To further investigate the results of the P. falciparum AK2 protein the current study 
focused on biochemical analyses of both transgenic parasite lines obtained from Ma and 
colleagues. The biochemical analyses consisting of SLO and saponin lysis of the 
parasitized cells combined with a protease protection assay showed that the  
PfAK2/GFP protein was protected by the PVM, but not by the PPM after Proteinase K 
treatment. This indicates that the fusion protein is located either at the outer leaflet of 
the parasite plasma membrane or at the inner leaflet of the PVM. However, to date, no 
method is known to distinguish between these two locations. The biochemical analysis 
further revealed that the PfAK2G2A/GFP protein was not secreted to the outer face of the 
PPM, which is consistent with the findings of Ma and colleagues. This indicates that the 
N-myristoylation site affects the subcellular localization of the AK2/GFP protein similar 
to the finding for CDPK1 and the Leishmania HASPB. Further, the removal of the  
N-myristoylation site prevents membrane attachment and leads to a cytosolic 
localization of the AK2 protein.  
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In a next step Ma and colleagues performed a multiple sequence alignment (MSA) of  
PfAK2 with Pfadenylate kinase 1, adenylate kinase-like proteins of P. falciparum and 
adenylate kinases of other species. They showed that the N-terminus of PfAK2 clearly 
differed from the N-termini of the other adenylate kinases (Ma et al., 2012). The  
N-terminus of PfAK2 contained in addition to the glycine residue at the N-terminus, 
which is a requirement for N-myristoylation, also a cysteine residue at the 4th position 
and a stretch or polybasic cluster of lysine residues. In the current study the MSA was 
extended by including putative adenylate kinases of other Plasmodium species, a 
verified adenylate kinase 2 of P. cynomolgi and adenylate kinase 2 of two other 
parasitic protozoa: Babesia bovis and Leishmania infantum. The sequence alignment 
showed that only PfAK2 differs in the N-terminus from the N-termini of the other 
adenylate kinase 2 proteins. PfAK2 is the only protein, which contains the 
aforementioned motifs in contrast to the AK2 proteins of the other species, which were 
analyzed in the MSA. 
To further investigate the additional motifs of the PfAK2 protein of P. falciparum 
different variants of the PfAK2 protein were generated. The role of the putative 
palmitoylation site and the polybasic cluster of lysine residues at the N-terminus of  
PfAK2 were analyzed. Protein, which are known to be N-myristoylated are usually also 
dually acylated proteins meaning that they are modified at their N-terminus with 
myristate and palmitate. For example members of the Src family contain this 'two-signal 
model' which enables membrane binding (Resh, 1999). Analysis of the PfAK2C4A/GFP 
protein showed a different signal to the PfAK2/GFP fusion protein indicating that the 
cysteine residue close to the N-terminus affects the subcellular localization of this 
protein. This was further supported by biochemical analyses. The fusion protein was 
found to be soluble and membrane-bound and compared to the PfAK2/GFP fusion 
protein was not translocated across the PPM. The C4A variant was protected within the 
parasite according to the SLO and saponin analyses in combination with the Proteinase 
K treatment. The equal amount of membrane-bound to soluble protein indicates that 
although the N-myristoylation site is present and membrane-anchoring can take place, 
the low binding energy of the myristate to the phospholipids of its target membrane is 
not sufficient to achieve a stable membrane anchoring (Peitzsch and McLaughlin, 
1993). However, protein palmitoylation in addition to N-myristoylation is known to lead 
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to a stable membrane anchoring of a myristoylated protein due to the increased 
hydrophobicity of the protein (Resh, 2006). That is possibly why an equal amount of 
soluble to membrane-bound fraction of the PfAK2C4A/GFP chimera was found in the 
cell fractionation study. A similar phenotype to the PfAK2C4A/GFP chimera was also 
found with the PfCDPK1AC3/GFP (putative palmitoylation site was removed) chimera in 
the studies of Möskes and colleagues and with a palmitoylation-deficient mutant of the 
Leishmania HASPB (Denny et al., 2000). In the studies of Denny and colleagues they 
observed some association of the palmitoylation-deficient mutant - which was still able 
to be myristoylated - with the outer leaflet of the Golgi, why they proposed a model 
where HASPB is co-translationally myristoylated in the cytoplasm, then trafficked to 
the Golgi membrane to be palmitoylated by a putative palmitoyltransferase at the outer 
leaflet of the Golgi before being targeted and translocated across the plasma membrane 
(Denny et al., 2000).  
 
Another variant of this protein was generated where both the N-myristoylation site and 
the palmitoylation site were removed: PfAK2G2AC4A/GFP. Biochemical analysis 
revealed no membrane-bound fraction of this protein and no secretion to the outer face 
of the PPM due to the lack of the potential dual acylation sites. Similar to the study of 
the PfCDPK1 by Möskes and colleagues the studies on these three variant proteins -  
PfAK2G2A/GFP (Ma et al., 2012), PfAK2C4A/GFP and PfAK2G2AC4A/GFP –showed that 
a N-myristoylation site and the putative palmitoylation site are required for membrane-
targeting, correct localization to the parasite plasma membrane and stable membrane-
anchoring. The analyses of these proteins strongly suggests that stable membrane 
anchoring can only take place when the protein is dually acylated as for example known 
for members of the Src family (Resh, 1999). Intriguingly, a third motif present at the N-
terminus of the AK2 protein – a polybasic cluster of lysine residues – also affects the 
subcellular localization of the fusion protein. Although the phenotype of the PfAK2Δ21-
30/GFP transgenic parasites is similar to the wildtype phenotype of AK2 according to 
live cell imaging, the biochemical analysis revealed no secretion of this protein beyond 
the PPM. A polybasic cluster in proximity to a N-myristoylation site seems to increase 
the membrane anchoring due to the electrostatic interactions between the positively 
charged amino acids of the protein and the phospholipids of the parasite plasma 
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membrane (Resh, 2006). A similar feature was observed for MARCKS protein which 
uses a cluster of basic residues at the N-terminus in close proximity to the N-
myristoylation site to achieve stable membrane anchoring (Resh, 1999).  
A removal of the lysine residue stretch at the N-terminus still enabled a stable 
membrane-anchoring by myristate and possibly palmitate of the protein. This is 
consistent with the result of the hypotonic lysis of the parasitized cells, where only a 
membrane-bound fraction of this protein was detected. The absence of the lysine 
residues at the N-terminus prevents secretion of the protein beyond the PPM indicating 
a possible role of the cluster of basic amino acids in the translocation process of PfAK2 
across the PPM. This observation corresponds to the findings with the CDPK1 protein, 
which also contains these three membrane anchoring features, which were shown to be 
required for membrane binding and membrane anchoring (Möskes et al., 2004).  
To further analyze these findings the N-terminus of the AK2 protein (residues 1 to 37 
amino acids) was fused to GFP, the plasmid was transfected into 3D7 parasites and the 
subcellular localization of this fusion protein was analyzed. The PfAK21-37/GFP fusion 
protein showed a similar phenotype to PfAK2/GFP when visualized by live cell 
imaging. Furthermore, observation of the late-stage parasites showed that the signal of 
the fusion protein was found around each of the merozoites. Biochemical analysis also 
revealed a secretion of this protein to the outer face of the PPM, but not beyond the 
PVM. These results are similar to the findings for the PfAK2/GFP fusion protein by Ma 
and colleagues. This indicates that the N-terminus of the AK2 protein is sufficient for 
secretion of this protein beyond the PPM. These findings are similar to what is known 
about the Leishmania HASPB. Dual acylation of this protein has been shown to be 
important for plasma membrane targeting and plasma membrane anchoring. 
Furthermore, the N-terminus of this protein (residues 1 to 18 amino acids) fused to GFP 
was sufficient for translocation across the plasma membrane (Denny et al., 2000). These 
results are similar to the findings with PfAK2/GFP. This indicates that the P. falciparum 
AK2 protein belongs to the small number of proteins, which is secreted by an 
alternative secretory pathway involving dual acylation to the ER/Golgi route.  
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4.2.1 How much of the N-terminus of PfAK2 is required for targeting other 
myristoylated proteins like PfARF1 to the PPM and beyond?  
Compared to PfAK2 N-myristoylated PfARF1 localizes to the Golgi-membrane. The 
targeting mechanisms of myristoylated proteins to a specific membrane, however, is not 
understood (Murray et al., 1998). Interestingly, the study of the PfARF11-17/+C4/-
V5AK2+18-37/GFP transgenic parasites – the fusion protein consists of the N-terminus of 
ARF with incorporation of a putative palmitoylation site and a polybasic cluster of 
lysine residues - showed a similar phenotype to the wildtype fusion protein when 
visualized by epifluorescence microscopy. Also a predominant membrane-bound 
fraction was found as a result of the hypotonic lysis indicating that this protein is 
strongly anchored to the PPM. However, the biochemical analysis did not show any 
secretion of this protein to the outer face of the PPM. The schizont-stage also showed 
that the fusion protein localizes individually around the newly formed individual 
merozoites. This would indicate that the protein is indeed targeted to the parasite plasma 
membrane. A stable membrane-anchoring is also achieved, however, the additional 
putative palmitoylation site and the polybasic cluster of amino acids are not sufficient to 
secrete this protein beyond the PPM. These findings suggest that the PPM targeting and 
membrane anchoring are driven by the three motifs found at the N-terminus of PfAK2: 
a N-myristoylation site, a putative palmitoylation site and a polybasic cluster of lysine 
residues. However, the N-terminus of the modified PfARF1 still differs in 
approximately 11 amino acid positions from the AK2 N-terminus. This indicates that 
also other amino acids at the N-terminus of PfAK2 are possibly involved in the 
secretion process for the AK2 protein. Further variants of AK2 should be generated to 
find out which other amino acids apart from the already identified crucial motifs are 
required and involved in the secretion of this protein. Furthermore, it should be kept in 
mind that only the N-terminus of PfARF1 was analyzed and modified. Whether or not 
the full-length PfARF1 would show the same phenotype (PPM targeting instead of 
Golgi-membrane localization) upon N-terminal modification is not clear according to 
these results. Another experiment with the full-length ARF1 and the additional AK2 
motifs should be performed to see whether or not the results will be consistent. 
More interestingly, two slightly different phenotypes could be observed for the ARF11-
17/+C4/-V5AK2+18-37/GFP transgenic parasites. The fluorescence signal of the fusion 
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protein showed a clear 'loop' structure in some of the parasites similar to the findings 
with PfAK2/GFP. On the other hand, the signals of the fusion protein in some parasites 
was a less prominent 'dot' like structure instead of the 'loop'. Since it is not known what 
causes the 'loops' it is also is not clear why parasites expressing the same fusion protein 
can show slightly different fluorescence patterns. To analyze the 'loop' structure, the 
ratio between these two phenotypes should first be determined by live cell imaging.  
 
4.2.2 An analysis about the folding state of PfAK2 as it translocates from the 
parasite cytosol into the PV 
Eilers and Schatz applied the mDHFR system to investigate the translocation state of 
mitochondrial proteins. They could show that mDHFR fused to a mitochondrial 
presequence must be kept in a 'translocation-competent' state (unfolded) before crossing 
the membrane (Eilers and Schatz, 1986). Gehde and colleagues applied the mDHFR 
system for the first time in the investigation of cytosolic P. falciparum proteins, which 
were known to be trafficked to the host cell. They succeeded in showing that the GFP 
chimera consisting of the N-terminus of the soluble protein GBP130 - which is known 
to enter the host cell – and mDHFR and GFP have to be unfolded prior to entering the 
host cell. Therefore they postulated that soluble proteins destined to be secreted beyond 
the PVM possibly require a translocon for translocation across the PVM (Gehde et al., 
2009). Indeed, an ATP-driven translocon, the so-called PTEX machinery, was found in 
the PVM and was proposed to be a possible candidate of protein translocation for 
soluble proteins (de Koning-Ward et al., 2009; Bullen et al., 2012).  
The mDHFR system was applied to analyze the folding state of the PfAK2 protein and 
the possible involvement of a translocon before the protein is secreted from the 
cytoplasmic site of the PPM into the PV. Fluorescence analysis showed no difference 
between the phenotype of the fusion protein of PfAK2/mDHFR/GFP transgenic 
parasites in the presence and absence of WR. A ring-like structure with a knob-like 
protrusion was observed. Since SLO lysis of the PfAK2/GFP wildtype parasites had 
already shown that the protein was not secreted beyond the PVM, this time the analysis 
was performed only with saponin treated lysates. It was investigated whether or not the 
protein is unfolded when it passes the PPM in order to enter the PV, which could mean 
that the secretion mechanism involves a translocon located in the PPM. Biochemical 
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analysis could show that the addition of the folate analogue WR, which is known to 
stabilize the tertiarty structure of mDHFR had no effect on the localization of the fusion 
protein. As found in the biochemical analysis of the PfAK2/GFP parasites, the  
PfAK2/GFP fusion protein was secreted beyond the PPM. This indicates that the protein 
did translocate across the PPM in a possibly folded configuration and was degraded 
upon exposure to Proteinase K. Although a positive control in this particular experiment 
is missing - to verify that WR indeed was able to bind to mDHFR and stabilize it - this 
experiment was performed in a way consistent with the protocol of prior mDHFR 
experiments with parasite proteins. Furthermore, the mDHFR system was usually 
applied to cytosolic proteins (Eilers and Schatz, 1986; Salvador et al., 2000) and not to 
membrane-attached proteins. The possible strong parasite plasma membrane attachment 
via the dual acylation sites and the polybasic cluster of lysine residues of the PfAK2 
protein would rather suggest a different mode of translocation.  
 
4.2.3 A model for PfAK2 protein anchoring to the PPM and secretion  
The study of Ma and colleagues already showed that N-myristoylation plays a key role 
in the secretion process of PfAK2 into the PV (Ma et al., 2012). The current study has 
further confirmed these findings by creating and analyzing different variants of the AK2 
protein. Thereby, a putative palmitoylation site and a polybasic cluster of amino acids 
were also found to be involved in the secretion process of this protein. However, a gene 
expression profile of the AK2 protein (PF3D7_0816900) during P. falciparum’s life-
cycle based on a high-density oligonucleotide array showed that this protein is not 
highly expressed during the erythrocytic asexual stages (Le Roch et al., 2003). Instead, 
a low gene expression was proposed in the first sexual stages of the parasite, the 
gametocytes, based on the transcriptome data (using a microarray approach) (Young et 
al., 2005) (see appendix). 
Although these high-throughput genomic and proteomic screening approaches enable a 
better understanding of gene and protein expression patterns in the different stages of  
P. falciparum’s life-cycle, incorrect findings cannot be excluded. This could mean that a 
gene is incorrectly given a low expression value, although it might be expressed in the 
asexual erythrocytic stage. In case of  PfAK2 (PF3D7_0816900) a further approach 
consisting of designing an antibody against PfAK2 would give a clue about whether or 
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not this protein is expressed in the asexual erythrocytic stages. Nevertheless, the 
findings of the reporter construct study of the AK2 protein still mirrors an atypical 
secretory signal of a secretory pathway involving N-myristoylation similar to the 
findings of PfCDPK1 (Möskes et al., 2004) and Leishmania HASPB (Denny et al., 
2000). In the following the results of the experiments with PfAK2 and its variant forms 
are summarized in an illustration as a model for a potential novel secretory pathway in  
P. falciparum: 	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Figure 4.1 A hypothetical model how PfAK2 is anchored to the parasite plasma membrane  
Initially the 14-carbon saturated fatty acid (myristate) is irreversibly attached to the glycine residue at the 
second position of the N-terminus of PfAK2 by the N-myristoyltransferase (NMT). (1) Due to the low 
binding energy of myristate the protein ist not stably anchored and can dissociate from the parasite 
plasma membrane. 2) To achieve stable membrane anchoring a 16-carbon saturated fatty acid (palmitate) 
is attached to a cysteine residue of a putative palmitoylation site at the N-terminus of PfAK2 via 
palmitoyl transferase (PAT). However, palmitoylation can also occur in the absence of PAT if  palmitoyl-
CoA is present (alternative palmitoylation mechanism), which is why this step is shown in brackets. 3) In 
the case of PfAK2 a third motif – a polybasic cluster of lysine residues at the N-terminus – is also 
involved in plasma membrane anchoring and subsequent translocation across the PPM.  	  	  
4.3 Concluding remarks on the analysis of PfAK2 as a candidate 
protein of an alternative secretory pathway in P. falciparum 
The initial experiments with PfAK2 were performed by Ma and colleagues who 
proposed a PVM localization of this fusion protein (shown by co-localization study with 
PfExp1). The biochemical approach of the current study suggests a localization either at 
the outer leaflet of the PPM or the inner leaflet of the PVM. The generation and 
subsequent analysis of variants of AK2 revealed that the N-terminus of this protein is 
important for parasite plasma membrane anchoring and subsequent secretion. 
Interestingly, the phenotypes of the fusion proteins of the PfAK2Δ21-30/GFP parasites 
and the PfARF11-17/+C4/-V5AK2+18-37/GFP parasites were similar to the phenotype of the 
fusion protein of the PfAK2/GFP parasites (Ma et al., 2012) when visualized by 
epifluorescence microscopy. All showed a ring-like structure with a clearly visible 
knob-like protrusion. However, they differed in their subcellular localization according 
to biochemical analyses: the PfAK2/GFP fusion protein is located beyond the PPM, 
while the variant proteins were located at the cytoplasmic site of the PPM. These 
findings indicate that the N-myristoylation site, the putative palmitoylation site and the 
cluster of basic residues are involved in plasma membrane targeting, anchoring and 
subsequent translocation across the PPM. However further amino acids at the N-
terminal region between the palmitoylation site and the row of basic amino acids also 
seem to be involved in the secretion process of this protein. 
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A difference in the localization between PPM and PVM via conventional fluorescence 
microscopy cannot be made due to the limited resolution. Electronmicroscopy or super 
resolution microscopy techniques might help further investigation of the proposed PVM 
localization of the fusion protein by Ma and colleagues similar to the proposal of this 
study which is localization of PfAK2 at the outer leaflet of the PPM or at the inner 
leaflet of the PVM.  
 
The knob-like protrusion which was observed in many of the cells expressing the 
variant proteins still remain an enigma. These 'extensions' have not been seen before 
with other parasite proteins fused to GFP. However, it is not known whether or not this 
observation is related to GFP expression, the expression of AK2 itself, or is a result of 
parasite plasma membrane anchoring via dual acylation of the fusion protein.  
 
One more important aspect regarding the biochemical analysis should be taken into 
consideration. The biochemical approach involving saponin treatment of the parasite is 
technically challenging. Although the SLO and saponin concentrations used for each of 
the experiment was not altered a proper lysis after SLO and saponin treatment, 
respectively, was most of the time not achieved. To achieve lysis of the PVM and to 
prevent lysis of the PPM at the same time required extensive titration of the saponin 
concentration to find out the right concentration to disintegrate the RBCM and the PVM 
and to avoid rupture of the PPM at the same time. Even then, a proper lysis without 
lysis of some parasites during the procedure was not achieved. As can be seen from the 
results minimal amounts of the marker protein aldolase, the parasite internal control, 
was frequently detected in the supernatant fraction after SLO and saponin treatment, 
respectively, indicating that during the procedure some parasites were lysed. However, 
the majority of aldolase could still be detected in the SLO and saponin pellet fractions 
indicating that most of the parasites remained intact. The marker protein of the PV - the 
soluble serine rich protein (SERP) - was always detected after saponin treatment not 
only in the supernatant fraction as expected, but also in the pellet fraction. This 
indicates that this protein sticks to membranes and is difficult to remove despite many 
washing steps during sample preparation. This explanation is likely to be valid, since 
Proteinase K treatment of the saponin pellet fraction led to the removal of SERP in the 
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saponin pellet fraction. The difficulty to achieve proper lysis is a general issue since the 
parasite internal control aldolase and the soluble PV protein SERP are never found 
completely in the expected fractions as could be shown for different localization studies 
of P. falciparum proteins involving these two lysis methods (Ansorge et al., 1997; 
Spielmann et al., 2006; Heiber et al., 2013). The efficacy of Proteinase K digestion in 
the SLO and saponin pellet fractions was performed on one of the variant form, the  
PfAK2G2AC4A/GFP transgenic parasites. Therefore the parasite plasma membrane was 
permeabilized with Triton X 100 with and without Proteinase K addition. In the 
detergent permeabilized parasites Proteinase K was able to degrade the fusion protein 
indicating its efficiency to degrade the fusion protein. However, a weak-point of all of 
these results might be the lack of positive control for all of the experiments performed 
individually, although the efficiency of Proteinase K digestion of an acylated protein 
(PfAK2) and a non-acylated protein (PfAK2G2AC4A/GFP) was shown. An indirect 
evidence that Proteinase K treatment worked for each of the experiment is that in 
saponin treated cells the SERP protein disappeared from the pellet fraction (possibly 
sticking to membranes) compared to the saponin pellet fraction treated with Proteinase 
K indicating the efficiency of Proteinase K digestion. 
Although the majority of the control proteins in each of the experiment was detected in 
the expected fractions after SLO and saponin treatment, respectively, indicating that the 
majority of the parasites analyzed remained intact during SLO and saponin treatment 
the results should still be carefully interpreted, especially because they mostly represent 
1-2 experiments where the SLO and saponin treatment almost worked properly meaning 
that a statistical significant result is missing.  
 
Most surprising is the fact that the N-terminus of PfAK2 differs from the N-terminus of 
the other adenylate kinases and that it was found localized beyond the PPM. These 
findings are surprising, especially because adenylate kinase 2 is usually found located at 
the intermembrane space of mitochondria of various tissue cells as for the human AK2, 
which is known to play an important role in the energy metabolism (Dzeja and Terzic, 
2009). It is difficult to speculate on why the parasite expresses the AK2 protein with a 
clearly different N-terminus compared to other AK2 proteins and why the N-terminus 
drives this protein into the PV. Nevertheless, the results of analysis for PfAK2 reveals 
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PfAK2 as a further candidate protein using a different pathway to the conventional 
ER/Golgi route with a similar mechanism found for PfCDPK1 (Möskes et al., 2004) and 
Leishmania HASPB (Denny et al., 2000).  
 
A screening of the P. falciparum genome for proteins with a predicted N-myristoylation 
site, a putative palmitoylation site and a large number of basic amino acids of the first 
50 amino acids of the N-terminus revealed quite a few potential proteins as candidates 
of this putative secretory pathway. In the following five of these proteins (including 
PfAK2 and PfCDPK1), which were found in the screening are listed (a list with further 
candidate proteins can be found in the appendix). It would be interesting to perform 
similar experiments with these candidate proteins in a future study. 
Table 4.1 Potential proteins of the P. falciparum genome as candidates of a novel secretory pathway 	  
 N-Myristoy-
lation 
Palmitoy- 
lation 
Basic 
residues 
Acidic 
residues 
Blood 
stage 
Sexual 
stage 
Pf adenylate kinase 2 
(PF3D7_0816900)  
! ! 17 7 ---- ! 
Pf calpain 
(PF3D7_0502300)  
! ! 15 11 ---- ! 
Pf protein 
phosphatase, putative 
(PF3D7_0810300)   
! ! 14 11 ! ! 
Pf CDPK1 
(PF3D7_0217500)  
! ! 13 5 ! ! 
Pf cAMP-dependent 
protein kinase 
(PF3D7_1223100)   
! ! 12 13 ! ! 
! 	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5 Outlook 	  
Interestingly, a large number of atypical signal sequences and secretion mechanisms of 
parasite proteins were discovered as a result of the analyses of parasite protein secretion 
to the parasite’s different compartments (Lingelbach, 1993; Marti et al., 2004; Hiller et 
al., 2004). However, the secretion mechanisms of many parasite proteins into the PV or 
even to destinations in the host cell are still not understood. 
 
In this study two N-myristoylated proteins were analyzed as candidate proteins of an 
alternative secretory pathway: the PfADP-ribosylation factor 1 and the Pfadenylate 
kinase 2. While the results strongly support the localization of PfARF1 to compartments 
of the early secretory pathway, PfAK2 was found to be targeted to the plasma 
membrane of the parasite (PPM) and subsequently translocated across the PPM. Further 
analyses of the PfAK2 revealed the importance of a N-myristoylation site, a putative 
palmitoylation site and a polybasic cluster of lysine residues at its N-terminus for PPM 
targeting, membrane anchoring and subsequent secretion. The N-terminus of PfAK2  
(1-37 amino acids) was sufficient for trafficking this protein beyond the PPM. But the 
secretion of another N-myristoylated protein (PfARF1) was not achieved by the addition 
of the palmitoylation site and the polybasic cluster of amino acids (results of the 
analysis of the fusion protein of the PfARF11-17/+C4/-V5AK2+18-37/GFP parasites). This 
indicates that other amino acids at the N-terminus of PfAK2 also seem to play a role in 
the secretion process. Therefore more variants of AK2 should be generated and 
analyzed to figure out which other amino acids are important in the secretion process. 
However, the underlying mechanism of the secretion process for PfAK2 is not 
understood so far.  
 
Even if PfAK2 appears to be not expressed in the erythrocytic stage of the parasite’s life 
cycle (Le Roch et al., 2003) – this still needs to be verified via immunodetection with an 
antibody against PfAK2 with samples prepared from the intraerythrocytic stage of the 
parasite - it still represents a novel mechanism of protein secretion similar to the 
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findings of the PfCDPK1 (Möskes et al., 2004) and the Leishmania HASPB (Denny et 
al., 2000). Therefore it would be interesting to express this fusion protein in a 
mammalian system in regard to the anaylsis of the protein's subcellular localization. 
 
Intriguingly, the PfN-myristoyltransferase appears to be a promising drug target since 
essential parasite proteins require N-myristoylation to perform their biological function 
(Möskes et al., 2004; Rees-Channer et al., 2006). Hence, current research is focused on 
the design and synthesis of inhibitors of PfNMT and only recently PfNMT was 
validated to be an antimalarial drug-target (Rackham et al., 2013; Wright et al., 2013). 
Therefore, the discovery of further PfNMT candidate proteins contributes to the 
understanding of the importance and influence of PfNMT in different cellular processes. 
In the case of PfAK2/GFP N-myristoylation via PfNMT seems to be a prerequisite for 
membrane targeting, membrane anchoring and protein secretion. Further experiments 
could include studies with NMT inhibitors to analyze their effect on the subcellular 
localization of PfAK2/GFP. 	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7 Appendix 
7.1 Coding sequences (PlasmoDB, version 10.0) 	  
Sequence encoding the PfADP-ribosylation factor 1 (ARF1) (PF3D7_1020900) 
 
ATGGGTTTATATGTAAGTAGGTTATTTAATCGTTTATTTCAAAAAAAAGATGTACGTATT 
TTAATGGTTGGATTAGATGCTGCTGGAAAAACTACAATATTATATAAAGTAAAACTTGGT 
GAAGTTGTTACGACTATTCCAACAATAGGTTTCAATGTTGAAACTGTCGAATTTCGTAAC 
ATTTCATTTACCGTATGGGATGTAGGAGGACAAGATAAGATCCGACCTTTATGGAGACAT 
TATTATTCCAACACAGACGGATTAATATTTGTCGTAGATAGTAATGATAGAGAAAGAATA 
GATGATGCTCGTGAAGAATTACATAGAATGATAAATGAAGAAGAATTAAAAGATGCTATA 
ATTTTAGTCTTCGCTAATAAACAAGATTTACCAAATGCTATGTCAGCAGCTGAAGTTACA 
GAGAAATTACACCTTAACACTATAAGGGAAAGGAACTGGTTTATTCAATCCACCTGTGCC 
ACAAGGGGTGACGGATTGTACGAAGGTTTTGATTGGCTAACCACACACTTAAATAATGCC 
AAATAA!  
 (Sequence length: 546 bp) 
 
Predicted protein sequence of PfARF1 
 
MGLYVSRLFNRLFQKKDVRILMVGLDAAGKTTILYKVKLGEVVTTIPTIGFNVETVEFRN 
ISFTVWDVGGQDKIRPLWRHYYSNTDGLIFVVDSNDRERIDDAREELHRMINEEELKDAI 
ILVFANKQDLPNAMSAAEVTEKLHLNTIRERNWFIQSTCATRGDGLYEGFDWLTTHLNNA 
K 	  
(Sequence length: 181 aa) 
 
Sequence encoding the Pfadenylate kinase 2 (AK2) (PF3D7_0816900) 
 
ATGGGATCATGTTATAGTAGAAAAAATAAAGTATCAACAATATCATTAGATGAAGAGGAA 
AAAAAAAAAGAAAAAAAGAAGAAAAAAAAAATATATATTTTAAATGGAGCATCTGGGTCA 
GGAAAAGATACACAATGTAGATTATTAGAAAAAAAATACAATTATAAAATAATTTGTATA 
AGTAAATTATTAAAAGAATATAAAGAAGAATATAATAAAGAAAATGTATTAAATGAAGAA 
GAAAATTATTTTGATGAAATAGAAAAATGTATGATAGATGGATCTTTAGTTAATGATCAA 
ATTGTTATAGAGATATTTCATAAACAATTGAACAAATATATAAATGATGATAAATATAAT 
GGTATTATAATAAATGGTTTTCCTAGAAATTATGAACAAGCTTTATTAATTATACAAAAC 
AATATAAGTATAACGAAATTTATAAATATACAAGTAGGAAAAGATACTCTATGGACAAGA 
ATAAATAATAGAATTATCGATCCAATTACAAATATAAGTTATAATGAAAATATAATACAA 
ATAATTAAAAAAAAAAGAGAAGGACAAGAACTATCAGACAAAGAACAAAAACAATTGATC 
ATAGACAATCATTTATATAATAATTTAAGTAATGATATTTTAGAAAGATTAACAAAAAGA 
AAAGATGACGAAGAACAGGTTTTCAATAAAAGGTTTCAATTATATATAGAAAGCGAACAA 
AAAATTAATTCTCTATTTAAAAATATTTGTAAAAATGTTGATGGAGAAAAATCGATAAAT 
GATATATTTGATCAAATATGCTCCATTATAGATGATAACCCCAATTAA! 	  
Sequence length (828 bp) 
 
Predicted protein sequence of PfAK2 
 
MGSCYSRKNKVSTISLDEEEKKKEKKKKKKIYILNGASGSGKDTQCRLLEKKYNYKIICI 
SKLLKEYKEEYNKENVLNEEENYFDEIEKCMIDGSLVNDQIVIEIFHKQLNKYINDDKYN 
GIIINGFPRNYEQALLIIQNNISITKFINIQVGKDTLWTRINNRIIDPITNISYNENIIQ 
IIKKKREGQELSDKEQKQLIIDNHLYNNLSNDILERLTKRKDDEEQVFNKRFQLYIESEQ 
KINSLFKNICKNVDGEKSINDIFDQICSIIDDNPN  
(Sequence length: 275 aa) 
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7.2 Multiple sequence alignment (Clustal W: T-coffee) 
Pf_AK2          MGSC----------YSRKNKVSTISLDEEEKKKE--KKKKKKIYILNGASGSGKDTQCRLLEKKYNYKIICISKLLKEYKEEYN 
Pf_AK1          MNE-------------NLENFSTIDLLNELKRRYACLSKPDGRYIFLGAPGSGKGTQSLNLKKSHCYCHLSTGDLLREAAEKKT 
PBANKA_AK2_p    MVP---------------------------------PPPKKKVYIMNGPPGSGKDTHCVALSKKYNFEIITISELLKKYVKDNT 
PCHAS_AK2_p     MVS---------------------------------Q-KKKKVYIMNGPPGSGKDTHCVSLSKLYNFEIITISELLKKYVKENT 
PKH_AK2_p       MEQ----------------------------------KKGPKVFILNGAAGSGKDTQCRLIAEKYNFAVITISTLLKEYVSENE 
PVX_AK2_p       MSD-------------NLEKFSTVDLLNELKRRYSCLSKPDGRYIFLGAPGSGKGTQSLNLKKSHCYCHLSTGDLLREAAEKKN 
PYYM_AK2_p      MVS---------------------------------QKKKKKVYIINGPPGSGKDTHCVSLSKKYNFEIITISELLKKYVKDNT 
PCYB_AK2        MSD-------------NLEKFSTVDLLNELKRRYSCLSKPDGRYIFLGAPGSGKGTQSLNLKKSHCYCHLSTGDLLREAAEKKN 
BbAK2           MIFLRVLSLLFFATMSGLHGYETQTLVEELRRRYDCLSKPQGNFIFMGAPGSGKGTQSLLLRDSHCYCHLSTGDILRSAIRSGD 
LiAK2           M-----------------------------------------KIVMEGPPQGGKTTVASVVKERYGLCYVSTSEAVRNAVRLGN 
                *                                           :: *.. .** * .  : . :    :  .  ::.       
 
 
Pf_AK2          KE---N--------V--LNEEENYFDEIEKCMIDGSLVNDQIVIEIFHKQLNKYI----------------NDDKYNGIIINGF 
Pf_AK1          E----------------------LGLKIKNIINEGKLVDDQMVLSLVDEKLK-------------------TPQCKKGFILDGY 
PBANKA_AK2_p    NKD--DSCGKYAPGL--TDEEKNDLENIEKCICNGSLAPDNIVNKIFLKYFKSYSENSE------QDQTSESDIPSNGIIINGF 
PCHAS_AK2_p     SKD--PSCGKYVPGL--TDEEKKDLESIEKCISNGSLAPDNIVNKIFLKYFRRYSENGE------QDKASGSDTTSNGIIINGF 
PKH_AK2_p       ETGGGTSLSKDDESIEEIGKKNEDIKRIKRCMEDGSLVPDDTVIKVFVHRLGKYI---------------NGEKPCAGIVVNGF 
PVX_AK2_p       D----------------------LGNKIRNIINEGKLVDDDVVLTLVDDKLK-------------------SPQCKKGFILDGY 
PYYM_AK2_p      NKD--DSCGKYAPGL--TDEEKKDLENIEKCICNGSLAPDHIVNKIFLKYFKSYSENSEQDKNSEQDQAPESTTSSNGIIINGF 
PCYB_AK2        D----------------------LGNKIRNIINEGKLVDDDVVLTLVDDKLK-------------------SPQCKKGFILDGY 
BbAK2           P----------------------IGMEAKTYMDQGKLVPDDVVVKLIEGNIN-------------------SPRCSRGFILDGF 
LiAK2           SA---------------------YSSQLKQLIDNDELIPDSLEVKVVCEATR-------------------RPDCVNGFVLDGF 
                                                .  :  :..*  *      :.                        *::::*: 
 
 
Pf_AK2          PRNYEQALLIIQ----NNISITKFINIQVGKDTLWTRINNRIIDPITNISYNENIIQIIKKKREGQELSDKEQKQLIIDNHLYN 
Pf_AK1          PRNVKQAEDLNKLLQKNQTKLDGVFYFNVPDEVLVNRISGRLIHKPSGRIYHKIF------------------------NPPKV 
PBANKA_AK2_p    PRTYEQALLFKK----YKINVTKFINIVVSKETILKRIMNRAKDPVTNINYNLQIVKLIKKKRQGIKLTSEEEELLASQDDSYQ 
PCHAS_AK2_p     PRTYEQALLFKK----YKINVTKFINIVVSRESLLKRIMNRAKDPVTNINYNFQIIKLIKKKRQGIQLTSEEEELLASQNDSYQ 
PKH_AK2_p       PRTYEQALLFAK----NGIQVTSFINIQVKKENLMSRISSRMVDPVTNINYNAKAVEVLLKKKQGGHLTPEEGLILSSQGDAFK 
PVX_AK2_p       PRNVKQAEDLNKLLQTNQMKLNGVFYFNVPDDVLVKRISGRLIHKPSGRIYHKIF------------------------NPPKT 
PYYM_AK2_p      PRTYEQALLFKK----YKINVTKFINIVVSRETLLNRIMNRTKDPVTNINYNLQIVKLIKKKKQGIKLTIEEEELLASQDDTYQ 
PCYB_AK2        PRNVKQAEDLNKLLQTNQMKLNGVFYFNVPDDV---------------------------------------------------    
BbAK2           PRTETQADRLKTLLSNLGKRLNAVFLFECPDDEIQRRITGRLVHEPSGRVYHMTS------------------------KPPKV 
LiAK2           PRTRKQSRMMQDL---ENVKVDIVVELEISDKELQTRFGGRWYHPKSGRIYHTFY------------------------NPPLN 
                **.  *:  :          :  .. :    . 
 
 
Pf_AK2          NLSNDI-LERLTKRKDDEEQVFNKRFQLYIESEQKINSLFKN--ICKNVDGEKSINDIFDQICSII-------------DD---- 
Pf_AK1          PFRDDVTNEPLIQREDDNEDVLKKRLTVFKSETSPLISYYKNKNLLINLDATQPANDLEKKISQHI------------------- 
PBANKA_AK2_p    NLNDEI-IMRLERREDDNESTFNKRYNLYKENEEKIIPLFID--ICKNVDGENDINHNFQQICKII-------------QEE--- 
PCHAS_AK2_p     NLSDEI-IMRLERREDDNESTFNKRYNLYKENEEKIIPLFID--ICKNVDGENDINYNFQQICKII-------------QEE--- 
PKH_AK2_p       NISDEV-IARLSKRADDDEATFLKRFHLYEHNEEKIISLFPT--VYRSVDGNGSIEETFAQICAIL-------------DGEHEY 
PVX_AK2_p       PFKDDITNEPLIQREDDNEEVLKKRLNVFKSETTPLINYYKNKNLLINLDATQPANDLEKKISQHI------------------- 
PYYM_AK2_p      NLTDEI-IMRLERREDDNESTFNKRYNLYKENEEKIIPLFID--ICKNVDGENDINYNFQQICKII-------------QEE--- 
PCYB_AK2        --LDDITNEPLIQREDDNEEVLKKRLNVFKSETTPLINYYKNKNLLINLDATQPANDLEKKISQHI------------------- 
BbAK2           PMRDDITNEPLTQRKDDTLEVIRTRLDAYHKQTAPLIKYYENMHLLHRIDANRPEMKVNEEINKIV-------------ER---- 
LiAK2           AGKDDYTGEPLVQHSEDTPERIRQRMSQYRQQLSEVRSTFVG-NAWVTVEASGNVESVRNNVFAVLDPLYFAQTSKKVPKPW--- 
                   ::     * :: :*    :  *   :  .   :   :        ::.         ::   :                   
 
 
Pf_AK2          -NPN 
Pf_AK1          --DG 
PBANKA_AK2_p    ENYA 
PCHAS_AK2_p     ENYA 
PKH_AK2_p       TRLS 
PVX_AK2_p       --GG 
PYYM_AK2_p      ENYA 
PCYB_AK2        --GG 
BbAK2           VCTN 
LiAK2           WKFW 	  
 
Figure A-1  A multiple sequence alignment of PfAK2 and other verified and putative adenylate 
kinase 2 proteins, respectively, in other Plasmodium species and other parasitic protozoa 
PfAK2 (PF3D7_0816900) was aligned to PfAK1 (Pf3D7_1008900), PbAK2, putative 
(PBANKA_071390), PcAK2, putative (PCHAS_072300), PkAK2, putative (PKH_051560),  
PvAK2, putative (PVX_094660), PyAK2, putative (PYYM_071400), PcAK2 (PCYB_081850),   
BbAK2 (bbov|XP_001609458.1) and LiAK2 (linf|LinJ.34.0130). The N-terminus of PfAK2 clearly 
differs from the N-termini of the other aligned proteins, insofar as it contains a verified N-myristoylation 
site (Rahlfs et al., 2009), a putative palmitoylation site at the 4th position and a polybasic cluster of lysine 
residues (each motif marked in grey). None of the other AK2 proteins contain either of these motifs. The 
alignment was created using ClustalW (T-coffee).  
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7.3 Expression profiles of PfAK2 (PlasmoDB 10.0 version) 	  	  	  	  	  	  
 
 
 
 
 
 
 
 
 
 
Figure A- 3 Gametocyte stages (I–V) transcriptomes of PF3D7_0816900 (Pf AK2) 
The expression profile of PF3D7_0816900 is based on a oligonucleotide microarray analysis (Young et 
al., 2005). In red: 3D7 parasites; in pink: MACS purified 3D7 parasites; in purple: isolate NF54. Different 
gametocyte stages (stage I–V) were analyzed (x-axis): days of gametocytogenesis. Y-axis: (rma) 
Affymetrix RMAExpress expression value (normalized by experiment). 	  
Figure A-2 Expression profile of PF3D7_0816900 (PfAK2) 
The expression profile of PF3D7_0816900 is based on a oligonucleotide microarray analysis (Le Roch et 
al., 2003). In blue: Sorbitol-synchronized 3D7 parasites; in purple: Temperature-synchronized 3D7 
parasites. Different stages of P. falciparum’s life-cycle were analysed (x-axis): ER= Early Rings; LR = 
Late Rings; ET= Early Trophs; LT= Late Trophs; ES=Early schizonts; LS= Late Schizonts; M=Merozoites; 
S=Sporozoites; G=Gametocytes. Y-axis: Log (base 2) ratio of Affymetrix RMAExpress expression value 
(normalized by experiment) to average RMAExpress value for all time points for a gene. 
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7.4 Potential proteins of the P. falciparum genome as candidate 
proteins of an alternative secretory pathway 
 N-Myristoy-
lation 
Palmitoy- 
lation 
Basic 
residues 
Acidic 
residues 
Blood 
stage 
Sexual 
stage 
Pf adenylate kinase 2 
(PF3D7_0816900)  
! ! 17 7 ---- ! 
Pf calpain 
(PF3D7_0502300)  
! ! 15 11 ---- ! 
Pf protein phosphatase, 
putative 
(PF3D7_0810300)   
! ! 14 11 ! ! 
Pf CDPK1 
(PF3D7_0217500)  
! ! 13 5 ! ! 
Pf cAMP dependent 
protein kinase 
(PF3D7_1223100)   
! ! 12 13 ! ! 
Pf ABC transporter (MDR 
family) (PF3D7_1339900)   
! --- 12 6 ---- ! 
Pf protein phosphatase 2c-
like (PF3D7_1309200)   
! ! 12 9 ---- ! 
Pf glideosome associated 
protein (PF3D7_1222700)   
! ! 11 20 ! ! 
Pf Conserved Plasmodium 
membrane protein, 
unknown function 
(PF3D7_0930800)   
! ! 10 12 ---- ! 
Pf conserved plasmodium 
protein (PF3D7_0913800)   
! ! 9 12 -- ! 
Pf secretory complex 
protein 61 alpha 
(PF3D7_1310600)   
! ! 8 3 ! ! 
Pf armadillo-domain 
containing rhoptry protein 
(ARO) (PF3D7_0414900)   
! ! 8 9 ! ! 
Pf inner membrane 
complex protein, putative 
(PF3D7_1011000)   
! - 7 8 ! ! 
!
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